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P R E F A C E • . w -.••:-• -••«•; , - -
Despite significant progress in the prevention and treatment of
cardiovascular diseases, heart failure is still a leading cause of morbidity and
mortality in industrial countries. Sustained cardiac hypertrophy, which is defined
as an increase in heart size resulting from an increase in cardiomyocyte cell .•
volume, has been recognized as the single most important risk factor for heart
failure development, and can be initiated by a wide array of growth factors
in response to increased workload, injury, or intrinsic defects in contractile
performance. To understand the molecular determinants of the hypertrophic
response and to achieve rational drug design to treat heart failure, investigation
currently focusses on identifying and characterizing intracellular signal
transduction pathways in the heart.
The experiments presented in this thesis topic a signaling pathway that
is thought to play a key role in the hypertrophic transcriptional response of
the myocyte. This signaling route employs the Ca^-calmodulin-dependent
phosphatase calcineurin and its downstream transcriptional effector Nuclear
Factor of Activated T-cells (NFAT).
Compelling evidence for a role of calcineurin as a transducer of hypertrophic
signals came from the observation that exposure of cardiomyocytes in tissue
culture or rodents to the immunosuppressant drugs, cyclosporine (CsA) or FK-
506 blocked the enzymatic activity of calcineurin and partially prevented the
ability of cardiomyocytes to undergo hypertrophy in response to angiotensin II,
phenylephrine or pressure overload. These drugs interact specifically with the
cytoplasmic immunophilin proteins, cyclophilins and FK-506 binding protein-12
(FKBP1 2), respectively, to form inhibitory complexes that bind the calcineurin A
subunit.
Chapter one reviews the studies that employed these substances to block
calcineurin-induced cardiomyocyte hypertrophy and the limitations involved using
this pharmacological approach. Although several studies indicated these drugs to
be potent inhibitors of calcineurin activity in vivo, all these studies were hindered
to some degree by intra-and extracardiac side effects of the drugs, especially
in vivo. These side effects underline the need to find alternative experimental
strategies to further elucidate the (patho)physiological role of calcineurin in the
myocardium. A more elegant approach would be to use targeted inhibition of
calcineurin or gene targeting of calcineurin in genetically modified mice. Genetic
modification provides a superior tool to more specifically evaluate the importance
of calcineurin as a regulator of cardiac hypertrophy in vivo. In recent years,
different classes of proteins with calcineurin inhibitory properties have been
described. These proteins allow a genetic approach to specifically inhibit cardiac
calcineurin activity, by using transgenic mice expressing one of these calcineurin-
inhibitory proteins in the heart.
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One such molecule is modulatory calcineurin interacting protein 1 (MCIP1).
MCIP1 blocks calcineurin signaling by binding directly to the catalytic subunit of
calcineurin. Transgenic mice with cardiac specific overexpression of the MCIP1
protein driven by the a-MyHC promoter, are protected against several forms of
cardiac hypertrophy, which suggest an important role for calcineurin signaling in
diverse forms of cardiac hypertrophy. Accordingly, in chapter two the involvement
of calcineurin in myocyte hypertrophy after myocardial infarction (Ml) is discussed.
Calcineurin activity was found to be upregulated after Ml and overexpression
of the MCIP1 protein resulted in inhibition calcineurin activity, hypertrophic
remodeling post-MI, reinduction of fetal gene expression, and attenuated the
progression to cardiac dysfunction and heart failure. These results reveal a
protective role for MCIP1 in the post-MI heart and suggest that calcineurin is a
crucial regulator of postinfarction-induced pathological LV remodeling.
In chapter three, the function and requirement of NFAT factors as primary
downstream targets of calcineurin signaling in the heart is further elucidated,
the significance of each separate isoform in the heart is evaluated and whether
they are functionally redundant. All four members of the NFAT transcription
factor family (NFATcl -c4) were found to be expressed in cardiomyocytes. They
all showed calcineurin-dependent nuclear translocation, and were able to exert
transcriptional activity. Viral mediated gene transfer of a dominant negative
NFAT molecule resulted in the blockade of calcineurin induced cardiomyocyte
hypertrophy, indicating the necessity of NFAT downstream of calcineurin to
produce cardiomyocyte hypertrophy.
Since members of the NFAT transcription factor family are known to be
relatively weak activators alone and require nuclear partners, the functional
interactions between NFAT and myocyte enhancer factor-2 (MEF-2) proteins in
skeletal muscle, led us to investigate whether this is pertinent to the myocardium
as well. In chapter four, we discussed our findings that suggest the existence of
a regulatory complex formed between MEF2 and NFAT on promoter sequences
of several cardiac genes that are known to be upregulated during calcineurin-
provoked pathological cardiac hypertrophy. This transcriptional complex also
contained chromatin remodeling enzymes with histone acetyl-transferase (HAT)
activity that facilitate gene expression by inducing histone acetylation. Since
transcriptional activity of MEF2 under unstimulated conditions is actively repressed
by class II histone deacetyltransferase (HDAC) activity, the synergistic interaction
between NFAT and MEF2 may be under the regulation of the balance between
HDAC and HAT activity.
The discovery that the hypertrophic action of calcineurin in cardiomyocytes
is partly dependent of MEF2 transcriptional activity, which is actively repressed
by HDACs in unstimulated cells, provided us with the hypothesis that systems
devoid of HDAC activity may very well prove to be more sensitive to calcineurin
activity. Indeed, mice with targeted ablation of HDAC9 demonstrate to be
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sensitized to hypertrophic signals and exhibit stress-dependent cardiomegaly. In
chapter five we discuss the effect of subjecting HDAC9 deficient mice, which is
the predominant HDAC9 isoform in the heart, to Ml. Although we were expecting
to find a hypertrophy related phenotype, implicate a predominant involvement of
angiogenesis, rather than hypertrophic remodeling in the absence of HDAC9.
Chapter six reviews our findings and extrapolates the results described in
this thesis to the current knowledge on hypertrophic signaling and transcriptional
remodeling to give direction to future research.
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Chapter 1 Introduction
Calcineurin and hypertrophic heart disease:
novel insights and remaining questions
Orlando F. Bueno, Eva van Rooij, Jeffery D. Molkentin,
Pieter A. Doevendans, LeonJ. De Windt
a s l
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In the past few years, an emerging body of research has focused on a
novel transcriptional pathway involved in the cardiac hypertrophic response.
Ever since its introduction, the significance of the calcineurin-NFAT module has
been subject of controversy. The aim of this review is to provide both an update
on the current status of knowledge and discuss the remaining issues regarding
the involvement of calcineurin in hypertrophic heart disease. To this end, the
molecular biology of calcineurin and its direct downstream transcriptional effector
NFAT are discussed in the context of the genetic studies that established the
existence of this signaling paradigm in the heart. The pharmacological mode-
of-action and specificity of the calcineurin inhibitors cyclosporine A (CsA) and
FK506 is dicussed, as well as their inherent limitations to study the biology of
calcineurin. A critical interpretation is given on studies aimed at analyzing the
role of calcineurin in cardiac hypertrophy using systemic immunosuppression. To
eliminate the controversy surrounding CsA/FK506 usage, recent studies employed
genetic inhibitory strategies for calcineurin, which confirm the pivotal role for
this signal transduction pathway in the ventricular hypertrophy response. Finally,
unresolved issues concerning the role of calcineurin in cardiac pathobiology
are discussed based upon the information available, including its controversial
role in cardiomyocyte viability, the reciprocal relationship between myocyte Ca**
homeostasis and calcineurin activity and the relative importance of calcineurin in
relation to other hypertrophic signaling cascades.
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Molecular biology of calcineurin
The calcineurin-NFAT pathway was one of the first signaling paradigms
that provided molecular insight how extracellular signals travel from the cell
membrane into the nucleus. The precise components of the pathway were defined
by working backwards from the T- lymphocyte nucleus to the cell membrane. The
regulatory region in the interleukin-2 (IL-2) gene was found to be under control
of a transcriptional factor designated Nuclear Factor of Activated T-cells (NFAT),
which shuttled between cytoplasmic and nuclear components under influence of
a Ca^ signal. Subsequently, nuclear NFAT import was defined to be regulated by
dephosphorylation steps catalyzed by the phosphatase calcineurin, which in its
turn was subject to regulation by Ca^-calmodulin binding.' * Finally, calcineurin
was identified as the cellular target of the immunosuppressive agents CsA and
FK506.'*
Calcineurin itself is a heterodimer composed of two distinct subunits,
designated calcineurin A, a 58-59 kDa subunit which contains the catalytic site
of the enzyme, and a small ~ 1 9 kDa calcineurin B subunit which contains the
Ca^-binding regulatory domain of the holoenzyme. Three different mammalian
genes, designated a. (3 and v, encode calcineurin A, and share substantial homology
in the domain encoding the catalytic site. Of these isoforms, calcineurin Ay
displays a testis-restricted expression pattern, while calcineurin Act and A(5
exist in an overlapping fashion in multiple tissues, including the heart. Multiple
alternative splice isoforms of calcineurin Aa and A(3 have been reported." The
smaller calcineurin B subunit is encoded by two genes, each having alternative
splice isoforms.' Only mutant mice lacking calcineurin Aa have been created and
these animals display a subtle defect in the antigen-specific T cell response,*
accumulation of a hyperphosphorylated form of tau in the mossy fibers of the
hippocampus, accompanied by cytoskeletal changes and altered synaptic plasticity
in the central nervous system." The phenotype of the calcineurin Aa knockout
is surprising in that it does not reveal the full scale of phenotypic characteristics
associated with CsA or FK506 administration, suggesting functional redundancy
between the calcineurin Aa and Ap isoforms. The creation and phenotypic
characterization of genetic mouse models mutant for either calcineurin Ap or
calcineurin B will be instrumental for resolving these issues and efforts along this
line are in progress.'
To date, five genes encoding NFAT complexes have been identified and
designated NFATcl (NFATc or NFAT2), NFATc2 (NFATp or NFAT1), NFATc4
(NFAT3), NFATc3 (NFAT4 or NFATx) and NFAT5, of which only the latter appears
to be constitutively nuclear and not subject to regulation by calcineurin.'•'" The
NFATc members share high homology within their DNA binding region, which
is related to the Rel domain present in the transcription factor NF-KB.' NFATC
members transactivate target genes by interacting with other transcription factors
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like c-Maf, activator protein-1 (AP-1), and CATA-4." '*•"
Calcineurin physically interacts with NFATc members and dephosphorylates
serine residues within SP repeats and the serine-rich region. Dephosphorylation
of these residues results in the unmasking of two nuclear localization sequences
required for its nuclear import.'* Nuclear export, on the other hand, is dependent
upon rephosphorylation of these same residues by glycogen synthase kinase-
3p (GSK3fS)" and the p38 and c-Jun NH^-terminal protein kinase (JNK) members
of the mitogen-activated protein kinase (MAPK) superfamily.""'The biological
significance of the individual NFATc members is rapidly being elucidated due
to the availability of murine models deficient for the single NFATc isoforms.' Of
interest to the cardiovascular field, mice lacking NFATc 1 die in utero from failure
to develop semi lunar cardiac valves,™^' while the combined disruption of NFATc3
and NFATc4 results in embryonic lethality due to abberant vascular patterning."
First evidence for a role of calcineurin in cardiac hypertrophy
Molkentin and colleagues first established the existence of a myocardial
calcineurin-NFAT module." Using a yeast-two-hybrid screening of interacting
factors for the cardiac embryonic transcription factor CATA-4, a specific
interaction was observed between zinc finger domains of CATA-4 with the DNA
binding domain of NFATc4 (NFAT3). Since interaction between NFATc4 and
GATA-4 drove synergistic activation of a brain natriuretic peptide (BNP) promoter-
reporter construct, a specific role for NFATc4 activation and hypertrophic gene
induction was suggestive (Figure 1.1)."
In line with this hypothesis, CsA (calcineurin inhibition) prevented the
hypertrophic growth response of cultured cardiomyocytes in response to humoral
factors as angiotensin II (Angll) and phenylephrine (PE)." To elucidate the
functional significance of the calcineurin-NFATc4 pathway in vivo, several lines
of transgenic mice were generated containing either truncated activated mutants
of NFATc4 or the calcineurin Aa subunit specifically in the heart. Persistent
calcineurin activation was sufficient to promote a hypertrophic response in 11
separate TC founder lines, varying from relatively benign forms of concentric
hypertrophy to severe forms of dilated cardiomyopathy and early lethality in
low and high copy number TC mice, respectively. Pharmacological inhibition
of calcineurin through CsA injections (25 mg/kg/day) resulted in complete
prevention of the pathology." NFATc4 TC mice also demonstrated a hypertrophic
myopathy associated with re-expression of fetal genes. As a testimony to the
specificity of the proposed pathway, CsA was unable to prevent the morphologic
pathology of the NFATc4 TC animals, which express a calcineurin-independent
form of the transcription factor."
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Figure 1.1. Model for calcineurin function in cardiac hypertrophy as postulated by Molkentin
and colleagues in 1998.12 In this scheme, Ca2+/calmodulin-dependent phosphatase
calcineurin is activated by hypertrophic agonists such as Angiotensin II (Angll) or
phenylephrine (PE) or by intrinsic defects, which trigger an increase in intracellular Ca2+.
Upon activation, calcineurin dephosphorylates one single nuclear factor of activated T-cell
(NFATc) target, which translocates to the nucleus upon activation. NFATc4 (NFAT3) physically
associates with the transcription factor GATA-4 to synergistically activate gene transcription
of hypertrophic genes such as the brain natriuretic peptide gene (BNP).
This initial study was soon followed by one which analyzed whether
calcineurin may also be involved in the ventricular growth response in other
animal models of cardiomyopathy and LV hypertrophy. Accordingly, CsA
administration prevented hypertrophy in tropomodulin overexpressing mice,
a model of dilated cardiomyopathy due to sarcomeric disruption." " CsA also
proved to be effective in TC mice expressing a non-phosphorylatable form of
myosin light chain 2v (MLC-2v), which display hypertrophic cardiomyopathy (HCM)
as a result of inefficient cross-bridge cyc l ing / " " " and in mice overexpressing
p-tropomyosin, a model of hypertrophic cardiomyopathy and defective calcium
handling."' '" ' CsA was ineffective, however, in a retinoic acid receptor (RAR) TC
driven pathology"", indicating the possibility that calcineurin activation might
act as a molecular driving force behind some, but not all forms of ventricular
myopathies. The authors were further able to demonstrate activation of calcineurin
enzymatic activity concurrent with a 27% increase in indexed heart weight in a
rat model of pressure overload created by surgical constriction of the abdominal
aorta. CsA administration resulted in complete prevention of calcineurin activation
and LV hypertrophy six days following coarctation."
These two initial studies suggested several novel implications for cardiac
pathobiology. (1) The existence of a conservational preservation of a calcineurin-
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NFATc pathway in the myocardium, such as defined earlier in T lymphocytes, (2)
the potential of this transcriptional pathway to activate a fetal gene expression
profile consistent with LV hypertrophy (Figure 1.1), (3) pharmacological
inhibition of (transgenically driven levels) of activated calcineurin prevents the
histopathology resulting from its activation. These initial studies immediately
evoked questions related to the significance of this novel pathway in view of the
complexity and hierarchy of the multitude of hypertrophic signaling pathways
known to govern cardiac hypertrophy. To address these issues the vast majority
of these studies, unfortunately, made use of the pharmacological inhibitors
of calcineurin. The inconsistent outcome of these studies ignited controversy
regarding the requirement of this pathway in the LV hypertrophic response.
Pharmacological inhibitors of calcineurin
Csa (Sandimmune) and FK506 or tacrolimus (Prograf) are the most
important immunosuppressive agents used in organ transplantation and in the
treatment of diverse immune disorders. These agents produce similar effects
on signal transduction pathways in T lymphocytes, however, they do not share
similar chemical structure nor do they react with the same target. CsA is a neutral,
lipophilic and very hydrophobic, cyclic polypeptide of 11 amino acids extracted
from Tolypocladium inflatum Cams. Following oral or intravenous administration,
CsA distributes rapidly between blood cells and plasma with an apparent large
volume of distribution of 4 to 8 L/kg." CsA accumulates in erythrocytes (50%
to 60%) and in leukocytes (10% to 20%), the remainder of the drug is bound to
plasma lipoproteins. Tissue drug concentrations depend on actual cyclophilin
and lipid content. CsA is metabolized predominantly in the liver by cytochrome
P-450IIIA enzymes to more than 30 metabolites. These metabolites do not
contribute significantly to the immunosuppressive effects of CsA since the most
active ones only retain 1 0% to 20% of the activity of the parent compound. CsA
does not cross the blood-brain barrier, but it crosses the placenta and it can be
detected in amniotic fluid and fetal blood. The elimination half-life of CsA has
been estimated of approximately 6 hours."
FK5O6 is a macrolide antibiotic extracted from Streptomyces tsukubaensis.
FK506 can be administered orally or intravenously and its elimination half-life is
approximately 20 hours. It is extensively metabolized in the liver since less than
1 % of the drug is excreted unchanged. FK506 is approximately 100 times more
potent than CsA in its calcineurin inhibitory characteristics.
The mechanism of action of these two immunosuppressive agents has been
investigated extensively in immune cells. CsA and FK506 bind with high affinity to
the ubiquitous cytosolic peptidyl-propyl isomerases cyclophilin and FK506-binding
protein-1 2 (FKBP1 2), respectively. The complex of CsA-cyclophilin or FK506-
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FKBP1 2 associates with calcineurin and inhibits its phosphatase activity as well as
its interaction with a variety of substrates. CsA and FK506 also inhibit the peptidyl-
propyl isomerase activity of cyclophilin and FKBP12, but this effect is not involved
in the immunosuppressive mechanism of these drugs since CsA analogues with
no effect on T cell activation are still able to block the peptidyl-propyl isomerase
activity.
It is generally accepted that calcineurin inhibition by CsA and FK506
blocks the dephosphorylation and subsequent nuclear translocation of the NFATc
transcription factors.'"" However, novel, calcineurin-independent mechanisms of
action for CsA and FK506 have recently been proposed. It has been hypothesized
that part of the immunosuppressive effects of CsA are mediated through TGFpi,
a cytokine with immunosuppressive effects in diverse cells and tissues.'"'
However, this is still a matter of controversy since other studies have failed to
show an induction of TGF-pi production during CsA treatment." This issue could
potentially be of interest to the current topic in view of the recent demonstration
that selective TCFp-activated kinase (TAK1) activation can result in a
cardiomyopathic phenotype in mice." CsA was also found to inhibit the activation
of some family members of the mitogen-activated protein kinases (MAPK) in
different cell types, although this may still be an indirect response to calcineurin
inhibition."""' Chronic CsA administration produces changes in the properties of
the sarcoplasmatic reticulum (SR) Ca^-release channel"^ and in isolated guinea-pig
cardiomyocytes alterations in the kinetics of L-type Ca^ channels."'
The ryanodine receptor (RyR2) is a multiprotein complex including
several phosphatases, kinases, achoring proteins and FKBP12.6. Altered RyR2
channel function has been postulated to play a role in cardiomyopathy, since
hyperphosphorylation of the complex was observed in human heart failure
biopsies, which results in dissociation of FKBP1 2.6 from its cognate receptor.
These events result in increased Ca *^ sensitivity for activation, elevated channel
open probability, and impaired myocyte Ca *^ homeostasis."" Genetic ablation of
FKBP12 resulted in severe septum defects and dilated cardiomyopathy in mice."*
Much less is known about the cardiac biology of the target of CsA, the cyclophilin
A-D family.
Accordingly, it is becoming increasingly clear that CsA and FK506 have
calcineurin-independent effects in multiple organs, and do not constitute the
optimal tool to test for a potential role of calcineurin in the setting of cardiac
hypertrophy. If these agents are to be used in a systemic fashion, precaution
should be taken for dosage, mode of delivery, and severe extra-cardiac toxicity on
major target organs besides the heart muscle (e.g. neural tissue, smooth muscle,
kidney), which may influence the outcome of hypertrophy studies.
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CsA and FK506: evidence in support of a role for calcineurin in
hypertrophy
Endothelin-1 (ET-1) is an established humoral factor that induces cardiac
hypertrophy. ET-1 was reported to increase the activity of CaMKII and calcineurin
in cultured cardiac myocytes and pretreatment with KN62 (CaMK inhibitor) or
CsA strongly suppressed ET-1-induced increases in phenylalanine uptake and
in cell size. Pharmacologic inhibition of calmodulin, CaMK or calcineurin or
overexpression of dominant-negative mutants of CaMKII and calcineurin strongly
suppressed hypertrophic gene activation."* Similarly, leukemia inhibitory factor
(LIF), a hypertrophic cytokine employing gpl 30 receptors for transmembrane
signaling, enhanced both calcineurin and CaMK activities. KN62 and CsA
administration significantly reduced LIF-induced hypertrophy and fetal gene
expression, suggesting a crucial role for these Ca^-activated pathways in LIF-
mediated cardiomyocyte growth (Table 1.1)."
CsA demonstrated to be highly effective in tropomodulin overexpressing
mice, in mice expressing a non-phosphorylatable form of myosin light chain 2v
(MLC-2v) and in mice overexpressing B-tropomyosin." An additional genetic model
of hypertrophy, the Cqa overexpressing mouse, was found to be partially sensitive
to comparable doses of CsA/*
Shimoyama and colleagues analyzed the effectiveness of FK506 in a rat
model of pressure overload hypertrophy. A drug dosage-effect preceded this
study to minimize toxic side-effects on parameters as blood pressure, cardiac
hemodynamics, and operative mortality. Accordingly, a dosage of 1 mg/kg/day
FK506 injected intramuscularly was found to have negligible side-effects, yet still
inhibited LV calcineurin activation. A 3-week treatment regimen on abdominal
aortic constricted animals was associated with a near complete prevention of the
increase in (indexed) heart size, fibrosis formation, and hypertrophic marker gene
expression.'"
Using the same rat model, Lim and colleagues demonstrated that a 14-
day CsA regimen resulted in a dose-dependent prevention of the morphologic,
histological and molecular aspects of LV hypertrophy. Although this study suffered
from a moderate post-operative mortality (-25%), mortality was unaffected by the
drug. One striking and clinically relevant finding demonstrated that treatment of
CsA (20 mg/kg/day) was associated with a regression of established myocardial
hypertrophy resulting from a 14-day pressure overload."
Hill and colleagues were able to demonstrate a progressive and
reproducible hypertrophic response following a 5-week period thoracic aortic
banding protocol in mice (45% increase in HW/BW). A relatively high dose of CsA
resulted in a near complete blockade of this response (Table 1.1). The authors
found no evidence of deleterious effects of CsA on myocardial hemodynamics, the
transstenotic pressure gradient, weight gain, physical activity or mortality." Mice
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Table 1.1 Studies using CsA and FK506 to analyze the role of calcineurin on the development of cardiac
hypertrophy.
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LIF, leukemia inhibitory factor; PE, phenylephrine; Angll, angiotensin II; ET-1, endothelin I; HD, hypertrophic
development; AC, aortic constriction; ca, constitutively active; RAR, retinoic acid receptor; TC, transgenic; CnA,
calcineurin; DS, Dahl salt-sensitive; SHR, spontaneously hypertensive rats; CsA, cyclosporin; NA, not applicable;
NR, not reported; HF, heart failure; 0CM, obstructive cardiomyopathy; AM, accelerated mortality; WL, weight
loss; DBP, decreased blood pressure; PI, pulmonary infection; FHC, familial hypertrophic cardiomyopathy; MLC-
2V*, nonphopshorylatable myosin light chain 2V.
§ FK5O6 induces hypertrophy when used in combination with rapamycin
page 22 | CHAPTER 1
with renovascular hypertension, created by a two kidney one clip method, also
demonstrated substantial LV calcineurin activation and CsA prevented hypertrophy
in this model (Table 1.1).»
Using the Dahl salt-sensitive rat model, which develops a rapid onset
hypertension and both pressure and volume overload hypertrophy, Shimoyama
and colleagues demonstrated a substantial reduction in indexed left ventricular
weight using only very low doses of FK506 (0.1 and 0.01 mg/kg/day) over a 6
week period of severe hypertension. In fact, cardiac enzymatic calcineurin activity
was elevated at any time point examined in this hypertensive model. FK506
also prevented fibrosis deposition and expression of certain fetal-type cardiac
genes. Sakata et al. demonstrated LV blockade and prevention to heart failure
development in the same model when FK506 (1 mg/kg/day) was administered
early (from 8 weeks), but no attenuation of heart failure remodeling when
administered late in life (from 1 7 weeks)."
Using TC rats harboring both the human renin and angiotensin genes,
Mervaala et al. investigated CsA effectiveness to protect against Ang ll-induced
myocardial and renal damage. In their model, CsA completely prevented
cardiovascular death, decreased 24-hour albuminuria by 9096, lowered systolic
blood pressure by 35 mm Hg, and protected against the development of cardiac
hypertrophy."
Calcineurin activation may also play a role in distinct hypertrophic stimuli."
Following 10 weeks of voluntary exercise training to evoke a physiological
adaptive hypertrophy response in rats, indexed LV weight and LV calcineurin
activity were increased by 20% and 2.5 fold, respectively, and CsA was effective in
preventing both parameters." Post-infarction failure is usually associated with a
strong volume overload stimulus. Rats subjected to chronic myocardial infarction
(Ml) and administered CsA over a 14-day post-MI recovery period demonstrated a
significant attenuation of cardiac hypertrophy and a-skeletal actin gene induction.
However, the inhibition of hypertrophy led to an increased incidence of LV dilation
and reduced hemodynamic performance, suggesting acceleration of the heart
failure development in this model."
CsA and FK5O6: no correlation between calcineurin and cardiac hypertrophy
Boluyt and colleagues demonstrated significant activation of 70-kDa S6
kinase (P70***) following phenylephrine-stimulation, and rapamycin pretreatment
prevented this effect." Rapamycin mediates its effects through specific binding
to the intracellular immunophilin FKBP. Since FK506 and rapamycin both bind
FKBP and act mutually antagonistic, the authors used FK506 at a 1 0-fold molar
excess to competitively reverse the anti-hypertrophic, rapamycin-mediated effects.
This study implicates that FK506 may have both anti-hypertrophic (calcineurin
THE CALCINEURIN/NFAT PATHWAY | page 23
inhibition) as well as pro-hypertrophic properties, albeit that latter effects only
play a role at excess concentrations, and emphasizes the need for correct CsA or
FK506 dosage use to study calcineurin biology.
In the initial report of Sussman and coworkers, the RAR overexpressing
TC model failed to morphologically respond to CsA." This model was created to
study the function of excessive retinoid signaling during cardiac morphogenesis,
and resulted in severe heart failure in neonates and juvenile mice when a
consititutively activated RAR was driven to the embryonic ventricle by the p-
MyHC promoter. Interestingly, postnatal ventricular expression of the same
receptor (driven by the a-MyHC promoter) did not result in cardiac pathology,
suggesting a critical role for retinoid signaling during developmental stages
of ventriculogenesis. Nevertheless, the failure of the RAR model to respond
to systemic immunosuppressive therapy suggests that retinoid signaling acts
independently from calcineurin during cardiomorphogenesis.
Muller and coworkers found that CsA administration of 25 mg/kg twice
daily did not attenuate cardiac hypertrophy in mice with transverse aortic
constriction, but, unfortunately, calcineurin activity assays were not provided."
Ding and colleagues investigated CsA effectiveness in a murine model of
ascending aortic constriction." Morphometric analyses of hearts subjected to this
very severe form of pressure overload revealed no statistical differences between
non-treated and CsA-treated, banded animals. In fact, calcineurin activity assays
revealed a lower enzymatic activity following pressure overload compared to
sham operated animals. Given this, one would not expect a significant impact
from further CsA administration (calcineurin inhibition), yet the authors reported
development of heart failure by drug treatment."
Meguro et al found a substantial prevention of LV hypertrophy by CsA
treatment in transverse aortic constricted mice over a period of 3 weeks. However,
a disproportionate number of premature deaths in the CsA treated group was
observed, all within the first 7 days of the study and accompanied by pleural
efflusion. Invasive LV hemodynamic analysis revealed a significant lower ascending
as well as abdominal systolic aortic pressure in the presence of comparable trans
stenotic pressure gradient, suggesting both an intrinsic myocardial depressive
and a distal blood pressure lowering effect by CsA. The authors concluded
that inhibition of LV hypertrophy might be of detriment to the heart, and could
accelerate decompensation and heart failure.^
Luo and colleagues investigated a similar pressure overload model in
the rat by constriction of the abdominal aorta as initially employed by multiple
groups"'*"" and randomized their groups to receive different doses of CsA or
FK506.6' No effect of CsA or FK506 on the development of LV hypertrophy was
observed, but a significant increase in mortality was evident with increasing
dosages of CsA or FK506. In fact, the highest FK506 dose (4 mg/kg/day) was
associated with 90% mortality.*'
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Zhang and colleagues demonstrated that 6 week CsA treatment (5 mg/
kg/day) was associated with a significant elevation of blood pressure in the
spontaneously hypertensive rat (SHR) model, but this additive blood pressure
increase was not associated with increased heart weight." To avoid interpretative
complications due to the genetic component of the SHR model, the authors next
turned to normotensive rats to address the effect of CsA on pressure overload
induced hypertrophy. Two weeks of CsA treatment resulted in a 2896 increase
in indexed LV weights in abdominal aorta constricted rats compared to a 38%
increase in vehicle-treated, banded animals, a difference that was not found to
be statistical significant. Four weeks of aortic banding resulted in an increase of
46% in vehicle treated animals, while CsA treated banded animals demonstrated
an increase of 27 and 22% at CsA dosages of 10 and 20 mg/kg/day, respectively.
Again, the difference was not indicated as statistically significant, even though
CsA appeared to have dose-dependent effects on the development of LV
hypertrophy. This particular study was also associated with a substantial post-
operative mortality, ranging from 33 to 67%, and a reduction in pressure gradients
at 4 weeks, most notably in CsA treated groups."
Hayashida and coworkers observed increased LV calcineurin activity
in hypertensive hypertrophied Dahl-lssei rat strain, but not during the later
congestive heart failure phase. However, a CsA regimen started at 11 weeks of age
did not prevent LV hypertrophy, nor heart failure development.'"'
Finally, in a murine model of familial hypertrophic cardiomyopathy
(FHC) bearing a knock-in missense mutation in the cardiac myosin heavy chain
(aMyHC"/+)6", both CsA and FK506 resulted in accentuated LV hypertrophy and
worsening of pathology." Pre-treatment with diltiazem (1^ antagonist) prevented
the exaggerated pathology in aMyHC"^* mice. Long term treatment with a K*-
channel agonist, minoxidil, mimicked the morphologic pattern associated with
CsA and FK506 in this model. These changes were attributed to drug-induced
elevation of diastolic Ca** concentration."
Interpreting the CsA and FK506 studies
How can we reconcile these differing accounts on CsA/FK506 effectiveness?
By far the easiest explanation would be to assume some level of model-
dependency for calcineurin involvement, implicating that other signaling modules
may take over in relative importance to the expense of calcineurin. Indeed, it
has been postulated that calcineurin inhibition effectively blocks Ang ll-mediated
cardiac hypertrophy, such as that developing in response to abdominal aortic
banding or following reduced renal perfusion in renovascular hypertension. In
support of this view, all reports involving models with Angll activation (abdominal
aortic constriction"'"; renin-angiotensin TC rat^"; two-kidney-one-clip")
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reported a higher degree of CsA/FK506 effectiveness (Table I). This view must
be an oversimplification, since constriction of the aortic arch (transverse aortic
constriction) does not activate the renin-angiotensin system," yet one report still
demonstrated near complete prevention of hypertrophy by CsA administration"
(Table 1.1). :•:•• -
Genetic variability between the animals and their sensitivity to CsA/FK506
may play an underestimated role and coincides with substantial variability in drug
dosage. To date, Sprague-Dawley rats, Wistar rats and FVB/N mice exhibited a
relatively higher degree of drug tolerance than Dahl-lwai rats and C57BL/6 mice
(Table I). The most striking example of drug tolerance and strain dependency
is provided by the studies of Shimoyama and colleagues'"", where Wistar rats
tolerated 1 mg/kg/day FK506", while the same group found a 1 O-fold lower
whole body upper limit tolerance in rats with the Dahl-lwai background." This
contrasts with dosages of up to 4 mg/kg/day FK506 used in Sprague-Dawley rats
(40 to 400-fold excess vs Shimoyama et al.") which, not surprisingly, resulted in
up to 90% mortality in pressure-overloaded animals. Clearly, the vast variations in
genetic background and drug dosage must have influenced the interpretation of
calcineurin involvement in cardiac hypertrophy.
Careful inspection further suggests some degree of variance associated
with surgical procedure, peri-operative milieu and route of drug administration.
A number of studies have reported a high degree of drug-associated premature
mortality, up to 90% in drug administered animals, an effect which might have
preselected interindividual variations. In fact, careful inspection suggests an
inverse relation between high mortality and drug-effectiveness (Table I).
Differences in timing, route and duration of drug administration could be
another factor relating to some of the differences between the studies. Ding et al.
reported no drug effectiveness following 4 weeks of administration, while Eto et
al., employing a similar model of ascending aortic constriction and comparable
CsA dosage, demonstrated a clear effect on the early phase (1 week post-surgery),
but not on later stages (4 weeks post-surgery) of hypertrophy development.
Two groups reported efficient hypertrophy prevention in the Dahl-Salt sensitive
model using low doses of FK5O6 and starting drug administration early in life (6
or 8 weeks),"•" while another reported no effectiveness when they started CsA
injections at 11 weeks of age." Luo and colleagues reported high mortality and
no CsA effectiveness in rats administered the drug in the drinking water.*' The
majority of studies, however, have injected CsA or FK506 subcutaneously (often
twice daily) due to its low solubility in aqueous solutions and limited half-life.
A final issue concerns the phenotypic interpretation following drug
administration. Meguro et al. reported high mortality in their CsA banded animal
groups, interpreted as development of heart failure since a disproportionate
number of animals displayed pleural effusion upon autopsy.^" It is unlikely,
however, that heart failure was the true cause of death. Only a 28 and 1 6%
page 26 | CHAPTER 1
decrease in LV dP/d t^ and LV ejection fraction in CsA-treated, banded vs
vehicle-treated, banded animals was observed, respectively.'" A more plausible
explanation for their observations would be enhanced susceptibility to pleural
infection in treated animals" due to the systemic immunosuppressive therapy."
Conclusively, the vast majority of studies, regardless of their qualitative
outcome, were hindered to some degree by intra-and extracardiac side effects
of the drugs. Latter notion underscores the problematic situation of using CsA
or FK506 as experimental devices, virtually excludes their potential as future •
treatment options for patients with hypertrophic heart disease, and motivated
some research groups to find alternative experimental strategies to elucidate the
myocardial (patho)physiological role of calcineurin.
Genetic inhibition of calcineurin
In recent years, different classes of proteins with calcineurin inhibitory
properties have been described. AKAP79 (for A-kinase anchoring protein) was the
first protein discovered to have calcineurin inhibitory characterstics.^ AKAP79
acts as a scaffold protein, which binds protein kinase A and protein kinase C
besides calcineurin and is thought to anchor multiple classes of signaling modules
in the vicinity of substrates to facilitate their proper and timed activation."
One interesting class of calcineurin inhibitors are the products of the (Down's
Syndrome Critical Region) DSCR1 gene and its relatives, DSCR2 orZAK14."
DSRC1 is located on human chromosome 21 in the so-called Down's syndrome
critical region. The small gene products of DSCR1 and DSCR2, designated MCIP1
(for modulatory calcineurin interacting p_rotein-l) and MCIP2, respectively,
are remarkably potent inhibitors of calcineurin activity in striated muscle.'"
Interestingly, it was demonstrated that calcineurin activity upregulates the MCIP1
gene product in cardiomyocytes through an intragenic segment in the MCIP1
gene, which includes a dense cluster of consensus NFAT binding sites/' MCIP1
may therefore participate in a negative feedback circuit to diminish potentially
deleterious effects of unrestrained calcineurin activity in striated muscle cell
lineages. Two additional classes of cellular calcineurin inhibitors are Cain
(for calcineurin inhibitory protein) and the calcineurin B homologous protein
(CHP). Cain (also known as Cabin) is a large 240-kDa protein with multiple
binding domains that functions as a scaffolding protein attaching numerous
proteins besides calcineurin." Cain is a noncompetetive inhibitor of calcineurin
phosphatase activity with a K^  of 440 nM and antagonizes NFATc translocation."•'*
CHP has a high similarity to the calcineurin B subunit and is able to compete with
the calcineurin B subunit for binding the calcineurin A subunit."'*
The identification of specific cellular antagonists of calcineurin have
provided an excellent platform to design experimentation that circumvents
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the issue of drug specificity and whole body toxicity. This strategy was first
reported by Taigen and co-workers, who created adenoviral vectors expressing
the specific calcineurin binding domains of the Cain and AKAP79 proteins
(designated ACain and AAKAP, respectively)." AdACain and AdAAKAP infection
resulted in attenuation of Angll, PE and growth factor-induced calcineurin
activity, cardiomyocyte hypertrophy, and atrial natriuretic factor (ANF) expression
(Figure 1.2). The same non-competitive calcineurin inhibitors were recently
overexpressed in a cardiac-restricted manner in mice. ACain and AAKAP79 TC
animals demonstrated stable transgene expression in the cardiac compartment,
reduced cardiac calcineurin activity and a significant attenuation of hypertrophy in
response to catecholamine infusion or pressure overload stimuli (Figure 1.2).™ In
the same study, the ACain adenovirus was used for viral-mediated gene transfer
of the ACain peptide into the adult rat myocardium. Overexpression of the ACain
protein resulted in inhibition of pressure-induced calcineurin activation and
cardiac hypertrophy™ and supports the feasibility to acutely intervene in reactive
hypertrophic signaling using gene therapy approaches."
control
Adpgal + PE
AdACain + PE • H I 14 V *Cain TC
banded
Figure 1.2. Genetic inhibition of calcineurin with calcineurin inhibitory protein (Cain)
abrogates the LV hypertrophy response. The left panel summarizes the in vitro results
obtained with adenoviral ACain gene transfer (AdACain) in cardiomyocytes. Phenylephrine
(PE) induces a massive increase in cardiomyocyte size in cultures infected with a control
adenovirus (Adpgal) compared to uninfected, non-stimulated cells (top left and middle left
panels). In contrast, blockade of calcineurin in the presence of ACain prevents PE-induced
hypertrophy (lower left panel). Cardiomyocytes were visualized by immunocytochemical
«-actinin detection, nuclei were visualized with bisbenzamide (white). Hematoxylin-Eosin
stained cross-sections demonstrate that similar effects were observed following ACain
overexpression in vivo. A 14 day pressure overload stimulus resulted in a visible increase in
heart weight in wildtype animals, as compared to sham-operated, wildtype mice (top right
and middle right panels). Mice overexpressing the non-competetive ACain protein in the
cardiomyocyte component are protected against this pressure-overload stimulus (lower right
panel). Full colour image page 1 77
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As an alternative approach to inhibit calcineurin, transgenic mice ••>:•• • :: >~-
expressing a truncated form of human MCIP1 in a cardiac-selective manner ^ :
were created. Remarkably, unstressed MCIP1 TC animals revealed a 5-10%
smaller heart size, establishing a role for calcineurin in normal, developmental
myocardial growth. MCIP1 overexpression prevented the massive hypertrophic
response, fetal gene induction and progression to dilated cardiomyopathy in ; -
the calcineurin TG mouse." MCIP1 TC mice demonstrated resistance towards
cardiac hypertrophy as a result of long-term p-adrenergic stimulation and exercise
training. Finally, myocardial overexpression of a dominant negative (dn) form of
calcineurin provided protection against pressure overload hypertrophy following
abdominal aortic banding in mice.*° The results from these three reports utilizing
four distinct genetic strategies to inhibit calcineurin activity (ACain, AAKAP79,
MCIP1 and dn-calcineurin) make it hard to dispute that calcineurin is a required
component of hypertrophic signaling following diverse stimuli.™*"*'
The existence of viable calcineurin Ace and Ap somatic knockout mice
may provide a means of obtaining further genetic evidence for the involvement
of calcineurin in the hypertrophic response. Because the viability of double-null
calcineurin Act and Ap mice is still uncertain, the establishment of transgenic
animals with a dominant-negative calcineurin inhibition based approach'**"*' may
still prove to be of significant value. A preferential approach would be to identify
the critical calcineurin A isoform and ablate it in an inducible, ventricular myocyte
cell lineage-dependent fashion, which would also permit definitive insight into the
temporal aspects of calcineurin involvement in the distinct stages of heart failure
development.
Still many other questions remain and concern calcineurin's precise
pathobiological role in terms of biochemical properties, subcellular localization,
crosstalk with other notorious hypertrophic signaling modules, its suggested role
in myocyte viability and its precise contribution in the progression of human heart
failure. The current status of knowledge of these issues is discussed below.
Reciprocal relationship between Ca^ homeostasis and calcineurin
activity
One fundamental question relates to the processes leading to myocardial
calcineurin activation. How can the cardiac myocyte distinguish between changes
in Ca** that result in calmodulin activation versus the vast fluctuations in Ca^ *
that occur upon each cycle of contraction and relaxation? Studies in other
cell types have demonstrated that NFATc remains nuclear only in response
to prolonged, low-amplitude Ca^ signals and is insensitive to transient, high-
amplitude Ca^ * alterations.*^ Interestingly, the activity of CaMK, another important
Ca^/calmodulin regulated hypertrophic signal transducer," was reported
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to be uniquely sensitive to transient, high amplitude Ca^ fluctuations." The
differential response of two major Ca^/calmodulin-regulated hypertrophic signal
transducers to fundamentally distinct Ca^ * fluctuations may implicate that they
fulfill specialized pathophysiological functions within the cardiomyocyte. Whether
calcineurin and CaMK also differentially respond to distinct Ca** alterations in
striated muscle cell types and what these functions might be remains to be
explored.
Furthermore, the actual source of Ca** that activates calcineurin (or other
Ca^/calmodulin signaling modules for that matter) is incompletely understood.
Studies using nicardipine and verapamil suggest a critical involvement of the L-
type Ca^ * channel, which may respond downstream of G-protein coupled receptor
(CPCR) agonists such as ET-1, Angll or PE""^ and gpl 30 receptor agonists like
LIF."' LIF enhances intracellular Ca^ transients through an increase in L-type Ca**
current (1^ )^ in adult cardiomyocytes.®* LIF-mediated activation of 1^ ,_ resulted
in increased calcineurin and CamK activities and nicardipine and verapamil
pretreatment fully prevented their activation, suggesting at least one plausible
source of Ca^ that activates calcineurin and CaMK.
Findings in other cell types suggest a reciprocal relation between
calcineurin on the one hand, and the RyR, IP3 receptor and L-type Ca^ channel, on
the other."" In line with this notion, we have previously reported that adenoviral
expression of calcineurin in neonatal cardiomyocytes resulted in positive
inotropy and increased Ca^ * transients." In addition, adult myocytes derived from
the calcineurin TC mouse exhibited increased 1 ^ amplitude and density and
shortened time to half decay compared to wildtype myocytes."* Since the total
number of L-type Ca^ channel al and p2 subunits was unaltered, the increased
density of l<.^ is due to an increased fraction of channels that open during the
repolarization phase. Interestingly, therapeutic doses of CsA had no effects on 1 ^
in wildtype mice, suggesting that calcineurin indirectly affects L-type Ca^ channel
properties. This contrasts observations in the mammalian brain, where calcineurin
is the major phosphatase responsible for L-type Ca^ * channel inactivation.^ One
plausible explanation for the effects of myocardial calcineurin on the profile
of myocyte Ca^ * handling may relate to SR Ca^ * handling. Indeed, Janssen and
coworkers demonstrated that CsA induces sustained SR Ca** leakage from adult
rabbit and human ventricular myocytes at therapeutic doses.'" Collectively,
calcineurin inhibition may have the potential to alter myocardial intracellular Ca**
homeostasis and influence the susceptibility to the occurrence of lethal ventricular
arrhythmias.
The finding that CsA exacerbated the hypertrophic response in a murine
FHC model" has further complicated our understanding of cardiomyocyte Ca^
homeostasis and Ca^/calmodulin-regulated signaling in the LV hypertrophy
response." Fatkin and coworkers observecd an increase in Ca** transient in
wildtype myocytes, and, to a lesser extent, in myocytes from mice carrying
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the FHC mutation. Pretreatment with diltiazem, a L-type Ca** channel blocker,
prevented the wosening of the phenotype in mutant mice, suggesting that CsA
infavourably modulated 1 ^ properties." Latter interpretation appears to contrast
their finding that CsA subtly increased the Ca *^ transient of ciMyHC"^* myocytes.
Moreover, Yatani and coworkers** failed to observe a response of CsA on L-type
Ca** channel kinetics in wildtype myocytes, and Janssen and coworkers observed
a reduction of the Ca** transient in human failing trabeculae following CsA ,
administration.'"
Nevertheless, latter study poses the interesting question whether blockade
of calcineurin is of detriment to FHC-associated LV hypertrophy yet effective to
reduce acquired forms of LV hypertrophy and dilated cardiomyopathies. The
finding that CsA and FK506 proved to be highly effective in rescuing the cardiac
phenotype of tropomodulin or MLC-2v transgenic mice," while exacerbating the
phenotype of aMyHC""'* animals suggests several possibilities. Alterations at
the sarcomere may either induce cardiomyopathy through fundamentally distinct
alterations in intracellular Ca** homeostasis, and/or these studies might have
suffered from the short-comings of the particular animal model investigated,
and/or the findings are related to calcineurin-unrelated effects of the drugs
investigated. Genetic approaches to inhibit calcineurin in these and other models
of FHC^6 may become helpful in answering these questions.
As a result of these uncertainties regarding momentous calcineurin
activation, a major experimental problem relates to the current assessment of
cardiac calcineurin activity. The calcineurin activity assay depends upon inclusion
of several phosphatase inhibitors to reduce background phosphatase activity
and enhance specificity, since different phosphatases besides calcineurin exist
in cardiac tissue. One required inhibitor (okadaic acid) also partially inhibits
calcineurin activity, leading to an inherent reduction of output. Furthermore,
calcineurin is subject to rapid oxidation in vitro, which underscores the notion
that calcineurin may be several folds more active in situ compared with purified
protein extracts. Thus, regardless whether the complicated technical aspects of
the assay are performed correctly, the relevance of the information it provides is
still questionable. Other assays are required to objectively monitor instantaneous
calcineurin activation in situ.
The identification of MCIP1, as part of a self-promoting negative feedback
loop of calcineurin biology, may provide an indirect readout of calcineurin
activation status. Before such an assay could be implemented, additional
investigation is required to assess whether MCIP1 is specifically induced upon
calcineurin (NFATc translocation) activation or whether it is a more general
marker of hypertrophy status. Another approach could be to use the intragenic
MCIP1 region, which contains an unusual dense cluster of NFAT consensus
binding sites," and link this to reporter genes to create transgenic models that
provide a constant readout of (myocardial) calcineurin activity. Alternatively,
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transgenic models with multimerized NFATc consensus binding sites linked to a
reporter output" may provide an alternative to monitor the temporal dynamics of
calcineurin activation during the progression of LV hypertrophy.
Studies on calcineurin involvement in failing human hearts further
underscored the complex pathobiology of calcineurin. Human hypertrophic
biopsies revealed that calcineurin activity (as measured by the enzymatic
assay) correlated well with absolute calcineurin Ap protein levels (as measured
by immunoblot analyses)." It appears that in addition to an acute increase in
enzymatic activity of pre-existing protein (Ca^ activation), activity may also
be subject to positive feedback mechanisms at the transcriptional and/or
translational level. Therefore, future calcineurin assays may simply become based
upon assessment of absolute myocardial calcineurin Ap protein levels.
Calcineurin and cardiomyocyte viability
Mitochondria occupy an unusual large fraction of intracellular volume
within adult cardiomyocytes. Multiple death signals impinge upon the
mitochondrial membrane potential, resulting in hallmark apoptotic events
such as loss of mitochondrial matrix components and activation of caspases.
Since cardiomyocytes are limited in their ability to enter the cell cylce reentry,
cummulative loss of single cardiomyocytes is regarded as a contributing factor
in the genesis of human heart failure." Given this, remarkably few studies have
assessed whether calcineurin activity may influence muscle cell viability.
To test whether programmed cell death may contribute to the rapid
transition from hypertrophy to overt heart failure in the calcineurin TG mice,
calcineurin adenoviral infected cardiomyocytes were tested for their viability.
Morphological analyses and TUNEL assays provided evidence that calcineurin
activtion afforded protection against 2-deoxyglucose and staurosporine-mediated
apoptosis. Moreover, endogenous calcineurin activation through PE stimulation"
resulted in substantial protected cardiomyocytes from apoptosis, and this effect
could be antagonized by targeted inhibition of calcineurin by adenoviral ACain
gene transfer." The mode of protection was found to be partially associated with
NFATc translocation and protein kinase B (Akt) activation. In support of these
findings in vitro, it was demonstrated that massively hypertrophic hearts from
adult calcineurin TG animals displayed a remarkable level of resistance against
ischemia/reperfusion-induced TUNEL laddering. Conversely, CsA treatment did
not render cardiomyocytes more vulnerable towards programmed cell death, not
even in the apoptosis prone Gqa-overexpressing, cardiomyopathic mouse model,
suggesting that endogenous calcineurin activation promotes cardiomyocyte
viability.'°° These findings were largely supported by a recent report from Kakita
and colleagues, who were able to demonstrate that ET-1 -mediated protection of
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cardiomyocyte apoptosis requires calcineurin activation, since CsA and FK506 >
negated ET-1-induced protection against apoptotic cell death and expression of
the anti-apoptotic factor Bcl-2.""
In contrast, Saito and co-workers demonstrated a 3-fold increase in
calcineurin enzymatic activity following isoproteronol exposure concomitant
with DNA fragmentation, while CsA and FK506 reversed this effect. TG animals
expressing a dominant-negative mutant of calcineurin in the heart were resistant
towards isoproteronol-induced cardiomyocyte apoptosis, suggesting that
calcineurin may act downstream of catecholamine-induced apoptosis.'"
Although these findings appear to be in contradiction with one another,
it is known that calcineurin can activate opposing pathways that either suppress
or induce apoptosis in the same cell type.'" Indeed, Saito et al. reported that
myocardial ischemia/reperfusion (oxidative stress) resulted in significantly more
cardiomyocyte apoptosis in their dominant negative-calcineurin TG model than
in wildtype littermates'", supporting the findings of the initial two reports.'""
Conclusively, it seems reasonable to hypothesize that calcineurin-induced
hypertrophy protects the heart from apoptotic death, depending upon the actual
death signal and (sub)cellular context. The precise molecular mechanisms behind
the anti-apoptotic properties of calcineurin are most complex and could well be
associated with the initiation of the hypertrophic response itself.'"*
Calcineurin and (human) heart failure
The vast majority of reports to date have remained focussed upon assessing
the involvement of calcineurin on the initiation and early progression phase of LV
hypertrophy. Although justified in view of the intimate relationship between LV
hypertrophy and progression of congestive heart failure, remarkably few studies
have directly addressed the more clinically relevant question whether altering the
balance of calcineurin activity directly alters the pathogenesis of (experimentally
induced) cardiac failure.
Current experimental efforts have been limited to the demonstration
that CsA prevents morphological remodeling in the tropomodulin or MLC-
2v overexpressing mice with dilated cardiomyopathy,"" and hemodynamic
recordings of the rescued phenotypes are still lacking. In light of recent
evidence that CsA has direct cardio-depressive actions on rabbit and human
cardiomyocytes,^ an assessment whether genetic calcineurin inhibition per se has
negative inotropic/lusitropic effects in these and other valuable murine models of
severe heart failure'"*"".
A recent study established the activation of calcineurin in biopsies
of patients with hypertrophy secondary to hypertension ("compensatory
hypertrophy") and patients with heart failure secondary to coronary artery disease
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or idiopathic DCM. One interesting feature of the study is that both increased
specific calcineurin activation and calcineurin Ap protein was evident in patients
with "compensatory hypertrophy", while calcineurin activation in the failing hearts
seemed to be due to only a relative increase in protein content. These findings
were supported by Lim and Molkentin, who reported increased can isoform
expression in the failing human heart."" In contrast, Tsao and colleagues reported
lower CnAp mRNA levels in human failing hearts, but the probe used was directed
against a minor splice isoform of gene of interest.'"
Due to their substantial extra-cardiac side-effects in humans, the use of
CsA or FK506 as treatment options for hypertrophic heart disease in patients is
doubtful. In fact, long term CsA treatment is associated with renal toxicity and
hypertension, which lead to cardiac hypertrophy in certain subjects. The concept
that CsA or FK506 may have direct pro-cardiohypertrophic properties in humans"*
(and calcineurin inhibition associated with myocardial growth) is incorrect. More
likely, systemic immunosuppression may induce hypertension in select subjects,
which influences myocardial growth secondarily. In addition, the dose of CsA and
FK506 required to prevent cardiac hypertrophy in experimental animals studies is
approximately 10-fold higher than used to achieve immunosupression in humans,
a phenomenon related to a higher myocardial calcineurin content, differential
tissue accessibility or the higher metabolic rate of small rodents.
Integrated signal transduction: calcineurin, crosstalk and
transcriptional events
Various reports suggest that multiple signaling networks play a role in
hypertrophic remodeling."' For example, altering the balance of myocardial
RSC4 expression, or cardiac introduction of a dominant inhibitory G^ peptide
or disruption of theJNK MAPK pathway have been demonstrated to impact on
hypertrophic remodeling. How is it possible that inhibition of separate signaling
networks can have such dramatic whole organ effects? Clearly, myocardial growth
is not regulated by the additive activation of signaling modules, but by a more
complex mechanism, involving the activation of multiple (intergrated) transduction
pathways.
One aspect that undoubtedly contributes to the integration of cardiac
signaling is the interdependence or crosstalk between parallel signaling
pathways. We have previously demonstrated that hearts from calcineurin TG
mice demonstrated robust JNK MAPK activation, and activation of several PKC
isoforms. Adenoviral expression of calcineurin resulted in marked hypertrophy
in cultured myocytes"'°°, and was prevented by JNK or PKC inhibition.*' Also,
CsA treatment of pressure overloaded rat hearts prevented PKCa, PKC6 and JNK
MAPK activation.^ Later studies supported this concept of interconnectiveness
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between calcineurin, PKC and MAPK factors," "* which coincide with the finding
that PKC6 and calcineurin synergize to activate theJNK MAPK pathway in control
of the interleukin-2 promoter in T-cells."* Collectively, these studies suggest the
existence of a conserved, interconnected, regulatory circuit between calcineurin,
PKC and JNK MAPK that controls myocardial growth, and it suggests that inhibition
of either component may abrogate the entire integrated cascade.*'
Some level of functional diversity and hierarchy among the multitude of
hypertrophic pathways may still be anticipated. Transgenic lines expressing a .
constitutively activated mutant of the ERK1/2 MAPK-selective activator MEK1
display a physiological form of hypertrophy with increased contractility parameters
throughout their complete life span,'"' while activation of another MAPK member,
ERK5, results in pure eccentric hypertrophy and heart failure."' Transgenic
overexpression of protein kinase Cpil (PKCpil) sufficed to result in juvenile lethality
and cardiac hypertrophy/failure in mice,"®but its targeted disruption failed to
significantly abrogate pressure overload-induced myocardial growth,'" suggesting
that certain networks are not a required component of the hypertrophic response.
Given the above notions and data from contemporary literature, how
should we define the role of calcineurin in cardiac hypertrophy? Given the
massive hypertrophic response in calcineurin (and CaMK) TG animals, the
overall success of CsA/FK506 studies to inhibit myocardial growth, and the
recent demonstration that genetic calcineurin inhibition strategies successfully
abrogate hypertrophic growth, it is difficult to dispute that calcineurin plays both
a sufficient as well as an indispensable role in transducing hypertrophic signals
following most pathophysiological stimuli. In addition, it seems reasonable
to assume that calcineurin may be a crucial factor especially during the early
phases of hypertrophic heart disease based upon the following notions. (1)
The rise in intracellular Ca^ in cardiomyocytes most probably constitutes an
early phenomenon during the LV hypertrophy response'*"'*' and (2) calcineurin
activation was observed predominantly in hearts from patients in a compensatory
hypertrophic phase and to a lesser extent in overtly failing patients."
A more fundamental aspect of calcineurin signaling involves the
contribution of downstream transcriptional effectors. NFATc4 (NFAT3) is still
viewed upon as the critically effector downstream of myocardial calcineurin
activation, based upon its ability to interact with GATA-4 and since NFATc4
TG animals display a massive hypertrophic phenotype." However, given the
overlapping expression patterns and redundant functions of single NFATc
isoforms in other cell types, it is conceivable that some level of NFATc isoform
redundancy may also exist in the heart. In that case, a simple genetic loss-of-
function approach for each NFATc isoforms may prove to be insufficient to
assess whether NFATc activity is the sole downstream transcriptional effector of
calcineurin, due to the co-existence of up to four cardiac NFATc family members
with largely overlapping functions. Recent evidence indeed suggests that at
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least NFATc 1 (NFATc) is also present in the ventricular myocyte, can associate
with CATA-4 and responds to calcineurin activation, in a manner analogous to
NFATc4. Dominant negative NFATc approaches that simultaneously abrogate
NFATc function may become useful to circumvent such complications as recently
demonstrated forT lymphocytes.'" Alternative downstream transcriptional
effectors may also be responsible for the nuclear events downstream of
calcineurin. Recent evidence implicates myocyte enhancing factor-2 (MEF-2),
nuclear factor-icB and Elk-1. " • ' "
Agonists
Ca**/CaM
Cell membrane
Sarcomaric dysfunction
RyR-»-._
C«MK Cslclneurin I
NFATc1-c4-©
GSK3P
Gene expression MCIP1 -
Figure 1.3. Contemporary model for (patho)physiological calcineurin signaling in the cardiac
myocyte. Several stimuli can trigger activation of calcineurin, among which intrinsic defects
of sarcomere function, multiple humoral factors (e.g. Angll, ET-1, LIF, PE), which directly or
indirectly (by transient Ca^ * release from SR stores through ryanodine sensitive receptors
(RyR) or through L-type Ca^ * channels (VLDC) in T-tubuli) elevate free cytosolic Ca *^. The
Ca^/calmodulin complex initiates parallel activation of intracellular signaling targets such as
Calmodulin activated protein kinase (CaMK) isoforms, calcineurin, myosin light chain kinase
(MLCK) or conventional protein kinase C (PKC) isoforms, each of which have been implicated
in cardiomyocyte hypertrophy. Calcineurin differentially alters the activation status of
certain members of the mitogen-activated protein kinase (MAPK) or PKC superfamilies,
most probably as a reinforcement of cellular signaling. Activated calcineurin may recognize
up to four nuclear factor of activated T-cell (NFAT) isoforms in the heart and, in addition,
increases myocyte-enhancing factor (MEF2) activation status to direct hypertrophic gene
expression remodeling. One particularly interesting genetic target of calcineurin is myocyte
enriched calcineurin interacting protein-1 (MCIP1), which acts as a myocyte specific
calcineurin inhibitor. Similarly, activition of glycogen synthase kinase 3p (GSK3p counteracts
the activation status of NFAT isoforms induced by calcineurin. Calcineurin also positively
influences the viability of cardiac muscle cells by effects on the mitochondrial permeability
transition (MPT) and anti-apoptotic processes, probably depending upon the actual death
signal. Finally, an underrepresented feature of calcineurin function concerns its localization.
It has been reported to localize either in the cytosol or nucleus, associated with specialized
anchoring proteins," in the vicinity of the sarcoplasmatic reticulum (SR) or close to
sarcomeres by its specialized docking protein calsarcin.'"
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Collectively, the present review provided an update on the role of = *>
calcineurin in the pathogenesis of cardiac hypertrophy. An emerging concept
indicates that interference with distinct hypertrophic signaling pathways may
significantly abrogate the LV hypertrophy response.'" Therefore, future efforts
in this field requires a further analyses to identify the key integrated cascades
through which maladaptive hypertrophic signals are channeled to achieve the
ultimate goal of a better treatment of heart failure. It appears that calcineurin
will continue to be the focus of ongoing research, providing us with a platform to
understand the complexity of Ca^/calmodulin signaling on cardiac morphology
and function.
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MCIP1 overexpression suppresses left ventricular
remodeling and sustains cardiac function
following myocardial infarction
Eva van Rooij, Pieter A. Doevendans, HarryJ.M.C. Crijns, Sylvia Heeneman,
Daniel J. Lips, Marc van Bilsen, R. Sanders Williams, Eric N. Olson,
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SUMMARY v- - K ; ^ " n :
Pathological remodeling of the left ventricle (LV) following myocardial
infarction (Ml) is a major cause of heart failure. Although cardiac hypertrophy
following increased loading conditions has been recognized as a clinical risk
factor for human heart failure, it is unknown whether post-MI hypertrophic
remodeling of the myocardium is beneficial for cardiac function over time,
nor which regulatory pathways play a crucial role in this process. To address
these questions, transgenic (TC) mice engineered to overexpress modulatory
calcineurin-interacting protein-1 (MCIP1) in the myocardium were used to achieve
cardiac-specific inhibition of calcineurin activation. MCIPI-TG mice and their
wildtype (WT) littermates, were subjected to Ml and analyzed four weeks later.
At 4 weeks after Ml, calcineurin was activated in the LV of WT mice, which was
significantly reduced in MCIPI-TG mice. WT mice displayed a 78% increase in LV
mass following Ml, which was reduced by 38% in MCIP-TG mice. Echocardiography
indicated marked LV dilation and loss of systolic function in WT-MI mice, whereas
TG-MI mice displayed a remarkable preservation of LV geometry and contractility,
a pronounced reduction in myofiber hypertrophy, collagen deposition and p-MyHC
expression compared to WT-MI mice. Together, these results reveal a protective
role for MCIP1 in the post-MI heart and suggest that calcineurin is a crucial
regulator of postinfarction-induced pathological LV remodeling. The improvement
in functional, structural and molecular abnormalities in MCIP1 -TG mice challenges
the adaptive value of post-MI hypertrophy of the remote myocardium.
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INTRODUCTION
Despite significant progress in the prevention and treatment of
cardiovascular disease in the United States in the past two decades, statistics
indicate that the incidence and prevalence of heart failure have been increasing
steadily, especially in the elderly. Chronic heart failure affects 4.8 million
Americans and is the leading cause of hospitalization for people aged 65 years
and over. Despite improved medical treatment and intense investigation, heart
failure is a leading cause of morbidity and mortality in industrial countries.'•*
A fundamental shift in the underlying etiology of heart failure is becoming
evident, in which the most common cause of chronic heart failure is no longer
hypertension or valvular disease, but rather coronary artery disease (CAD) and
long term survival after myocardial infarction (Ml).' Unfortunately, the prognosis
of patients with heart failure and CAD is considerably worse compared to heart
failure without CAD.' Ml induces scar formation and global changes in surviving
myocardium, designated post-MI ventricular remodeling. This process consists of
an initial wall thinning of the infarcted area, ventricular chamber dilation, side-to-
side slippage and eccentric myocyte hypertrophy of the individual myofibers in
the noninfarcted (remote) portion of the myocardium.' In spite of clinical evidence
that the postinfarcted heart often progressively dilates and displays accelerated
deterioration of left ventricular function, the early hypertrophic remodeling of the
viable portion of the left ventricle (LV) following ischemic damage is considered an
adaptive response that compensates for the acute loss of functional myocardium,
hence preserving cardiac performance."
Sustained cardiac hypertrophy has been recognized as the single most
important risk factor for heart failure development, at least in conditions with
increased load such as chronic hypertension or valvular disease, and a powerful
predictor for cardiovascular morbidity and mortality.' One signaling pathway
that links extracellular stimuli to a hypertrophic transcriptional response of
the myocyte employs the Ca**-calmodulin-dependent phosphatase calcineurin
and its downstream transcriptional effector Nuclear Factor of Activated T-cells
(NFAT).">•' Pressure overload hypertrophy studies using genetic mouse models
that prevent calcineurin-NFAT activation have confirmed its crucial role in this
form of hypertrophic remodeling.*" Whether calcineurin is involved in myocyte
hypertrophy post-MI, or whether inhibition of this type of hypertrophic remodeling
may have therapeutic potential, remains uncertain. To address these questions, we
pursued a genetic approach to evaluate the functional significance of calcineurin
in post-MI cardiac remodeling, using a genetic mouse model with mild myocyte-
restricted overexpression of MCIP1, which was previously shown to efficiently
antagonize cardiac hypertrophy in response to an activated calcineurin transgene,
following pressure overload or |Vadrenergic stimulation.'"•'* Accordingly, MCIP1-
TC mice and their wildtype littermates were randomized to receive either a large
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transmural LV infarct or sham operation. We confirmed increased calcineurin **:-i
activation and substantial hypertrophy in the LV four weeks after Ml in WT mice,
while TG mice were protected against both endpoints. Remarkably, MCIP1-TC
mice also demonstrated preservation of LV geometry and contractility, improved
survival, a diminution of p-MyHC expression, and a pronounced reduction in
interstitial collagen deposition in the remote myocardium. These findings suggest
that calcineurin activation is crucial for maladaptive post-MI remodeling.
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EXPERIMENTAL PROCEDURES
Animals and surgical procedures
All protocols were approved by institutional guidelines. All surgeries and
subsequent analyses were performed in a blinded fashion for genotype. Eight-
week old mice from both sexes carrying the human MCIP1 transgene under the
control of the aMyHC promoter (an order of magnitude overexpression of MCIP1
at the mRNA level) in a C57BL/6 background (TG)'° and their non-transgenic
littermates (WT) were anesthetized with 2.4% isoflurane and placed in a supine
position on a heating pad (37*C). Animals were intubated ventilated with room
air using a MiniVent mouse ventilator (Hugo Sachs Elektronik, Germany; stroke
volume 250 ul, respiratory rate 210 breaths per minute). Ml was induced by
permanent ligation of the left coronary artery (LCA) with a 6-0 prolene suture.
Occlusion of the LCA was confirmed under a dissecting microscope (Olympus
SZ30, Japan) by discoloration of the ischemic area. Sham operated animals
underwent the same procedure without occlusion of the LCA.
Transthoracic echocardiography
Three days and four weeks following Ml, the mice were re-anesthetized
with 2.4% isoflurane and placed on a heating pad (37'C). Echocardiography was
performed using a Sonos 5500 ultrasound machine (Hewlett-Packard) with a
1 2 MHz transducer applied parasternally to the shaved chest wall. For optimal
resolution, the transducer was covered with a surgical latex finger filled with
ultrasound transmission gel to obtain a standoff of 0.5-0.7 cm and used at a
depth setting of 2 cm. The transducer was maneuvered to obtain both live 2-
dimensional images in a parasternal long-axis and short axis view and 2D guided
M-mode tracings crossing the anterior wall, LV cavity and posterior wall. Images
were analyzed offline using EnConcert Image Diagnosis Application (Philips,
Netherlands). All parameters were averaged from 4 cardiac cycles.
Invasive pressure measurement
After the animals were anesthetized with urethane, a 1.4F high-fidelity
micromanometer catheter (Millar Instruments) was introduced into the right
carotid artery, advanced into the left ventricle, and pressure measurements were
performed as described previously.'*
Northern blot analysis
Northern blot analysis for MCIP1 was performed with 20 ug of total RNA
in each lane and probed in Ultrahyb (Ambion, Austin, TX) with a "p-|abeled DNA
fragment encompassing the exon 4, 5' splice variant of murine MCIP1 (Radprime,
Invitrogen). Northern blot analysis for ANF, (3-MyHC and 1 8S was performed as
previously described.''' Signals were detected using a phosphor imaging screen
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(Biorad), and quantified with Quantity 1 software (Biorad). * ' ••
Immunoprecipitation and Western blot analysis
To detect LV calcineurin Ap abundance, 500 ug LV extract was -
immunoprecipitated with a pan-calcineurin A subunit antibody (AB1695,
Chemicon), and probed with an anti-calcineurin Ap antibody (sc-61 24, Santa
Cruz). To analyze the phosphorylation status of NFAT, 500 ug of LV protein
extract was immunoprecipitated with either anti-NFATcl (sc-1 3033, Santa
Cruz) or anti-NFATc3 (sc-8321, Santa Cruz), and Western blotted with an anti-
phospho-serine antibody (61 -8100, Zymed). Immunoreactivity was detected with
Chemiluminescence (ECL, Amersham Pharmacia Biotech).
Calcineurin activity assay
Phosphatase activity was measured using the calcineurin (PP2B) Assay
kit (cat # 20700, Calbiochem) according to the manufacturer's instructions.
Calcineurin activity was measured as the dephosphorylation rate of a synthetic
phoshopeptide substrate (Rll peptide).
Histological analysis
Four weeks after Ml all animals were anesthetized, the hearts were arrested
in diastole and perfused antegradely at physiologic pressures with PBS containing
1 mg/ml sodium nitroprusside and 5% formalin. Heart tissue was fixed in 3.7%
formaldehyde, cut either (1) longitudinally and perpendicular to the infarcted area
and aortic root, or (2) transversally, and embedded in paraffin. Four urn sections
were cut and stained with AZAN, laminin, haematoxylin and eosin (H&E), or Sirius
red.'^ Longitudal AZAN stained sections were used to determine infarct size. A
computerized morphometric system (Quantimet 570, Leica, The Netherlands)
was utilized to calculate the percentage infarcted tissue of total left ventricular
tissue. Laminin and Sirius red stained sections were used to determine myocyte
hypertrophy or to visualize interstitial/perivascular collagen amount, respectively.
Myocyte fiber size was assessed by digital surface measurement of approximately
300 cells per animal in 4-6 animals per group. Only myofibers with a centrally
positioned nucleus were included. The amount of collagen was determined as
the percentage of left ventricular tissue stained positive for Sirius red. Since the
presence of collagen was more intense towards the apex, measurements were
presented for both the whole septum and the apical halve of the septal wall.
Statistical Analysis
The results are presented as means ± SEM. Statistical analyses were
performed by using INSTAT 3.0 software (CraphPad, San Diego) and ANOVA
followed by Tukey's post-test when appropriate. Statistical significance was
accepted at a P value < 0.05.
THE CALCINEURIN/NFAT PATHWAY | page 53
RESULTS
MCIP1 overexpression attenuates postinfarction-induced calcineurin
activation A
After Ml, the heart
undergoes an adaptive response that is
accompanied by eccentric hypertrophy
of the noninfarcted myocardium.
Although calcineurin is activated
and intimately involved in pressure
overload-induced hypertrophy,®''^^
it is uncertain whether calcineurin is
also activated during postinfarction
remodeling.
To explore this, calcineurin
(PP2B) activity was first measured as the
dephosphorylation rate of a synthetic
phosphopeptide substrate. Calcineurin
activity was elevated by 35% in the
remote myocardium of WT-MI mice (P
< 0.05). In contrast, total calcineurin
activity was decreased in TC-MI hearts
by 26% compared to WT-MI (Figure
2.1A).
nmol PO« 1 •'
released j Q .
0.8 .
0.6 .
0.4.
sham Ml
H wild type
Q MCIP1 transgenic
Fig. 2.1 A Cardiac extracts for the
indicated groups were assayed for Cn
activity, expressed as nmol released
phosphate. MCIP1 transgenic mice
displayed lower Cn activity both
under basal conditions and following
infarction. Data are expressed as
means ± SEM from n = 3-5 animals per
group. • P <0.05 vs. sham operated
group, # P < 0.05 vs. WT-MI group.
LV calcineurin AB abundance has previously been shown to correlate with
LV PP2B activity." Calcineurin Ap immunoreactivity was increased by 1 9% in WT-
MI compared to the corresponding sham group (P < 0.05), while this increase
amounted to only 6% TC-MI animals (N.S.; Figure 2.1 B).
B
WT TC
sham sham WT Ml
positive
TC Ml control
CnAp
Fig. 2.1 B Representative Western blot demonstrating CnAp expression for indicated groups.
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Since activated calcineurin dephosphorylates members of the NFAT t
family, which in turn drive expression of the MCIP1 exon 4 splice isoform via
an upstream cluster of NFAT binding sites,'* the phosphorylation status of two
cardiac NFAT members and expression level of the MCIP1 exon 4 splice isoforms
was determined. As expected, endogenous NFATcl and NFATc3 was found to be
in a hyperphosphorylated state in both sham groups, consistent with relatively
low calcineurin activity. In contrast, the levels of both phospho-NFATcl as well
as NFATc3 decreased by 51% and 1 6% (P < 0.05) in WT-MI mice, respectively,
consistent with relatively higher endogenous PP2B activity. In contrast, the levels
of phosphorylated NFATcl and NFATc3 in TC-MI mice revealed a less pronounced
decrease by 1 6% (P < 0.05) and 1% (N.S.), respectively (Figure 2.1C), suggestive of
calcineurin inhibition.
Fig. 2.1 C Representative
Western blot using an
antibody against phospho-
serine for the level of
hyperphosphorylated
NFATcl and NFATc3. The
data demonstrate decreased
phospho-NFAT levels following
Ml in wildtype mice, while
MCIP1 transgenic mice have
less pronounced decreases
in phospho-NFAT levels
compared to corresponding
sham group.
WT TC
sham sham WTMI TCMI
NFATcl
NFATc3
Expression of the MCIP1 exon 4 isoform provides an additional indication of
myocardial calcineurin activity in vivo (see discussion). The MCIP1 exon 4 specific
probe was designed to the untranslated 5' region of the endogenous mouse 2.2
kb mRNA, and therefore does not detect transcripts from the MCIP1 transgene.
Northern blot analysis indicated an approximate 9-fold induction of the 5' exon
4 splice variant of MCIP1 expression after Ml in WT hearts, while in TC-MI hearts,
only a 2-fold induction was observed (Figure 2.1 D and discussion). Collectively,
these results indicate that calcineurin is activated in the LV following Ml, and that
MCIP1 overexpression efficiently counteracts the activation characteristics of
cardiac calcineurin
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Fig. 2.1 D Representative Northern blot using a probe specific
for the exon 4 splice variant of murine MCIP1 on LV tissue
demonstrates significantly increased expression after Ml in
WT mice compared to sham operated animals. As a control
for loading a probe for 18S ribosomal RNA was used. Data are
expressed means + SEM from n = 4-7 animals per group. • P
<0.05 vs. sham operated group, # P < 0.05 vs. WT-MI group.
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MCIP1 overexpression attenuates LV hypertrophy after Ml
No significant difference in infarct size was observed between MCIPI-TC
animals and their non-transgenic littermates (WT-MI 41 ± 3% vs. TG-MI 38 ± 4%:
Figure 2.2A).
A more prominent increase in the HW/BW ratio was observed in the WT-MI
group (48%) compared to MCIPI-TC Ml mice (24%; P < 0.05). The hypertrophic
remodeling was more pronounced in the LV and this was reflected in LVW/BW
and LVW/TL ratios, which both showed a 77% and 78% increase WT-MI mice, and
only a 36% and 41% increase in the MCIP1 -TC groups, respectively (Table 2.1 and
Figure 2.2B).
B
percentage
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area LV X
50 -.
40 -
3 0 -
2 0 -
1 0 -
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wildtype
MCIP1 transgenic
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sham Ml sham Ml
Fig. 2.2AB (A) Morphometric
analyses of AZAN sections
indicate no significant
difference in infarct size
between the wildtype and
MCIP1 transgenic mice (n = 6
in both groups). (B) After Ml an
increase in LVW in the wildtype
mice is evident (n = 10), which
is significantly blunted in the
MCIP1 transgenic mice (n = 12).
* P <0.05 vs. sham operated
group, # P < 0.05 vs. WT-MI
group.
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Measurement of septal wall thickness in histological sections further supported
these findings (WT-MI 1.1 ±0.1 mm vs. TG-MI 0.8 ± 0.2 mm; P < 0.05). „,«
Interestingly, in both genotypes females exhibited less pronounced hypertrophy
than their male littermates (data not shown). Atrial weight (AW) and right
ventricular weight (RVW) increased to a similar extent in both WT-MI and MCIP1 -TC
animals (Table 2.1).
Laminin-staining demonstrated an 81 ± 2% increase of the cross sectional
area of myocytes in the spared myocardium in the WT-MI group, while TC-MI mice
only demonstrated a 29 ± 7% increase relative to corresponding, noninfarcted,
control groups (Figure 2.2C). Conclusively, these findings indicate that MCIP1
overexpression protects the myocardium against postinfarction hypertrophy.
wildtype
Ml
MCIP1
transgenic wildtype
MCIP1 transgenic
Cross sectional
area um'
Fig. 2.2C Laminin staining reveals a significant increase in
cardiomyocyte size after Ml compared to the sham operated
animals, which is more pronounced in wildtype animals
compared to MCIP1 transgenic animals (n = 4 in both sham
groups, n = 6 in both Ml groups). Bar represents 0.1 mm.
Quantification of cross sectional area of myofibers from
indicated groups show significant attenuation of myocyte
hypertrophy in MCIP1 transgenic mice. * P <0.05 vs. sham
operated group, # P < 0.05 vs. WT-MI group.-Full colour
image page 177
Sham
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Table 2.1.
Morphological characteristics in wlldtype and MClPI TC mice after sham operation and 4 weeks after myocardial infarct
n
HW, mg
LVW, mg
RVW, mg
Lung weight, mg
Liver weight, mg
Atria weight, mg
TL, mm
•W.g
HW/BW, mg/g
HW/TL. mg/mm
sham
WT
13
114 ± 2
77±2
19.5 ± 2
150 ± 4
909 ±33
10.9 ±0.8
21.5 ± 0.1
23.8 ±0.7
4.8 ±0.1
5.3 ±0.1
TC
12
112 ±4
76 ± 5
21.8±3
153*3
880 ± 34
10.5 ±0.5
21.9 ±0.2
22.9 ±0.4
4.9 ±0.1
5.1 ±0.1
myocardial infarction
WT
10
169.6 ±9"
137 ±10*
28.1 ±2*
162 ± 5
1042 ± 50
15.7 ± 2.2
21.5 ±0.2
23.9 ± 1.0
7.1 ±0.4*
7.9 ±0.5*
TC
12
143.7 ± 5*t
106 ± 6*t
27.3 ±3
152 ±4
981.5 ±49
15.9± 1.4
21.7 ± 0.1
23.5 ±0.6
6.1 ±0.3*t
6.6±0.3*t
% change
tg vs. wt
4 weeks post-Mi
•20.5
•38.5
-18.8
N.S.
N.S.
N.S.
N.S.
N.S.
•23.4
•19.7
Data are expressed as means ± SEM. TC, transgenic; HW, heart weight; LVW, left ventricular weight:
RVW, right ventricular weight; TL, tibial length; BW, body weight.
* Indicates P<0.05 vs corresponding sham group; t indicates P<0.05 vs wlldtype postinfarctlon group.
Preservation of cardiac geometry and function in MClPI TG mice after Ml
To examine the impact of MClPI -mediated attenuation of postinfarction
hypertrophy on hemodynamic behavior, all groups were subjected to 2D and M-
mode echocardiography three days and four weeks after Ml, since hypertrophic
remodeling in mice starts three days after the ligation of the coronary artery."
Representative images of M-mode recordings are shown in Figure 2.3A. Already
3 days after infarct, an increase in LVID and decrease in contractility was evident
in both Ml groups compared to sham operated animals, with no functional or
geometric differences between WT-MI and TG-MI (Table 2.2). In contrast, four
weeks after Ml, a thickening of the posterior wall in diastole (PWthd) and a further
increase in LVID was visible in WT-MI mice, suggestive of progressive LV dilation
(Table 2.2). These geometric changes were accompanied by a further functional
deterioration in WT-MI mice as indicated by progressive decreases in fractional
shortening (FS) and ejection fraction (EF) compared to the corresponding sham
group (Figure 3B). The presence of the MClPI transgene resulted in a significant
reduction of PWthd and LVID in response to Ml, and a preservation of FS (Table 2.2
and Figure 2.3B) and EF (Table 2.2).
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sham Ml sham Ml
Q MCIPI transgenic
Fig. 2.3AB Preservation of cardiac function in MCIPI transgenic mice after Ml. (A)
Representative M-mode images of sham or infarcted wildtype and MCIPI transgenic mice 3
days and 4 weeks after Ml. Data demonstrate comparable initial LV dilation in both groups,
with progressive dilation and loss of contractile behaviour in wildtype mice, which was
substantially attenuated in MCIPI transgenic mice. (B) Bargraph representation of FS, LVIDs,
and PWthd indicate that the presence of the MCIPI transgene attenuates functional and
morphological deterioration after Ml (n = 5 in both sham groups; n = 7-8 in Ml groups). • P
<0.05 vs. sham operated group, # P < 0.05 vs. WT-MI group.
To further evaluate the hemodynamic profile of all experimental groups,
invasive pressure measurements were performed. A relatively lower systolic
baseline function was observed in sham-TC compared to sham-WT mice (Table
2.3). At present we have no explanations for this difference. More importantly,
the response of both genotypes to Ml was clearly different. In the WT-MI group a
dramatic decrease in LV dP/dt^, LV dP/dt^, LVESP and LVDP was observed (P <
0.05). In contrast, TC-MI mice showed a marked preservation of these parameters,
and this level of preservation correlates well with the echocardiographic
observations (Table 2.2 and Figure 2.3).
Taken together, these results indicate that MCIPI overexpression
specifically alters the late phase of post-MI remodeling rather than the acute
response to the infarct itself, and efficiently counteracts the geometric and
functional deterioration after Ml.
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Table 2.2.
Echocardlographlcal characteristics in wlldtype and MCIP1 TC mice after sham operation and after myocardial infarction.
n
HR
PWthd
PWths,
LVIDd,
LVIDs.
%EF
XFS
, mm
mm
mm
mm
sham
WT
7
400 ± IS
0.68 ± 0.05
1.39 ± 0.07
3.52 ±0.12
1.68 I 0.08
62.75 1 2.3
52.2 12.0
TC
8
402 I 1 7
0.67 t 0.06
1.29 10.06
3.21 ±0.07
1.52 10.04
58 S 12.8
52.6 1 1.4
3 days after Ml
WT
7
388 1 12
0.73 10.05
1.31 10.03
4.44 i 0.1 3*
3.11 x 0 . l l '
35.5 l 3 . 4 -
29.3 ± 1.4-
TC
6
390 1 15
0.73 l 0.02
1.28 t 0.07
4 .34 i 0.1 3*
3.10x0.10'
32.5 11.5-
29.7 t l . 3 -
4 wki after Ml
WT
12
406 ± 11
1.09 t 0.08'
1.50x0.18
5.56 l 0.14'
4.3610.12'
26.0 i 2.5"
21.6 i 2.3"
TC
11
401 ±12
0.82 ± 0.04t
1.3010.07
4.69 1 0.24-t .
2.981 0.12't
36.3l4.8U
36.9ll.8-f
« change
IS vi »t
3 days post-MI
N.S.
N.S.
N.S.
N.S.
N.S.
N.S.
N.S.
« change
tg vv wt
4 weeks poll Ml
N.S.
-38
N.S.
12
• 6 4
21
29
Data are expressed as means ± SEM, Tg, transgenic; PWthd, posterior wall thickness in diastole. PWths, posterior wall thickness in systole;
LVIDd, left ventricular internal diameter in diastole; LVIDs, left ventricular internal diameter in systole;
FS. left ventricular fractional shorteninq calculated as (LVIDd-LVIDs>/LVIDd
EF, left ventricular ejection fraction
* indicates P<O.OS vs corresponding sham group; t indicates P<0.05 vs wildtype 4 weeks postinfarction group.
Table 2.3.
Hemodynamk characteristics in wildtype and MCIP1 TC mice after sham operation or myocardial infarction.
n
LVdP/dt™,. mmHg.s l
LVdP/d t™,mmHg.s l
LVDP, mmHg
LVESP
LVEDP
wildtype
sham
4
9.338 ±481
•6,645 ± 672
93.5 ±4 .9
94.6 ± 5.3
1.1 ± 1.0
Ml
5
6,202 l 903
-4,681 ± 5 1 7
72.9 ±4 .7
76.9 ±4 .3
4.1 ± 1.5
K change
vs. corresp.
sham group
• 3 4
•30
•22
•19
372
MCIPI transgenic
sham
5
5.524 ± 886
-5.128 ± 651
66.4 ± 6.2
67.1 ±6.1
0.8 ±0.3
Ml
6
5.402 ± 830
•4,832 ± 630
66.2 ± 5.8
67.3 ± 6.0
3.1 ±0.6
X change
w corresp.
lham group
• 2
6
0
0
388
Data are expressed as means ± SEM. LV dP/dt^,,, first maximal derivative of left ventricular pressure;
LV dP/du,,,, first minimal derivative of left ventricular pressure; LVDP, left ventricular developed pressure;
LVESP, left ventricular end systolic pressure; LVEDP, left ventricular end diastolic pressure
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Overexpression of MCIP1 improves survival after myocardial infarction
The survival rates of WT and MCIP1 -
TG mice were evaluated up to 4 weeks
after Ml. The survival of WT-MI mice was
89% and 61% at 1 and 4 weeks after
surgery, while MCIP1 -TG Ml mice displayed
a survival of 90% and 79%, respectively
(Figure 2.3C). Differences in survival
became evident in the last 3 weeks before
sacrifice (Figure 2.3C), and was more
pronounced in male littermates (data not
shown). These observations correlate well
with the fact that infarct sizes were equal
in both groups, and that infarct healing is
completed within 7 days after Ml in mice."
The combined observations suggest that
MCIP1 overexpression has no influence on
the early process of infarct healing, but
attenuates hypertrophic LV remodeling
that starts ~ 3-7 days after Ml in mice,
and improves postinfarction survival.
c
Survival 100
1 2 3
Weeks after Ml
Fig. 2.3C Early post-MI mortality was
comparable between wildtype and
transgenic mice subjected to Ml, but
became significantly higher for wildtype
mice in the last three weeks before
sacrifice (WT-MI, n = 51; TC-MI, n = 43).
Attenuated interstitial collagen deposition after calcineurin inhibition in Ml
H&E staining confirmed the presence of extensive myofiber hypertrophy
and disarray in WT-MI mice (Figure 2.4A), accompanied by a patchy presence
of cellular infiltrates in the interstitial compartment (indicated by arrowheads).
These histological alterations in response to infarction were nearly absent in TG-
Ml hearts similar to both sham operated groups (Figure 2.4A). In the noninfarcted
area, reactive fibrosis, such as perivascular and interstitial fibrosis, was observed
in a gradient with more pronounced presence of collagen deposition towards the
infarct. WT-MI mice exhibited the most severe fibrotic alterations, both expressed
as percentage of the complete septum (10%) as well as the lower apical half of
the septal wall (16%), and this was substantially attenuated in MCIP1-TG Ml mice
(Figure 2.4B). These results indicate that the presence of the MCIP1 transgene
led to a significant reduction of the major structural alterations of the remote
myocardium in the postinfarcted heart.
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B Whole septum Apical half septum
percentage 30 -,
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sham Ml sham Ml
Fig. 2.4AB MCIP1 transgenic animals are protected against Ml-induced structural
remodeling. (A) Representative images of histological staining for the indicated groups.
Upper panels are H&E stained images, lower panels Sirius red stained images (Bar indicates
0.1 mm). H&E stained images reveal remarkable myocyte hypertrophy, myofiber disarray
and cellular infiltrates (arrowheads) in a section from a representative postinfarcted wildtype
mouse. In contrast MCIP1 transgenic mice are largely protected against these structural
alterations. Sirius red staining indicates low levels of collagen deposition in the sham
operated mouse hearts from both phenotypes, a massive accumulation of fibrillar collagen
(interstitial and perivascular fibrosis) after infarction in wildtype mice, which is substantially
attenuated in MCIP1 transgenic mice. -Full colour image page 180 (B) Tissue content
of fibrillar collagen in septum (remote myocardium) is significantly more upregulated in
wildtype animals than in MCIP1 transgenic mice, a difference that is even more pronounced
in the lower half of the septal wall (n = 2 in both sham groups; n = 6 in both Ml groups).
* P <0.05 vs. sham operated group, # P < 0.05 vs. WT-MI group.
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Cardiac gene expression in infarcted hearts with calcineurin inhibition ?IO
We examined the gene expression profile of genes activated during
postinfarction hypertrophy. At 4 weeks after Ml an induction of both ANF and
p-MyHC was observed in WT-MI hearts relative to corresponding sham operated
mice, indicating the activation of a "fetal cardiac gene program". ANF expression
was similar in both TC-MI and WT-MI hearts. In contrast, the induction of p-MyHC
expression was significantly blunted in TG-MI hearts compared to WT-MI hearts
(Figure 2.5). These results indicate that the transcriptional response of the MCIPI
transgenic animals is different than that of wildtype animals during Ml-induced LV
remodeling.
WT TC
sham sham
WT Ml TC Ml
ANF
P-MyHC
18S
Fold Increase
In expression
p-MyHC ANF
4
2
0
8
6
4 .
2
0
1
#
Fold increase
In expression
wildtype
MCIPI transgenic
sham Ml sham Ml
Fig. 2.5AB Ml-induced fetal gene expression is differentially affected by MCIPI
overexpression.
(A) Representative Northern blot for ANF (upper panels), p-MyHC (middle panel) and 18S
ribosomal RNA from indicated experimental groups. Data indicate strong upregulation of
ANF and |5-MyHC following infarction in wildtype mice, and lower p-MyHC expression in
postinfarcted transgenic animals. (B) Quantification of Northern blot analyses indicates
significant upregulation of ANF and p-MyHC gene expression after Ml in wildtype mice. Only
Ml-evoked elevation of p-MyHC is significantly blunted in the MCIPI transgenic mice. * P
<0.05 vs. sham operated group, # P < 0.05 vs. WT-MI group.
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DISCUSSION WHH i r
Suppression of postinfarction hypertrophic remodeling by MCIP1
The involvement of calcineurin as a transducer of pro-hypertrophic signals
in the heart has gradually gained more acceptance. The use of genetically
modified mice with reduced or enhanced calcineurin activity in the heart has
confirmed the pathological role of this enzyme in cardiac muscle cell biology.*
n.16.20 Most studies, however, have focused on the function of calcineurin in
hypertrophy development following acute increases in loading conditions (e.g.
aortic banding procedures) or agonist infusion protocols. The potential role of
calcineurin in LV remodeling following ischemic loss of functional myocardium has
remained ill defined. In view of the increasing proportion of heart failure patients
with coronary artery disease as a primary etiology, ' elucidation of the regulatory
pathways controlling postinfarction remodeling will have both fundamental and
therapeutic avenues.
Preceding the present study, three groups have used rat models of
myocardial infarction (Ml) in combination with systemic delivery of the calcineurin
inhibitor cyclosporine A (CsA) to address the role of calcineurin in post-MI
remodeling. All three groups found a correlation between CsA administration
and reduced postinfarct hypertrophy.*'" CsA toxicity and potential calcineurin-
independent effects of CsA can confound interpretation of these studies.*° Our
findings from the present study using MCIP1 transgenic mice are in agreement
with the rat studies insofar as the attenuation of hypertrophy is concerned.
However, in contrast to some of the CsA studies, long term prognosis of the
MCIP1 transgenics is improved compared to wildtype rather than in the CsA
treated rats which showed a more rapid progression toward heart failure. The
MCIP1 -TG mice allowed us to achieve cardiac-specific inhibition of calcineurin
without the concern of secondary drug effects or systemic toxicity."
Quantification of calcineurin phosphatase activity from tissue lysates using
biochemical assays is problematic, due to the dynamic, calcium/calmodulin-
dependent regulation of activity, the sensitivity of calcineurin to oxidation of
the Fe-Zn active center, and does not reflect the proportion of the enzymatic
calcineurin pool that is actually in an active state. We could detect both increased
phosphatase activity and more abundant presence of the calcineurin Ap isoform
following Ml in wildtype mice. We also used the phosphorylation status of
endogenous NFATand expression levels of the NFAT-responsive exon 4 splice
variant of MCIP1 as criteria to monitor calcineurin activity.'° These assays were in
line with increased calcineurin activation in the postinfarcted heart. The present
study confirms the earlier documented calcineurin activation profile in the
postinfarcted LV, but our interpretation of its value in LV remodeling differs in
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several respects from other studies.
Postinfarction hypertrophy is matadaptive in nature
Myocardial hypertrophy is traditionally viewed as a long-term adaptive
response of the cardiac muscle to either altered mechanical loading conditions
(e.g. resulting from valvular disease or hypertension) or decreased performance
due to loss of contractile units (e.g. after Ml)." Following this interpretation,
increased wall thickness serves as the means to restore wall stress in line with the
law of Laplace." Recent insights into the particulars of the hypertrophic phenotype,
however, have demanded a more nuanced interpretation of this phenomenon of
"compensatory hypertrophy". First, ventricular hypertrophy is demonstrably a risk
factor for cardiovascular mortality in humans.' Second, beyond just increased
mass, the specific long-term transcriptional responses to increased load entail a
myriad of quantitative and qualitative changes in cardiac gene expression that are
reminiscent of fetal cardiac myocytes. In patients with cardiac failure, functional
improvement related to treatment with p-blockers is correlated with beneficial
changes in myocardial gene expression, most prominently exemplified by a
correction in the mRNA expression level of the (3-MyHC gene.*" In the present
study we also noted a pronounced decrease in p-MyHC gene expression and
no relative change in ANF expression in infarcted transgenic mice compared to
their wildtype counterparts (Figure 2.5). Of note, in the original description of
MCIP1 overexpressing mice '° this divergence between ANF vs p-MyHC fetal gene
expression was also evident. ANF and its receptor have been reported to possess
potent antihypertrophic activity " • " , while recombinant human BNP has been
shown to improve decompensated congestive heart failure in patients " . It will
become of interest to investigate the specific contribution of natriuretic peptides
in the calcineurin-NFAT axis. Conclusively, Laplace's Law, although conceptually
sound, does not take into account any qualitative alterations of the wall, and only
incompletely explains the phenotypic particulars of heart enlargement.
Third, several studies using genetically engineered mice with markedly
blunted growth responses to pressure overload appear to be protected from
adverse effects of stress signaling and heart failure progression.'*" In fact,
Esposito et al. subjected normal and hypertrophy resistant mice to aortic
constriction and observed that hemodynamic function and overall cardiac
geometries were better preserved in hypertrophy-resistant mice than in wildtype
mice, despite the inability of the transgenic mice to correct wall stress.** Hence,
the value of normalizing wall stress through hypertrophic myocardial growth is
dispensable for the preservation of cardiac function in the face of a long-term
hemodynamic burden.*' The findings in the present study fortify the conclusions
that postinfarction-, and load-induced reactive signaling and hypertrophic
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remodeling share fundamental similarities and may be equally deleterious in
nature." One outspoken observation in postinfarcted MCIPI overexpressing mice
was their marked inhibition of interstitial collagen deposition. It is important to
note, that the MCIPI transgene is targeted exclusively to the cardiac muscle cell
population, which suggests a crucial role and hierarchy for the cardiomyocyte
population in governing cardiac fibroblast proliferation and collagen production
through paracrine regulation of latter cell type.
Dual roles of MCIPI in calcineurin signaling
While we interpret the protective effects of MCIPI on post-MI cardiac
pathology to reflect the reduction in calcineurin activity in the hearts of MCIPI-
TC mice, it should also be noted that our recent studies have revealed positive
and negative effects of MCIPI on calcineurin activity. It is clear that high levels of
MCIPI expression can inhibit calcineurin activity through direct association with
the catalytic subunit of the enzyme. Paradoxically, however, MCIPI knockout mice,
which are viable, show a reduction in cardiac calcineurin activity and a diminished
hypertrophic response to pressure overload and chronic adrenergic stimulation.'"
We have attributed the latter findings to a permissive role of MCIPI in activation
of calcineurin, possibly via a chaperone or protein folding function of MCIPI. It
is also formally possible that MCIPI evokes activities through cellular effectors
in addition to calcineurin. Further confirmation of the precise roles of MCIPI and
calcineurin in post-MI hypertrophy and remodeling will be provided by studies of
these processes in calcineurin-TC mice and in knockout mice lacking calcineurin
and MCIPI.
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Chapter 3
Requirement of Nuclear Factor of Activated T-cells
in calcineurin mediated
cardiomyocyte hypertrophy
Eva van Rooij, Pieter A. Doevendans, Chiel C. de Theije, Fawzi A. Babiker,
Jeffery D. Molkentin and Leon J. De Windt
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SUMMARY . • •••-;•- <t*r* : « O ; T > - C , . > ^ ' < '
The calcium-activated phosphatase calcineurin has been implicated as
critical intracellular signal transducer of cardiomyocyte hypertrophy. Although
previous data suggested nuclear factor of activated T cell (NFAT) as it's sole
transcriptional effector, the absolute requirement of NFAT as a mediator ;
of calcineurin signaling has not been examined in the heart. We therefore
investigated the expression and activation profile of NFAT genes in the heart.
Four members (NFATcl-c4) are expressed in cardiomyocytes, elicit nuclear
translocation upon calcineurin activation, and are able to drive transactivation
of cardiac promoter luciferase constructs. To define the necessary function of
NFAT factors as hypertrophic transducers, a dominant negative NFAT construct
was created, encompassing part of the N-terminal region of NFATc4 containing
a conserved calcineurin-binding motif. Cotransfection of this construct dose-
dependently abrogated promoter activation, irrespective of the NFAT isoform
used, while a control construct with the calcineurin-binding motif mutated
displayed no such effects. Adenoviral gene transfer of dominant negative NFAT
rendered cardiomyocytes resistant towards all aspects of calcineurin or agonist-
induced cardiomyocyte hypertrophy, while adenoviral gene transfer of the
control construct had no discernable effect on these parameters. These results
indicate that multiple NFAT isoforms are expressed in cardiomyocytes where they
function as necessary transducers of calcineurin in facilitating cardiomyocyte
hypertrophy.
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INTRODUCTION
Heart failure is a leading cause of morbidity and mortality in industrial
countries, affecting over 10 million Americans and Western Europeans, with a 5-
year mortality approaching 50 percent despite current medical therapy.' * These
mortality figures reflect the lack of biologically efficacious therapies directed
against the underlying disease processes that lead to maladaptive left ventricular
remodeling and, ultimately, failure itself. In response to a plethora of intra- and
extracardiac stimuli, cardiomyocytes exhibit cellular enlargement or hypertrophy
as a compensatory adaptation to increased ventricular wall stress.^ However,
sustained cardiac hypertrophy is the single most important risk factor for the
development of heart failure."' Since intracellular signaling pathways are thought
to both initiate and perpetuate the cardiac hypertrophic response and its transition
to dilated failure, recent investigation has attempted to identify key regulatory
factors with the goal of defining novel therapeutic targets.^
One recently characterized intracellular signaling pathway that links
extracellular stimuli to a hypertrophic transcriptional response employs the
phosphatase calcineurin and its downstream transcriptional effector Nuclear
Factor of Activated T-cells (NFAT). Four of the five NFAT proteins (NFATcl,
NFAT2 or NFATc; NFATc2, NFAT1 or NFATp; NFATc3, NFAT4 or NFATx; NFATc4
or NFAT3) reside in the cytoplasm in unstimulated cells, but quickly translocate
to the nucleus in response to stimulation that promote Ca *^ mobilization.^ The
Ca**-calmodulin activated phosphatase calcineurin physically interacts with NFAT
members within the cytoplasm, where it directly dephosphorylates multiple serine
residues within the NH^-terminal regulatory domain of NFAT, resulting in the
unmasking of two nuclear localization sequences required for nuclear import."
Calcineurin-NFAT signaling has been implicated as a critical regulator of
the cardiac hypertrophic growth response. Molkentin et al. generated several
lines of transgenic mice expressing activated mutants of either calcineurin or
NFATc4 in a cardiac-selective manner, which developed robust hypertrophy
that quickly transitioned to ventricular dilation and overt heart failure.""' The
identification of calcineurin as a signaling factor has attracted considerable
interest, in part due to the demonstration that the calcineurin inhibitory drugs
cyclosporine (CsA) and FK506 were shown to abrogate the cardiomyopathic
response in several, but not all, rodent models of congenital and acquired forms
of hypertrophic heart disease (reviewed in '*•"). A central role for calcineurin in the
cardiac hypertrophic response was substantiated by the observation that hearts
from transgenic mice expressing either MCIP1, a dominant negative calcineurin
mutant or the calcineurin inhibitory domains of Cain or AKAP79, were largely
resistant to pleiotropic, hypertrophic stimuli.'" " More recently, calcineurin Ap
gene targeted mice were generated and shown to be defective in mounting a
cardiac hypertrophic response due to pressure overload or agonist infusion."
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While a large number of studies have convincingly demonstrated the importance
of calcineurin as a hypertrophic mediator, the importance of NFAT factors
downstream transducers have not been evaluated in cardiomyocytes.
In the present study we demonstrate the presence of all four, calcineurin-
sensitive members of the NFAT family (NFATcl, c2, c3 and c4) in the ventricular •
cardiomyocyte cell lineage. All four isoforms displayed calcineurin-dependent
nuclear translocation and the ability to transactivate cardiac promoters. To
simultaneously inhibit all myocardial NFAT factors in an effort to effectively " '•
examine their necessary function as hypertrophic transducers, a dominant
negative NFAT strategy was developed. Dominant negative NFAT dose-dependently
abrogated calcineurin-NFAT dependent transactivation of MCIP1 and BNP promoter
luciferase constructs. Adenoviral-mediated gene transfer of dominant negative
NFAT in cultured cardiomyocytes efficiently inhibited calcineurin- and agonist-
induced cardiomyocyte hypertrophy. Taken together, these data demonstrate
a previously unexpected level of redundancy of the downstream targets of
calcineurin and establish their requirement in pathophysiological signaling in the
cardiomyocyte.
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EXPERIMENTAL PROCEDURES v
Reporter constructs and expression vectors
Expression vectors containing a constitutively activated mutant of
calcineurin Aa (CnAa), NFATcl, c3 or c4 were described previously ">•" pEFBOS-
HA-NFATp, a vector containing an N-terminal HA-tagged full length murine
NFATc2, was generously provided by Laurie Climcher (Harvard, Boston). pCC-
CATA-4, a vector with full-length rat CATA-4 was generously provided by Anton
Moorman (AMC, Amsterdam). pCDNA3-NFATc4(Ala mut), an expression vector
containing the first 1 30 NH^-terminal aa of human NFATc4 with the conserved
PxIxIT box mutated to Ala residues (AxAxAA) was described previously and a
generous gift from Dr. Roger Davis (Harvard, Boston). A constitutively activated
flag-tagged NFATc3 clone was PCR-generated (fw 5'-GGTGGGTCAGGCCTTGGCCTT,
rv 5'-TTAGAGCCCATCAGATCTTCC) and lacks the first 315 N-terminal aa of the
published human NFATc3/NFATx sequence (PubMed U85429). The fragment
was cloned into the EcoRI site of the pECE vector to include a N-terminal Flag-
tag to generate pECE-(A31 5)NFATc3. A construct encompassing aa 3 through
191 of murine NFATc4 was PCR generated (fw 5'-GCCGCAAGCTGCGAGGATGAC,
rv 5'-GACGGCTCGGGCTGAAGA) and subcloned as an EcoRI fragment into
the pECE vector to incorporate an N-terminal Flag-epitope to generate pECE-
NFATc4(PxlxlT). A human BNP promoter-luciferase construct was obtained
by cloning an 1 800 bp PCR-amplified fragment of the proximal human BNP
promoter sequence from genomic DNA (fw 5'-GTAG AAACACCTTGTGATCAC,
rv 5'-GGGACTGCGGAGGCTGCT) into the Hindllll site of pGL3 (Promega) to
generate pGL3-hBNP(l 800)Luc. Site-directed mutagenesis was performed
using the Quickchange-XL kit from Stratagene. Two GATA sites centered at
-116 (10) were consecutively mutated to CCTC using the following primers
(mutated sequences small case, only forward primer sequences shown) fw-1
5'-GCCCGGAATGTGGCTcctcAAT AGAGATAACCCTGCAT and fw-2 5'-GGCTcctc
AATCAGAcctcACCCTGATGGCAGG to generate pGL3-(AGATA)-hBNP(l 800)Luc.
Subsequently, the NFAT site centered at -927 '° was mutated in pGL3-(AGATA)-
hBNP(1800)Luc using the following primer (mutated sequences in small case,
only forward primer sequence shown) fw 5'-CTATCCi I I I GtgaagaaTCCTG to
generate pGL3-(ANFATAGATA)hBNP(l 800)-Luc. An MClPl-luciferase reporter,
containing a 904 bp intragenic sequence encompassing the third intron of the
human MCIP1 (DSCR1) gene " , was PCR generated from genomic DNA (fw 5'-
CAACCTCTGGCATAAAT, rv 5'-CTTGAGCTGGTGCTTATAAA) and cloned as a Hindlll
fragment in pGL3 to generate pGL3-hMCIPl (lnt3)Luc. This reporter is identical as
described previously.'* All new PCR generated constructs were amplified using
Accutaq high fidelity system (Sigma) and confirmed by diagnostic restriction and
double strand sequencing analysis.
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Tissue culture and transient transfection assays
Adult mouse ventricular myocytes were isolated as described previously " ,
pelleted by centrifugation and stored at -80"C. Isolation and culture of neonatal
rat ventricular cardiomyocytes was performed as described before in detail.™ Low
passage COS-7 and HEK 293 cells were grown in DMEM (Invitrogen) supplemented
with 10% FBS. COS-7 cells were grown in 1 2-well plates and transfected using 5
ul FuGENE 6 reagent (Roche, Indianapolis) and a total of 2 ug DNA, consisting of
the above luciferase reporter constructs, in the presence or absence of expression
vectors for ACnA, NFATcl, c2, c3 or c4, pECE-NFATc4(PxlxlT), pCDNA3-NFATc4(Ala
mut), pECE-(A31 5)NFATc3, or pCC-CATA4 as indicated. In addition, 20 ng of
pRL-CMV (Promega), an expression vector containing the renilla luciferase gene
under control of a CMV promoter, was included in each experiment to correct for
transfection efficiency (see below). Empty expression vector was used to normalize
DNA amount. The cultures were harvested for luciferase activities 48 hours after
transfection. Fifty ul of cell extract (100 ul) was assayed for luciferase activity
for 3 s in a Biocounter Ml 500 luminometer (Lumac, Netherlands) using the Dual
Luciferase assay system (Promega), where firefly luciferase activity is normalized
for renilla luciferase activity to control for variations in transfection efficiency
according to the manufacturer's procedures.
RT-PCR and Northern blot analysis
Total RNA was isolated from the indicated murine tissues or cell types
using Trizol reagent (Invitrogen). Presence of NFATcl, c2, c3 or c4 mRNA in
adult C57BL/6 murine ventriculocytes was analyzed by RT-PCR using primers
specific for the individual NFAT isoforms as described before.^' Northern blot
hybridizations on size-fractionated total RNA (10 ug) from indicated tissues were
performed as described previously." To obtain probes specific for the NFAT
isoforms, the mRNA sequences of murine NFATcl through c4 were aligned (using
ClustalW software) and primers designed to the 3' untranslated regions showing
no or minimal overlap (Primers: NFATcl fw 5'-CATCCTCAACCTCACACCCC, rv
5'-CCCACCACCCACTCTCCTGT; NFATc2 fw 5'-ATTCCTATCTTACTAAAAT CAACC,
rv 5'-TAATCTCAA ACCAACA; NFATc3 fw 5'-CCTCATCACACACACTCC TCTCCC,
rv 5'-ATCATATAAAACTACCTA; NFATc4 fw 5'-CCGCACACCCTCACT CATCT, rv 5'-
GCCACCGCTCCTTCCTCC). The isoform-specific probes were randomly labeled
with "P-dCTP (Dupont de Nemours NV, Brussels Belgium), added to the blots and
incubated in Rapid Hyb hybridization solution (Amersham) at 58"C. Stringent post-
hybridization wash conditions were used. Filters were exposed to Phospholmager
screens (Biorad) and analyzed using Quantity 1 (Biorad) and Adobe Photoshop
6.0 software. The intensity of thel 8S ribosomal RNA band detected with a
radiolabeled 1 8S probe was used as a quantitative control.
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Western blot analysis
The method used is a minor modification of a recently described
protocol."" In brief, protein extracts were lysed in ice-cold buffer (0.5% NP40,
1 50 mM NaCI, 0.5 mM EDTA, 1 0 mM Tris-HCI pH 8.0, 2 ug/ml leupeptin, 1 0 ug/ml
PMSF (Sigma), 2 ug/ml soybean trypsin inhibitor). Protein concentration in lysates
was determined using a protein dye assay (Biorad) followed by separation on
gradient gels (Biorad), and transferred to PVDF membrane (Biorad). Filters were
blocked for 1 hour at room temperature using 10% non fat dry milk dissolved in
Tris buffered saline with 0.1%Triton-x (Sigma), TBST. Primary antibodies included
rabbit polyclonal anti-NFATcl (Santa Cruz, H-l 10), mouse monoclonal anti-NFATc2
(Santa Cruz, 4G6-G5), rabbit polyclonal anti-NFATc3 (Santa Cruz, M75), rabbit
polyclonal anti-NFATc4 (Santa Cruz, H-74) and mouse monoclonal anti-flag (Sigma,
F-3165). Anti-NFATcl-c3 were diluted 1:200 and anti-NFATc4 was diluted 1:1000
in blocking buffer (5% non fat dry milk dissolved in TBST). Membranes were
incubated with primary antibodies overnight at 4°C. Secondary antibodies included
swine anti-rabbit peroxidase or rabbit anti-mouse peroxidase (DOKA, Denmark)
and were used at a dilution of 1:2000 in blocking buffer and incubated for 2 hours
at room temperature. Signals were detected with an Enhanced Chemiluminescence
kit (ECL, Amersham) and analyzed using Adobe photoshop 6.0 software.
Generation of recombinant, replication-deficient adenoviruses
The adenovirus expressing p-galactosidase with a nuclear localization
signal (Adpgal) was a generous gift from Mark Sussman (Children's Hospital,
Cincinnati). The adenovirus expressing an activated mutant of calcineurin
(AdCnA) was described and characterized previously." " AdNFATc4(PxlxlT) and
AdNFATc4(Ala mut), replication-deficient adenoviruses expressing either Flag-
tagged NFATc4(PxlxlT) or NFATc4(Ala mut), were generated by subcloning PCR
amplified fragments (fw 5'-CCACAACTACTCAACC, rv 5'-ATGATCATTACTTA TCTA
and fw 5'-ACCCGCACCCAACATC, rv 5'-CCATTTACCT CACACTAT, respectively)
as Xba I fragments into the adenoviral shuttle vector pACCMVplpA, using either
pECE-NFATc4(PxlxlT) or pCDNA-NFAT3(Ala mut) as templates. The recombinant
shuttle vectors were cotransfected with pJMl 7 in HEK 293 cells to produce initial
recombinant adenovirus lysates. Procedures for plaque purification, expansion
and titering the replication-deficient adenovirus and infection of cardiomyocytes
were performed as described previously." " Cardiomyocytes were infected with
indicated adenoviruses at an MOI 100 for 2 hr, and cultured in serum-deficient
medium either or not in the presence of Endo-1 (1 OOnM; Sigma) or CT-1 (1 nM).
Immunocytochemistry
Fixed cultured cardiomyocytes underwent immunocytochemistry as
previously described in detail."•*"•" To visualize the subcellular localization of
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NFATcl, c2 and c3, primary, isoform-specific antibodies (See Western blots)
were used at a dilution of 1:400 followed by corresponding anti-mouse or anti-
rabbit Oregon green labelled secondary antibody incubation (Molecular Probes)
at a dilution of 1:400. Cells were washed with phosphate buffered saline/0.1%
NP40 including bisbenzimide (Sigma) to visualize nuclei. For visualization of
cardiomyocyte size, sarcomeric organization and perinuclear ANF expression,
the primary antibody included polyclonal anti-rat ANF (Peninsula laboratories),
followed by secondary anti-rabbit Oregon green (Molecular Probes) conjugated
antibody and a phalloidin Texas Red conjugated antibody (Molecular probes),
all used at a dilution of 1:400. An epifluorescence microscope (Eclipse E800,
Nikon) was used to visualize the cells at a 400x magnification. Quantitation of
cardiomyocyte cell surface area was performed on digitized images using NIH
image software. At least 50 cardiomyocytes in 10 to 20 fields were examined in
three independent experiments.
Statistical analysis
The results are presented as mean values ± standard error of the mean
(SEM). Statistical analyses were performed using InStat 3.0 software (CraphPad
Software Inc., San Diego, CA) and ANOVA followed by Bonferroni's post-test when
appropriate.
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RESULTS
Presence of four NFAT members in ventricular cardiomyocytes.
RT-PCR analysis was employed to investigate which members of the NFAT
transcription factor family are present in ventricular cardiomyocytes, and hence,
might function as calcineurin effectors. Using RNA from adult mouse ventricular
cardiomyocytes, transcripts of the expected size for NFATc2, c3 and c4 were easily
detected following a limited number of amplifications (Figure 3.1 A). NFATd was
also detectable albeit at lower levels than the other isoforms (Figure 3.1 A, top left
panel, lane 2). As a control for RT quality, a GAPDH RT-PCR was performed, which
resulted in robust product in RT material (data not shown). These data suggest
that transcripts of all NFAT isoforms are present in the ventricular muscle cell
lineage.
To extend these results, Northern blot analyses for the different NFAT
isoforms were performed on RNA isolated from several murine muscle types,
including the individual cardiac chambers (right and left ventricle, atria), three
skeletal muscle types (diaphragm, quadriceps and gastrocnemius) and visceral
smooth muscle (stomach) using NFAT isoform-specific probes. The NFATc4-
specific probe yielded the most intense signal in both cardiac chambers,
displaying two prominent transcripts, one of 6.0 and one of about 4.5 kb, with
the latter giving the most intense signal. The same two transcripts were present
throughout all muscle types, albeit at lower levels (Figure 3.1 B, lower panel).
NFATc3 gave two transcript sizes, with a smaller one of about 4.8 kb being the
most intense in all muscle types, but most prominently expressed in the cardiac
ventricular chambers. Two transcripts for NFATc2 were also detected, which were
each expressed at comparable levels in all tissues tested. NFATcl showed three
different transcripts, with the smallest transcript (2.0 kb) being expressed in the
left ventricle and the two larger transcripts being expressed at roughly equivalent
levels in most other tissues analyzed (Figure 3.1 B, upper panel). All blots were
probed for 1 8S to verify quality and equal loading of RNA (data not shown).
Collectively, these data indicate that transcripts for all four calcineurin-regulated
NFAT factors are present in cardiomyocytes, with those for NFATc3 and NFATc4
being present at the highest levels.
To verify whether these transcripts were also efficiently translated into their
respective protein products, a series of Western blots were performed on total
protein lysate from cultured neonatal rat ventriculocytes using isoform-specific
antibodies. Tissue extract of rat brain and rat thymus (data not shown) served as
a positive control. Figure 3.1 C demonstrates that signals for all four calcineurin-
regulated NFAT factors were obtained in cardiomyocytes, albeit at differing
intensity, and with products ranging in mass from 70 kDa to 200 kDa. For NFATcl
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and NFATc2 discrete protein signals were observed, while for NFATc3 and NFATc4
multiple bands in the range of 100 kDa to 200 kDa were observed. This may
reflect generation of proteins by alternatively spliced transcripts (see Figure 3.1 B)
and/or by differential phosphorylation states of the NFATc3 and NFATc4 proteins.
Although the different affinities of the separate antibodies used do not allow for
direct comparison of signal intensity, it is interesting to note that the relatively
higher intensity of the protein signals for NFATc3 (Figure 3.1 C) correlates with its
relatively high signal in the Northern blot analysis (Figure 3.1 B). Conclusively, RT-
PCR, Northern blot and Western blot analyses all point towards the existence of all
four calcineurin-regulated NFAT isoforms in the ventricular cardiomyocyte.
NFATci
1 2 3 4
NFATc2
1 2 3 4
NFATC4 NFATc3
1 2 3 4
Fig 3.1 ABC Presence of NFAT isoforms
in the ventricular myocardium. (A) RT-
PCR analyses using oligonucleotides
specific for the NFAT isoforms on adult
C57BL/6 ventricular cardiomyocytes
demonstrate the presence of transcripts
for NFATd , c2, c3, and c4. Lane 1,
positive control consisting of expression
vector for respective NFAT isoform; lane
2, +RT reaction; lane 3, -RT reaction;
lane 4, H^ O control. (B) Northern blot
analysis using probes specific for the
NFAT isoforms indicates ubiquitous
expression of the NFAT genes
throughout various murine muscle tissue
types. NFATc3 and c4 transcripts appear
to be most abundantly expressed in the
heart. (C) Western blot analysis confirms
the ubiquitous expression profile of
NFATd through NFATc4 at the protein
level in neonatal rat ventriculocytes (lane
2 in each panel). Lane 1 constitutes
a positive control of rat brain tissue
extract (Santa Cruz sc-2392).
NFATcl
NFATC2
NFATc3
NFATc4
1 2 1 2 1 2 1 2
NFATcl NFATc2 NFATc3 NFATc4
THE CALCINEURIN/NFAT PATHWAY | page 81
Nuclear translocation of all cardiac NFAT isoforms upon calcineurin
activation
NFAT transcription factors are dephosphorylated upon activation of the
Ca^/CaM dependent phosphatase calcineurin, resulting in unmasking of their
nuclear localization signals permitting nuclear import. To verify that NFATc
isoforms could be activated by calcineurin in cardiac myocytes, we performed
immunocytochemistry for each NFAT factor at baseline or after infection with
an adenovirus expressing a constitutively activated form of calcineurin (AdCnA)
or after stimulation with Endo-1. Cardiomyocytes were DAPI stained to visualize
the nuclei and facilitate observation of nuclear localization (Figure 3.2B, D, F
and H, left and right panel). NFATcl, c2 and c3 were easily detectable using
their respective antibodies and displayed a predominant cytosolic localization in
unstimulated cardiomyocytes (Figure 3.2A, left and right panel, NFATcl, c3, and
data not shown for NFATc2). AdCnA infection resulted in nuclear accumulation
of each NFAT isoform in nearly 100% of the myocytes evaluated. Stimulation
with the agonist Endo-1 for 1 2 hrs resulted in efficient NFATcl and c3 nuclear
translocation in about 70% of cardiomyocytes (Figure 3.2E, left and right panel).
Similar findings were obtained for NFATc2 (data not shown). To control for the
specificity of the antibodies used, the primary isoform-specific antibody was
omitted, which resulted in background fluorescence (Figure 3.2C, left and right
panel). All cells examined were also positive for sarcomeric actin using phalloidin
staining, thereby confirming their identity as cardiomyocytes (data not shown).
These results indicate that NFATcl, c2 and c3 are equally sensitive to endogenous
calcineurin activation as demonstrated priorly for NFATc4 '° and point towards
a potential contribution for all NFAT members in calcineurin signaling in the
ventricular cardiomyocyte.
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NFATcl DAPI
control
AdCnA
Endo-1
-1st Ab
control
AdCnA
Endo-1
-1st Ab
Fig. 3.2 Calcineurin-dependent nuclear translocation of NFATcl and c3 in cardiomyocytes.
Cultured cardiomyocytes were either left unstimulated (A, B), stimulated with AdCnA (C, D),
or endothelin-1 (Endo-1) (E, F) and immunostained for subcellular localization of NFATcl
(left Panel) or c3 (right Panel). Nuclei were stained with bisbenzemide (B, D, F, H). Under
serum free conditions, NFATcl and NFATc3 were localized cytoplasmatically (A). Following
stimulation with either AdCnA (C) or Endo-1 (E) both isoforms translocated to the nucleus.
Panels C and H represent negative controls by ommittance of the primary antibody. -Full
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All cardiac NFAT isoforms participate in MCIP1 induction
To explore whether the calcineurin-mediated, nuclear import of the cardiac
NFAT isoforms was associated with their ability to participate in transcriptional
activity of cardiac-specific, calcineurin-responsive promoters, a series of
transient cotransfection assays were carried out. Recently, a novel gene was
characterized that is present at low levels under physiological conditions in the
heart, but undergoes dramatic upregulation following calcineurin activation in
the hea r t . " " " Remarkably, the gene product itself is a highly specific inhibitor
of calcineurin and the gene was therefore designated modulatory calcineurin
interacting p.rotein-1 (MCIP1). It is thought that MCIP1 participates in a negative
feedback loop to prevent the deleterious effects of unrestrained activation of the
enzyme in the ventricular myocyte."'*" Analysis of the gene structure revealed
intron 3 to harbor multiple NFAT consensus sites and was found to be uniquely
sensitive to calcineurin-NFAT activation.'* Cotransfection of hMCIPl (lnt3)Luc
with expression vectors for the individual NFAT isoforms only slightly induced
transcriptional activity (Figure 3.3).
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Addition of a construct expressing a constitutively activated mutant of
calcineurin (ACnA) increased this induction several fold for all isoforms, ranging
from 3.5 fold for NFATc4 to over 20 fold for NFATc2 (Figure 3.3). Taken together,
these results suggest that all myocardial NFAT members are able to induce
transcriptional activation of the human MCIPI calcineurin-responsive enhancer
region.
10
1'
6'
4'w
25
20-
15-
10-
5-
0
14
.1
ID-
S'
6-
4 '
2 -
^ o-
5-
4-
3-
2-
1 •
< > •
ll
hMCIPl dm 3)Luc
NFATc Isoform
ACnA
Fig. 3.3 Activation of the human MCIPI-promoter by cardiac NFAT isoforms. COS-7 cells
were transiently transfected with a luciferase reporter gene linked to an intragenic segment
proximal of exon 4 of the human MCIPI gene (hMCIPl (lnt3)Luc) either or not in the presence
of expression vectors for NFATcl, c2, c3, c4, or activated calcineurin (ACnA) as indicated.
Forty-eight hours later, cells were harvested and luciferase activity was determined. The
hMCIPl (lnt3)Luc construct proved to be exceptionally sensitive to NFATc activation,
independent of the isoform studied. The data represent the mean ± SEM of four independent
experiments and are presented as fold activation compared to a control with hMCIP(lnt3)Luc
alone.
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Synergistic activation of the BNP gene by NFAT and CATA4
It was previously demonstrated that the BNP gene promoter is regulated
by a distal NFAT sequence element in cooperation with calcineurin and GATA4.'°
To assess whether the additional cardiac NFAT members are also capable of
synergizing with CATA4 in regulating this promoter, the hBNP(l 800)Luc reporter
was tested in the presence or absence of CATA4, ACnA and expression vectors for
the individual NFAT isoforms. CATA4 alone markedly upregulated hBNP(l 800)Luc
to about 1 7 fold over baseline (Figure 3.4A), confirming the previously
documented sensitivity of this gene to GATA factors.^"Each individual NFAT
isoform demonstrated relatively weak activation in the presence of ACnA (Figure
3.4A). In contrast, cotransfection of any single NFAT isoform in the presence
of ACnA and CATA4 resulted in robust upregulation of hBNP(l 800)Luc, ranging
from 25 to 50 fold induction depending upon the NFAT member studied (Figure
3.4A). These results indicate that all NFAT members can participate in synergistic
activation of the BNP gene in conjunction with GATA4.
hBNPH800)Luc
CATA4
NFATcl + ACnA
NFATC2 + ACnA
NFATC3 + ACnA
NFATc4 + ACnA
Fig. 3.4A Cardiac NFAT and CATA-4 synergistically activate the human BNP promoter. COS-
7 cells were transiently transfected with a luciferase reporter gene linked to an 1 800 bp
flanking region of the human BNP promoter (hBNP(l 800)Luc) either or not in the presence
of expression vectors encoding the individual NFAT isoforms, activated calcineurin (ACnA),
or CATA4, as indicated. Forty-eight hours later, cells were harvested and luciferase activity
was determined. As reported previously for NFATc4 (1 0), NFATcl, c2 and c3 were also able
to transactivate the hBNP(l 800)Luc construct synergistically with CATA-4. Luciferase values
represent the mean ± SEM of three independent experiments and are presented as fold
activation compared to a control with hBNPO 800)Luc alone.
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To test the specificity of this interaction and whether functional binding
sites for either factor are required in the synergistic activation of the BNP
reporter, a series of hBNP(l 800) promoter-luciferase mutants were generated and
examined. As a control, the activity of the wildtype hBNP(l 800)Luc is shown at the
left panel in Figure 3.4B. The two CATA binding sites centered around -116 bp
were mutated, which rendered the BNP promoter construct insensitive to CATA4,
but not to activation by NFATc3 or c4 (Figure 3.4B, middle panel). Next, in the
context of the CATA-mutated reporter (ACATA)hBNP(l 800)Luc, the distal NFAT site
at -927 was mutated, which showed no activation in the presence of NFAT and/or
CATA4 (Figure 4B, right panel). These data indicate that the synergistic activation
pattern initially described for NFATc4 with GATA4 in control of the BNP gene is
fully conserved among each myocardial-expressed NFAT and that this activation
profile is critically dependent upon the presence of both intact NFAT and CATA4
binding sites.
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Fig. 3.4B COS-7 cells were transfected with either the wildtype hBNP(l 800)Luc reporter (left
panel), the CATA-mutated (ACATA)hBNP(1800)Luc reporter (middle panel) or the CATA and
NFAT site mutated (ANFAT, AGATA)hBNP(l 800)Luc reporter either or not in the presence
of expression vectors encoding the most cardiac NFAT isoforms NFATc3 or c4, activated
calcineurin (ACnA), and CATA4. Forty-eight hours later, cells were harvested and luciferase
activity was determined. Luciferase values represent the mean ± SEM of three independent
experiments and are presented as fold activation compared to a control with either
hBNP(l 800)Luc reporter alone.
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Dominant negative NFAT inhibits calcineurin-mediated MCIP1 gene
expression . • . . • • • •-!'•• ::• ' •.• - • ~ h , - • i T A - ^ - i - K ^ :•;• r v . -
Because all four members of the NFAT transcription factor family are
present in cardiomyocytes, a dominant inhibitory strategy was developed that
targets NFAT activation. Such a strategy would bypass gene redundancy issues •,-./.•
to permit evaluation of NFAT's role as a calcineurin effector in the heart. Several
independent groups have demonstrated that constructs consisting of only the
NHj-terminal domain of NFAT can interfere with NFAT-mediated transcription in
a dominant inhibitory fashion. This region includes the Ser-rich region (SRR) and
three conserved Ser-Pro repeats (SP boxes A, B, and C) (Figure 3.5A). The SP boxes
represent major sites of interaction of NFAT with calcineurin in vitro," and sites of
NFAT phosphorylation in vivo have been identified in the SRR."''° Previous studies
identified the conserved Pro-Xaa-lle-Xaa-lle-Thr (PxIxIT) box (residues 114 to 119
in NFATc4) as the region that confers inhibitory NFAT transcriptional activity. To
globally inactivate all NFAT factors, we generated a construct encoding amino
acid residues 3-191 of the N-terminus from NFATc4 that contains this calcineurin
interacting region (Figure 3.5A).
3 x SP motif (SPxxSPxxSPxxxxxEE)
1 396
CnBP-A CnBP-B
RVLECPSIRITSISPT DQYLAVPQHPYQWAK
PxIxIT - • xLxVP
CMV H mNFATc4(3191) HP°ly
Fig. 3.5A Schematic representation of the NH^-terminal homology region of NFATc4 with
conserved domains depicted. Below a schematic representation of the dominant negative
NFATc4(PxlxlT) construct driven by a CMV promoter, encompassing the first 191 aa residues,
including the conserved calcineurin docking PxIxIT domain.
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Cotransfection assays in COS-7 cells were performed using this construct,
each of the NFATc isoforms, and the hMCIPl(lnt3)-luciferase reporter plasmid
(Figure 3.3B). Overexpression of ACnA and NFATcl through c4 each induced
robust NFAT transcriptional activity (Figure 3.5B). However, expression of the
dominant negative NFATc4(PxlxlT) construct, the NH^-terminal NFATc4 homology
domain (residues 3 to 191), dose-dependently inhibited transcription mediated
by each NFAT isoforms (Figure 3.5B). In the absence of full length NFAT isoforms,
transcriptional activity was not observed in either the absence or the presence of
NFATc4(PxlxlT) (data not shown). These data indicated that the NH^-terminal NFAT
homology domain interferes in a dominant inhibitory fashion with NFAT-mediated
regulation of a cardiac responsive promoter, regardless of the NFAT isoform
studied.
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Fig. 3.5B Transfection experiments in COS-7 cells using the hMCIP(lnt3)Luc reporter indicates
that increasing amounts of dominant negative (0.2, 0.4, and 0.6 ug) NFATc4(PxlxlT) dose-
dependently inhibits NFAT-mediated transcriptional activity exerted by each individual
NFAT isoform and in the presence of activated calcineurin (ACnA). No inhibitory effects are
seen when the control construct NFATc4(Ala mut), in which the PxIxIT is replaced with Ala
residues, is cotransfected (0.2 and 0.6 ug) with the hMCIP(lnt3)Luc reporter and the NFAT
isoforms in the presence of ACnA. Luciferase values represent the mean ± SEM of three
independent experiments and are expressed as fold activation compared to a control with
hMCIPl(lnt3)Luc alone.
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To test whether our dominant inhibitory NFATc4(PxlxlT) construct was
dependent upon the presence of an intact PxIxIT box and to exclude issues «
regarding cytotoxicity, a similar NH^-terminal NFATc4 construct, NFATc4(Ala mut)
was included in cotransfection assays. In this construct, the conserved PxIxIT box
residues were mutated to Ala residues to generate an AxAxAA box, which is now
ineffective in blocking calcineurin interaction. As anticipated, co-expression of this
mutant construct displayed no inhibitory effect on NFAT-mediated induction of •
the hMCIPl(lnt3)Luc reporter (Figure 3.5B). These data indicate that the PxIxIT box
mediates the dominant negative action of our NFATc4(PxlxlT) construct.
Dominant negative NFAT inhibits calcineurin-mediated cardiomyocyte
hypertrophy
To investigate the requirement of NFAT activation in calcineurin-mediated
cardiomyocyte hypertrophy, we generated two replication-deficient adenoviral
vectors expressing either the dominant negative NH^-terminal NFAT construct
NFATc4(PxlxlT) or the control construct NFATc4(Ala mut) under control of the CMV
promoter (Figure 3.6A).
B
CMV
CMV
riixiT
(~H mNFATc4(3-l91) H PotyA j
RVLECFS1RITSISPT
AlAxAA • - • •
H hNFATc4<A)i mut) |-| PotyA |
kDa ^ 6 ^ ^ % , ^
20-
10"
Fig. 3.6AB (A) Schematic representation of dominant negative NFATc4(PxlxlT) and the control
NFATc4(Ala mut) constructs expressed as adenoviral vectors. (B) Western blot analysis
using an anti-Flag antibody on COS-7 cell lysates infected with either Adpgal, the dominant
negative NFAT adenovirus AdNFATc4(PxlxlT) or the control virus AdNFATc4(Ala mut) at an
MOI of 100.
Infection of COS-7 cells with either AdNFATc4(PxlxlT) or AdNFATc4(Ala mut)
at an MOI of 1 00 resulted in robust expression of polypeptide fragments of ~1 9
and ~16 kDa, respectively, which were easily detectable on the basis of their Flag-
immunoreactivity (lane 2 and 3, Figure 3.6B). Conversely, Adpgal infection resulted
in the absence of any proteins reactive for the anti-Flag antibody (lane 1, Figure
3.6B). Taken together, these results demonstrate that AdNFATc4(PxlxlT) and
AdNFATc4(Ala mut) are correctly expressed and should represent an effective way
to inhibit NFAT activity in cultured neonatal cardiomyocytes.
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Cardiomyocytes were first infected with the control adenovirus Adpgal
(Figure 3.6C, panel AC), AdNFATc4(PxlxlT) (Figure 6C, panel D-F) or AdNFATc4(Ala
mut) (Figure 3.6C, panel C-l). After 24 hrs, the cultured cells were then stimulated
with the hypertrophic agonist cardiotrophin-1 (CT-1) or Endo-1 (data not shown),
by infection with the activated calcineurin-expressing adenovirus, or left untreated
for 24 hrs (Figure 3.6C). The data demonstrate that only AdNFATc4(PxlxlT)
infection prevented cardiomyocyte hypertrophy in response to AdCnA or CT-
1 (Figure 3.6C, panel E and F). Adenoviral infection with either Adpgal (Figure
3.6C, panel B and C) or the control adenovirus AdNFATc(Ala mut) (Figure 3.6C,
panel H and I) had no discernable effects on either AdCnA or agonist-induced
sarcomeric deposition and cellular enlargement. Importantly, neither Adpgal,
AdNFATc4(PxlxlT) or AdNFATc4(Ala mut) infection induced cardiomyocyte
apoptosis nor did it affect the morphology (Figure 3.6C, panel A, D and G) and
viability of unstimulated cells (data not shown).
AdCnA CT-1
Adpgal
AdNFATc4
PxIxIT
AdNFATc4
Ala mut
Fig. 3.6C Representative images of immunostained cardiomyocytes infected with the indicated
adenoviruses either or not in combination with the hypertrophic agonist CT-1. Phalloidin/
ANF double staining demonstrates less cellular enlargement, sarcomeric organization and
perinuclear ANF staining in the presence of AdNFATc4(PxlxlT) following AdCnA infection or
agonist stimulation. -Full colour image page 179
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Quantitation of cardiomyocyte hypertrophy was performed by video edge
detection on large numbers of myocytes (Figure 3.6D). Serum free (SF) cultured
cardiomyocytes demonstrated to have a similar cell surface area (11 53 ± 87 urn*)
as AdfSgal infected, SF cultured cardiomyocytes (1061 ± 69 urn?). In agreement
with previous studies, AdCnA, CT-1 or Endo-1 treatment (20,24) resulted in a more
than 2-fold increase in cell surface area (2295 ± 1 1 2 , 2274 ± 104 and 2072 ±151
and Mm*, respectively, P<0.01 vs SF). Prior infection with Adpgal and subsequent
stimulation with AdCnA, CT-1 or Endo-1 resulted in comparable cardiomyocyte
hypertrophy as priorly SF cultured myocytes (2080 ± 89, 2455 ±155 and 2347
±118 urn*, respectively, P<0.01 vs SF). AdNFATc4(PxlxlT) infection completely
abrogated the pro-hypertrophic effects of AdCnA, CT-1 or Endo-1 treatment to
1147 ± 52, 11 93 ± 56 and 11 84 ± 92 urn*, respectively (P < 0.01 vs AdCnA,
CT-1 and Endo-1, P = NS vs SF). In sharp contrast, AdNFATc4(Ala mut) infection
prior to AdCnA infection or treatment with CT-1 or Endo-1 had no effects on the
morphological alterations of these prohypertrophic stimuli (2384 ± 1 1 6 , 2905 ±
224 and 2476 ± 1 71 Mm*, respectively; P = NS vs AdCnA, CT-1 or Endo-1). The
data demonstrate that adenoviral dominant negative NFAT transfer was able to
prevent the hypertrophic remodeling of cardiomyocytes following calcineurin
activation.
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Fig. 3.6D Cell surface areas were quantified for each of the indicated conditions,
demonstrating that inactivation of NFAT signaling abrogates cardiomyocyte hypertrophy in
response to an activated calcineurin mutant, Endo-1 or CT-1 stimulation. Data in D represent
the mean ± SEM of three independent experiments. • indicates p < 0.05 vs serum free
conditions, t indicates p < 0.05 vs Adpgal followed by AdCnA infection.
THE CALCINEURIN/NFAT PATHWAY | page 91
Increased ANF expression is a hallmark of cardiac hypertrophy and is
readily detected by immunocytochemistry as perinuclear staining.^'" Serum-
free cultured cardiomyocytes infected with either Adpgal, AdNFATc4(PxlxlT) or
AdNFATc4(Ala mut) were stimulated with agonist or the activated calcineurin-
expressing adenovirus and scored for the numbers of cells with perinuclear ANF
expression (Figure 3.6C). The data demonstrate that only AdNFATc4(PxlxlT)
infection blocked ANF expression in response to the pro-hypertrophic stimuli
investigated (Figure 3.6C, panel E and F). Taken together, the results indicate
that dominant negative NFAT abrogated ANF expression following calcineurin
activation or agonist stimulation in cultured cardiomyocytes.
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DISCUSSION
Overlapping expression of NFAT isoforms in the heart
One unexpected finding of the present study is that the ventricular
cardiomyocyte population contains all four, calcineurin-sensitive NFAT isoforms
described in the literature to date (reviewed i n . " " * All NFAT members of the
transcription factor family are expressed in multiple isoforms, generated by
alternative splicing." "The results in the present study support this notion (Figure
3.1 B). The existence of multiple splice isoforms has been shown in detail for
NFATc2 and c4 in T lymphocytes and other cells," " and it has been shown that all
spliced isoforms elicit transactivation of NFAT-responsive promoters, albeit with
slightly differing efficiencies." The observation that cardiomyocytes express each
of the 4 calcineurin-regulated NFAT family members, which themselves undergo
differential splicing, justifies the dominant negative strategy employed here to
inhibit NFAT-mediated transcriptional activation.
Although initially characterized in T-cells, almost all tissues in the
mammalian organism express one or more NFAT family member. For example,
NFATc2 is somewhat restricted in expression to immune cells and skeletal muscle,
while NFATc3 expression is enriched in thymocytes and skeletal muscle cells,
but also present at lower levels in various other tissues. NFATcl and NFATc4
appear to be expressed in a more ubiquitous pa t te rn , ' " " where they influence
development, proliferation, and differentiation of a number of mammalian
tissues."^The data in the present study confirm this ubiquitous expression
pattern of NFAT members throughout several muscle types, supporting the
function of the calcineurin-NFAT signaling pathway regulating cardiac hypertrophy,
skeletal muscle myogenesis and fiber-type specification, and smooth muscle cell
proliferation and vessel remodeling."' '""
Crucial role for NFAT signaling in cardiomyocyte hypertrophy
The NFAT dominant inhibitory approach employed here specifically blocked
the ability of calcineurin or agonist stimuli to promote nuclear accumulation and
transcriptional activation of endogenous or overexpressed NFAT factors. Our
approach utilized overexpression of the NFAT NH^-terminal calcineurin docking
domain containing the conserved sequence Pro-Xaa-lle-Xaa-lle-Thr (PxIxIT box)."
It should be noted that NFATc4(PxlxlT), the dominant negative NFAT construct
used in the present study, encompasses aa residues 3 to 1 91 of human NFATc4,
while the "internal control" construct, NFATc4(Ala mut), was slightly shorter and
encompasses residues 2 to 1 30 of human NFATc4. Although it would have been
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formally more correct to use dominant negative and control constructs of the
same length, it is highly unlikely that the differing phenotypic effects observed
between the dominant negative construct and the control construct may be due to
this slight difference in length. Indeed, Chow et al. have clearly demonstrated that
the dominant inhibitory action of N-terminal portions of NFAT only depends upon
the presence of the PxIxIT box, which encompasses residues 114 to 119 in human
NFATc4, rendering relative length of truncated NFAT constructs beyond residue
119 in this particular context irrelevant."
To address whether NFAT signaling is required for (calcineurin-mediated)
cardiomyocyte hypertrophy, two model systems are routinely employed;
cultured cardiomyocytes and genetically altered mice. In this study we employed
adenoviral-mediated gene transfer in cultured cardiomyocytes to circumvent
potential difficulties associated with gene targeting such as isoform redundancy
or compensatory changes in gene expression. For example, gene targeting of
individual NFAT family members did not reveal a widespread defect in the ability
of T cells to proliferate or generate cytokines such as IL-2 "•s?", even though the
calcineurin-NFAT paradigm was established as a regulator of interleukin-2 gene
transcription. Germane to our study, Chow et al. established the involvement of
NFAT activity in regulating in IL-2 expression using a similar dnNFAT molecule."
This dnNFAT molecule selectively inhibited NFAT transcription activity by
interfering with the activation-induced nuclear import of NFAT and the active
component of this inhibitor correspondent to the PxIxIT box located in the
conserved NH^-terminal homology region of NFAT."
In addition to gene targeting, transgenesis in the mouse could be employed
as a means of blocking NFAT activation through overexpression of the dominant
negative NFAT protein domain in the heart. However, exhaustive attempts to
generate dominant negative NFAT transgenic mice failed, presumably due to
embryonic or early post-natal lethal effects associated with complete NFAT
inhibition in the heart (De Windt and Molkentin, unpublished observations).
Indeed, NFATc3 X NFATc4 double null mice die late during embryogenesis with
severe vascular abnormalities."'
Another documented approach to abrogate NFAT signaling is the use of
kinases that directly phosphorylate NFAT transcription factors, thus antagonizing
nuclear accumulation. For example, glycogen synthase kinase-3p (GSK-3p) is a
serine/threonine protein kinase with many targets, including at least two NFAT
proteins." In addition, GSK-3p has been identified as a critical negative modulator
of cardiomyocyte hypertrophy by directly antagonizing the prohypertrophic
effects of activated calcineurin." Recently, GSK-3p was also proven to be capable
of inhibiting hypertrophic signaling in the intact myocardium."Transgenic mice
expressing a constitutively activated form of GSK-3(5 in cardiomyocytes displayed
a severely blunted hypertrophic response to chronic p-adrenergic stimulation,
pressure overload, and the actions of the calcineurin transgene." However,
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CSK-3(3 also inhibits GATA-4 function in cardiomyocytes," suggesting that CSK-
3f5 likely also inhibits the hypertrophic response through NFAT-independent T-
mechanisms. Nevertheless, we favor the interpretation that calcineurin-NFAT
signaling is a dominant regulatory pathway for cardiac hypertrophy, and likely
the germane mechanism underlying the anti-hypertrophic effect of CSK-3|i
Indeed, cardiomyocytes infected with adenoviruses expressing truncated forms of
either the calcineurin inhibitory protein Cain/cabin-1 or AKAP79 *°, which target -
and inhibit calcineurin itself """ , also showed a severe attenuation of myocyte
hypertrophy in vitro. The combined observations suggest a pivotal role for
calcineurin-NFAT signaling in cardiomyocyte hypertrophy.
Cardiac NFAT signaling: functional redundancy or functional
specification?
Although this study establishes that NFAT activity is required for both
calcineurin as agonist-induced cardiomyocyte hypertrophy, the present data await
extrapolation to the in vivo situation. As discussed above, we were unsuccessful
in generating cardiac-specific transgenic mice expressing this dominant negative
NFAT protein. These observations suggest that NFAT factors are crucial during
developmental maturation of the myocardium. However, it is not known if all
NFAT factors contribute to the myocyte growth response through a generalized
mechanism, or if individual isoforms play specific functions. For example,
NFATcl gene targeted mice die during embryonic development due to defects
in heart valve formation."^° With respect to the adult heart and the regulation
of hypertrophic growth, we have recently targeted the NFATc4 gene in the
mouse. Surprisingly, NFATc4-null mice did not show a defect in their ability to
mount a hypertrophic response.">•*' By contrast, NFATc3-null mice did show a
significant attenuation of hypertrophy following diverse stimuli." Collectively,
these observations suggest that several NFAT isoforms might play critical
regulatory roles in the adult myocardium. Indeed, here we observed that NFATc3
is abundantly present in ventricular myocytes (Figure 3.1).
Alternatively, it is possible that certain NFAT factors have specified
to fulfill various pathophysiological roles in the heart, in addition to or even
excluding hypertrophic signaling. For example, we have demonstrated that
adenoviral expression of NFATc4 rendered cardiomyocytes less susceptible to
staurosporine or oxidative stress-induced apoptosis." Moreover, Kakita et al.
demonstrated that NFATcl plays a crucial role in endothelin-1 mediated protection
against oxidative stress-induced apoptosis in cardiomyocytes." Since NFATc4
apparently plays a minor role in cardiac hypertrophic signaling " , yet signals
a pro-survival phenotype " it is possible that certain NFAT factors have highly
specified functions in the heart. To more firmly establish the functional hierarchy
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or potential inter-isoform specific roles between the individual myocardial NFAT
members in the heart, generation of mouse models with loxP flanked alleles for
the four documented NFAT genes is warranted.
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Chapter 4
Regulation of cardiac gene expression and
hypertrophy by MEF2-dependent recruitment of
Nuclear Factor of Activated T-cells and p300
histone acetyltranferase
Eva van Rooij, Ralph J. van Oort, Anne-Sophie Armand,
and Leon J. De Windt
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SUMMARY :-,;;.• -
One central pathway that transduces prohypertrophic signals in the cardiac
muscle cell employs the Ca *^ activated phosphatase calcineurin (CnA), but to date,
little work has focused on the downstream Ca^-activated transcriptional circuits
that regulate hypertrophy. Members of the Nuclear Factor of Activated T-cells
(NFAT), the transcriptional effectors of Ca^-calcineurin signaling, are relatively >,
weak activators alone and require nuclear partners such as AP-1, C/EBP, GATA-
4 and the transcriptional coactivator p300 to allow maximal induction of target
genes. Ca^ induction of a subset of cardiac genes and hypertrophy in cardiac
muscle cells has been mapped to response elements recognized by the MEF2
family of transcription factors. Herein, we report transcriptional regulation of
genes by a combinatorial mechanism involving proteins of the NFAT and MEF2
families. Transient co-expression of MEF2C or -A, NFATc3, p300 and constitutively
activate CnA was sufficient to recapitulate the selective induction of a subset of
genes during cardiac hypertrophy. /« wVo, MEF2 and NFATc3/c4 formed a complex
containing histone acetyltransferase (HAT) activity on distal MEF2 c/s-elements in
the p-myos/n heavy ctoa/n (p-MyHC) and connecr/Ve r/ssue grovvr/? factor (CTCF)
genes, which are both elevated during pathological cardiac hypertrophy. Using
viral gene transfer of dominant negative MEF2, which prevents binding of MEF2
on its corresponding c/s-elements, we demonstrate that MEF2 is a required
component for cardiomyocytes to undergo Ca^/CnA-induced hypertrophy. Taken
together, these data provide evidence for the existence of a transcriptional
regulatory complex that integrates the Ca^-activated CnA/NFAT signaling pathway
with the myogenic transcriptional activity of MEF2.
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INTRODUCTION
Cytoplasmic members of the Nuclear Factor of Activated T-cells (NFATcl -
c4, Hugo Nomenclature Committee http://www.gene.ucl.ac.uk/nomenclature/)
represents a family of Ca^/calcineurin (CnA)-dependent transcription factors that
are activated by sustained, low-amplitude Ca** signals that provoke activation
of the heterodimeric phosphatase CnA.' Most NFAT isoforms are constitutively
expressed and exist as inactive, cytosolic phosphoproteins. CnA binds NFAT on
conserved motif and dephosphorylates serines residues within SP repeats and
serine rich motifs in the amino-terminus of NFAT family members, which unmasks
a nuclear localization sequence, triggering their nuclear translocation.
Although originally thought to be largely restricted to cells of the immune
system, NFAT family members have since been shown to play a role in other
cell types. In non-immune cells, NFAT has been shown to regulate heart valve
development," control differentiation of skeletal myocytes into slow- or fast-
twitch fiber types * and contribute to the development of hypertrophy in cardiac
and skeletal myocytes.^
DNA binding by NFAT proteins is quite weak and therefore NFAT family
members probably rare/y act a/one, but rather need transcriptional partners to
bind DNA. NFAT engages in direct protein-protein interactions and/or influences
transcription synergistically with transcription factors such as Maf, ICER, and
p21SNFT that belong to the same basic region-leucine zipper (bZIP) family as AP-
1 ;'•' the zinc finger CATA factors, and EGR;*'° and the helix-loop-helix domain
proteins Oct, HNF3, and IRF-4."•'* Thus, cooperative binding of NFAT proteins
with diverse transcription factors makes Ca** signaling dependent on coincident
activation of other signaling pathways in the transcriptional control of diverse
target genes.
Ca^ responsiveness of a number of promoters/enhancers has also been
mapped to another set of response elements recognized by the MADS (MCM-1,
agamous, deficiens, serum response factor) box transcription factor MEF2, which
binds to response elements bearing the consensus sequence CTA(A/T)^TAC. CnA
activates Nur77 in a MEF2-dependent manner in lymphocytes. CnA was shown
to enhance the DNA-binding activity of MEF2A by its direct dephosporylation.'^
Alternatively, CnA has also been reported to activate the Nur77 promoter in T-
lymphocytes by promoting nuclear translocation of NFATc2, which in its turn
forms a ternary complex with MEF2.'" Following this premise, NFAT may act
as a transcriptional activator for MEF2. More recently, a number of studies
have elegantly shown that a network of distinct transcriptional coactivators
and repressors modulates MEF2 function. MEF2 is actively repressed by class II
histone deacetylases (HDACs) in unstimulated cells," while chromatin remodeling
enzymes with histone acetyl-transferase (HAT) activity, such as p300 and CRIP-1,
have been found to associate with MEF2,'& were they are thought to facilitate gene
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expression by inducing histone acetylation. - i
Here we report the identification of a subset of MEF2-responsive cardiac
genes specifically upregulated following CnA activation. Transient co-expression
of MEF2, activated NFAT and p300 recapitulated the selective induction of genes
in CnA transgenic hearts. Multiple conserved, muscle regulatory motifs were
found within the distal regulatory regions of p-MyHC and CTCF, consisting of
NFAT sites, E-boxes, and CArC motifs surrounding a conserved MEF2 site. This •
cluster of regulatory elements display striking similarity to the enhancer of
the mouse musc/e crgat/ne k//iase gene.'^ The specific interaction of a MEF2/
NFAT/p300 transcriptional complex on the MEF2 site was demonstrated using
chromatin immunoprecipitation (ChIP) assays. The requirement of MEF2 for CnA
signaling was demonstrated by a dominant negative MEF2, which abrogated the
characteristic hypertrophic remodeling in cultured cardiomyocytes. Our results are
consistent with a model wherein MEF2 controls cardiac gene expression by acting
as a primary channel for Ca^*-activated NFAT signaling and chromatin remodeling.
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EXPERIMENTAL PROCEDURES
Recombinant piasmids
Expression vectors for NFATcl -c4 or an activated mutant of CnA were
described previously.' pCDNA3 vectors containing human MEF2A, or -C were
generously provided by Eric Oison. Expression vectors containing hemaglutinin
(HA) epitope tagged full length p300 or CBP under control of the CMV promoter
<pCMVp-p3GG-HA and pCMVp-CBP-HA) were kindly provided by Richard Eckner. The
mouse pMyHC promoter, containing a genomic fragment from position -5500 to
position +1 relative to the transcription start site (generous gift of Jeff Robbins),
was cloned as a BomH/ - Hmrf/// fragment into the 6g/// - H/nrf/// site of pCL3-Basic
(Promega). The rat CTGF promoter containing a genomic fragment from position
-3000 to +1 relative to the transcription site cloned adjacent to luciferase in pGL3
(Promega) and was a kind gift from Roel Goldschmeding. A CMV-driven expression
vector for murine DSCR1 was generated by RT-PCR on total RNA isolated from
adult mouse heart tissue using Trizol reagent (Invitrogen) and Superscriptll
Reverse Transcriptase (Invitrogen), subcloned into the £coR/ site of pECE to
incorporate a NH^-terminal FLAG epitope tag and PCR cloned into the H//?d/// site
of pCDNA3 (Invitrogen) to create pCDNA3-mMCIPl. The 3xMEF2-Luc plasmid,
generously provided by Eric Olson, contains three copies of a high-affinity MEF2
binding site from the MCK enhancer inserted upstream of pGL2 (Promega).
Cytomegalovirus (CMV) promoter driven eukaryotic expression plasmid (pCMV-
Tag5A; Invitrogen) coding for a COOH-terminal myc epitope-tagged polypeptide
corresponding to aa 2 through 11 7 from human MEF2 was PCR generated from
pCDNA3-hMEF2C using Accutaq high fidelity system (Sigma) followed by ligation
into the SamH/ site of pCMV-TagSA and confirmed by diagnostic restriction and
sequencing analysis. The vector pCMV-Tag5A-MEF2(R24L) expressing a dominant
negative MEF2 was constructed using site-directed mutagenesis from the parent
plasmid by replacing the argenine residue at position 24 by leucine using site-
directed mutagenesis (Quickchange-XL kit; Stratagene) and the following forward
primer (mutations bold and underlined): 5'-cgt aac aga cag gtg aca ttt aca aag ttg
aaa ttt ggg ttg atg. Deletion fragments encoding either full length or domains of
hMEF2C or hNFATc3/xl were PCR-generated to create NH^-terminal fusions with
the yeast DNA-binding domain of Gal4 by ligation into the SomH/ or So// site of
pBIND (Promega). The luciferase reporter pG5-Luc (Promega) multimerized binding
sites (5x) for GAL4 inserted upstream to luciferase. Detailed information about
piasmids and oligo sequences is available upon request.
Cell culture, transfections and luciferase assays
Low passage C0S7 cells were grown in DMEM (Invitrogen) supplemented
with 10% FBS. 2 x 10^COS7 cells seeded in 24-well plates and transfected at 50-
60% confluency with a total of 2 ng DNA in DMEM containing 2% FBS with 1.5 nl
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FuCENE 6 reagent (Roche, Indianapolis) per ng DNA. pDM-lacZ (Promega; 0.2 ng),
was included in each experiment to correct for transfection efficiency. The cells
were washed 48 hours after transfection with phosphate-buffered saline and lysed
with 100 ul of Reporter Lysis Buffer (Roche), centrifuged at 1 5,000 g for 5 min and
fifty ul of lysate assayed for luciferase activity using the Luclite luciferase reporter
gene assay kit (Packard Instruments, Meriden, CT) according to the manufacturer's
protocol on a 96-well Topcount liquid scintillation counter (Packard Instruments,
Meriden, CT). Twenty ul of cellular lysate was used for measuring p-galactosidase
activity. Isolation and culture of neonatal rat ventricular cardiomyocytes was
performed as described before in detail. '*
Coimmunoprecipitation assays
For coimmunoprecipitation experiments, 5 x 1 0 * COS7 cells grown in 6-
well dishes were transfected using 1.5 ul FuCENE 6 reagent per ug DNA with
expression vectors (1 ug each) encoding the indicated (see Figure 2) Cal4- or Flag
epitope-tagged hMEF2C or hNFATc3/x expression vectors. Twenty-four hours
later, cells were harvested in 500 ul lysis buffer (PBS containing 0.5% NP-40, 1 50
mM NaCI, 0.5 mM EDTA, 10 mM Tris-HCI, 2 ug/ml leupeptin, 10 ug/ml PMSF,
2ug/ml soybean trypsin inhibitor and protease inhibitors; Complete, Boehringer
Mannheim). Cells were subjected to brief sonication, and cellular debris removed
by centrifugation. Full-length hMEF2C or hNFATc3 was immunoprecipitated using
anti-pan-MEF2 or anti-NFATc3 polyclonal antibody (sc-10794 and sc-8321; Santa
Cruz, respectively) and 30 ul protein A/C agarose (Santa Cruz). Precipitated
proteins were resolved by SDS-PACE, transferred to PVDF membranes, and
sequentially immunoblotted with monoclonal antisera against Cal4 (sc-510, Santa
Cruz Biotechnology). Signals were detected with an Enhanced Chemiluminescence
kit (ECL, Amersham) and analyzed using Adobe photoshop 6.0 software.
Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitation was carried out using the Upstate
Biotechnology ChIP assay kit as per the manufacturer's instructions. Briefly,
neonatal rat ventricular myocytes either left untreated or infected with
adenovirus expressing an activated mutant of calcineurin (AdCnA)" on 10 cm
dishes containing 5 x 10' cells were crosslinked by adding 1/10'" volume of
formaldehyde solution (3.7 %) to the media at room temperature for 20 min with
gentle mixing. Soluble chromatin was obtained by sonicating cellular lysates to
shear genomic DNA, clarifying by centrifugation (10 min at 14,000 x g at 4'C),
diluting 10-fold in ChIP dilution buffer precleared with protein A beads. Equal
amounts of soluble chromatin from each sample were immunoprecipitated with
10 ug of one of the following antibodies: anti-acetylated histone H3 antibody
(#06-599, Upstate Biotechnology); monoclonal antisera against NFATc2 (sc-7296,
Santa Cruz) or NFATc3 (sc-8405, Santa Cruz); pan-MEF2 polyclonal antibody
THE CALCINEURIN/NFAT PATHWAY | page 107
(sc-10794, Santa Cruz). Following immunoprecipitation and immobilization
of immunocomplexes, the lysates were put at 65'C for four hours to reverse
the formaldehyde crosslinks. Associated DNA was purified by the Qiaex PCR
purification kit. PCR was carried out using specific primers to the promoter
regions for rat p-MyHC, and CTCF or mouse DSCR1. For primer sequences see
Supplemental Table 1.
Real time PCR and primer design
Primers were targeted against c-jun, ANF, CTCF, desmin, a-MyHC, f5-MyHC,
MLC2a, MLC2v, a-SkA, Glut4, MCK, MCIP1 Ex4, and L7. The primers were specific
for mouse sequences (www.ensembl.org) and selected based on the following
requirements: i) primer melting temperature of ~60'C, ii) CC-content of -55%,
iii) preferably no C at 5' end, iv) avoid runs of more than 3 identical nucleotides,
and v) amplicon length of -100 nucleotides. Specificity was checked with the
Basic Local Alignment Search Tool (BLAST) and the specific melting point of
the amplicons was analyzed using Biorad Dissociation curve software (iCycler,
Biorad). All primer sets were tested for PCR efficiency and alternative primers were
designed in case they fell outside the 5% efficiency range (3.14 ^ slope £ 3.47).
Ventricular tissue samples from wildtype and calcineurin transgenic mice
were homogenized using an Ultrathurax in 1 ml TRIzol reagent (Invitrogen) to
isolate total RNA according to the instructions provided by the manufacturer.
Three ugof the RNA was reverse-transcribed using Superscript II reverse
transcriptase (Invitrogen). In order to avoid the amplification of genomic DNA,
PCR primers were chosen so that the amplification product covered several
exons of the gene of interest. Real-time PCR using the BioRad iCycler (Biorad)
and fluorescence detection was performed in 96-well plates using SYBR Green.
PCR amplification was performed (in duplicate) as a singleplex reaction in a total
reaction volume of 25 ul. The PCR reaction was performed in a 25 uL volume
consisted of 400 nM forward and reverse primers (Supplemental Table 2), 40
ng cDNA, 1 2.5 pi 2xSYBR Green PCR master mix (Biorad). The PCR was cycled
between 95 'C/30 s and 60 'C/30 for 40 cycles, following an initial denaturation
step at 95 "C for 3 min. Amplification products were routinely checked using
dissociation curve software (Biorad), and transcript quantities were compared
using the relative C, method, where the amount of target normalised to the
amount of endogenous control (L7) and relative to the control sample is given
by 2 ' ^ ^ ' . Real time PCR results were verified by electrophoresis of the reverse
transcribed material in 1.2% agarose gels and visualized under UV illumination
after ethidium bromide staining.
Recombinant adenoviruses.
COOH-terminal Myc-tagged MEF2 encompassing residues 1-117 and
incorporating the R24L mutat ion" was cloned into the Nor/ site of pAdTrack-CMV
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viral shuttle vector (generous gift of Bert Vogelstein, John Hopkins University,
Baltimore) and recombined in BJ5183 bacteria (Stratagene) to obtain an E1-E3-
deleted adenoviral bicistronic vector to generate AdMEF2(R24L), which expresses
both MEF2(R24L) and CFP under separate CMV promoters. AdCFP was generated
as described previously.^ An adenovirus expressing an activated mutant of
calcineurin (AdCnA) was described previously.*'
Immunocytochemistry.
Myocytes were prepared as described previously.'^' To visualize
cardiomyocyte size and sarcomeric organization, cells were stained with
phalloidin-Texas Red (Molecular probes) at a dilution of 1:400 and nuclei
visualized with Vectashield/DAPI (H-1200, Vector Laboratories). An epifluorescence
microscope (Axiovert 1 35M Zeiss) was used obtain digitized images at a 400x
magnification and quantitaty cardiomyocyte cell surface area using NIH image
software on 80-100 CFP-positive cardiomyocytes in 10 to 20 fields in three
independent experiments. . . - . - . . , .
Statistical analysis.
The results are presented as mean values ± standard error of the mean
(SEM). Statistical analyses were performed using InStat 3.0 software (CraphPad
Software Inc., San Diego, CA) and ANOVA followed by Bonferroni's post-test when
appropriate.
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RESULTS
NFAT mediates activation of MEF2 by calcineurin.
NFAT is a known substrate for calcineurin (CnA) and translocates from
the cytosol into the nucleus upon dephosphorylation by CnA, making it a likely
candidate transcriptional effector of CnA-dependent MEF2 activation. To date,
NFATc2 has been shown to mediate such an interaction with MEF2, but the
functional significance of NFATc2 in the heart, unlike NFATc3, has not been
addressed so f a r . " " To verify the activation profile of MEF2 by calcineurin, we
ectopically expressed Cal4-MEF2C and pC5-Luc in the absence or presence of
the four NFAT isoforms, NFATcl, -c2, -c3, and -c4. Reporter gene activation was
increased by expression of either NFAT isoform, and was increased further by the
presence of a constitutively active form of CnA (ACnA), which dephosphorylates
NFAT even in the absence of a Ca^* signal (Figure 4.1 A). These data suggest all
four NFAT isoforms can stimulate MEF2 transcriptional activity (Figure 4.1 A).
Since, of all NFAT isoforms, NFATc3 demonstrated the most potent activation
potential of MEF2C, and this NFAT isoform was demonstrated to be required
component of CnA signaling in the heart," we concentrated on this NFAT isoform
for the remainder of the study.
ACnA
t
NFAT
I
pCSLuc
Fig 4.1 A COS7 cells were transiently
transfected with a Cal4 luciferase
reporter construct, and a Gal4-MEF2C
fusion protein either or not in the
presence of expression vectors for
NFATcl, c2, c3, c4, activated calcineurin
(ACnA). The data demonstrate that
MEF2 activity increased in the presence
of NFAT, regardless of the isoform
transfected.
Cal4MEF2C • + + + + + + + + + + +
NFATcl • • + +
NFATc2 + +
NFATc3 + + • -
NFATC4 +
ACnA . . . + . . + . . + . .
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p300 is a member of a family of coactivators involved in the regulation •-?-
of transcription and chromatin, and was shown to directly interact with either
NFAT or MEF2."""" To test the possibility that the MEF2/NFAT complex can
activate transcription by its ability to recruit p300, we expressed Cal4-MEF2C,
NFATc3 and ACnA in the presence of pC5-Luc, which gave a 1 5-fold increase in
the reporter gene activity, while addition of p300 further enhanced this level to
25-fold activation (Figure 4.1 B). These findings were confirmed by co-transfecting
Flag-MEF2C, NFATc3 and ACnA, but now using a reporter with luciferase under
control of multimerized MEF2 binding sites. In this case, presence of Flag-MEF2C,
NFATc3 and ACnA resulted in a 10-fold increase of the reporter construct, whereas
presence of p300 resulted in a 30-fold activation (Figure 4.1 C). Collectively, these
data indicate that all NFAT isoforms are able to stimulate MEF2-dependent gene
expression, and that presence of the co-activator p300 potentiates this effect,
most likely by ternary complex formation.
pCSLuc
Cal4MEF2C
NFATC3
ACnA
p30O
3xMEF2Luc
Fig. 4.1 BC NFAT and
p300 synergistically
activate MEF2
transcriptional activity.
(B) Transfection
experiments using a
Cal4 reporter indicate
that the MEF2/NFAT
complex is more
robustly activated
by addition of p300.
(C) A multimerized
MEF2 reporter was
synergistically activated
by the MEF2/NFAT/
p300 complex.
Minimal domains involved in protein-protein interaction between NFAT and
MEF2.
Recently, interacting domains on MEF2D and NFATc2 were mapped to the
MADS-box DNA binding in MEF2D and the C-terminal transactivation domain
(C-TAD) of NFATc2. To test whether these domains were conserved in distinct
MEF2 and NFAT isoforms, various truncation fragments of MEF2C were fused to
Cal4. Co-expression of Flag-NFATc3 and ACnA in the presence of the pG5-Luc
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reporter demonstrated efficient activation in the presence of full length MEF2C,
and deletion fragments harboring the MADS box (Figure 4.2A). In contrast, MEF2C
mutants lacking respectively the MADS box and MEF2 domain, or only the MADS
box (see Figure 2C for schematic representation of the various MEF2 mutants
used), were unable to transactivate the pGS-Luc reporter in the presence of
NFATc3 (Figure 4.2A).
Gal4-MEF2C(A2-473)
Gal4-MEF2C(A2-I17)
Gal4-MEF2C(A11 7-473)
Cal4MEF2C(A2 57)
Gal4-MEF2C(A2-57, A86-473)
Gal4-MEF2C(A56-473)
NFATc3 + A CnA
Fig 4.2AB Mapping of NFATc3 and MEF2C
interacting domains. (A) COS7 cells were
transfected with deletion mutants of Gal4-
MEF2C fusions with or without Flag-NFATc3.
The data show that the sensitivity of MEF2C to
NFATc activation depends on the MADS-box
in MEF2C. The data represent the mean ±
SEM of four independent experiments and
are presented as fold activation compared
to Cal4-MEF2C fusions without NFATc3. (B)
Protein extracts from COS7 cells transfected
with empty vectors (Gal4), Flag-NFATc3
and/or Cal4-MEF2C deletion constructs were
immunoprecipitated using an anti-NFATc3
antibody, and subjected to Western blotting
using an anti-Cal4 antibody (top panel). The
lower two panels are loading controls for Gal4-
MEF2C fusions or Flag-NFATc3.
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TAD
1)7 473 Interaction
With NFAT
Gal4MEF2C(A 2-473)
Cal4MEF2C(A2117)
Gal4MEF2C(Al 17-473)
Gal4 MEF2C(A 2-S7)
Gal4-MEF2C(A 2-57, A 86-473)
Cal4 MEF2CIA 56-473)
J-c
J-c
J-c
Fig. 4.2C Schematic overview of the Cal4-MEF2C deletion constructs and their ability to bind
NFATc3.
pGSLuc
To verify the transfection results, Flag-NFATc3, ACnA in the presence or
absence of various Gal4-MEF2C deletion constructs were co-expressed in COS7
cells, and immunoprecipitated with an anti-NFATc3 antibody. The presence of
Cal4-MEF2C deletion mutants was detected by immunoblotting against Gal4.
Among the NFATc3-interacting clones detected were full length MEF2C (Figure
4.2B, lane 3) and mutants that harbored the MADS box domain (Figure 4.2B,
lane 4, 6, and 7). MEF2C-mutants lacking either the MADS box and MEF2 domain
(Figure 4.2B, lane 5) or the MADS box alone (Figure 4.2B, lane 8) were unable to
interact with Flag-NFATc3.
Conversely, to map the
domain on NFATc3 that interacts
with MEF2, four Gal4-NFATc3
fusions were constructed,
harboring either full length
NFATc3, the N-terminal regulatory
domain, the Rel Homology Domain
(RHD), or the C-TAD. COS7 cells
transiently transfected with pG5-
Luc, Gal4-NFATc3 mutants and
Flag-MEF2C demonstrated efficient
transactivation when either full
length NFATc3 or the C-TAD of
NFATc3 linked to Gal4 (Figure
4.2D). In contrast, Gal4 constructs
lacking the C-TAD showed no
discernable activation of pG5-Luc
(Figure 4.2D).
1
I III
Gal4-hNFATc3(FL) + + • - •
Gal4-hNFATc3(Al 314) • - + . •
Cal4hNFATc3(A314-732) - • • + +
Gal4-hNFATc3(A732-lllO) • • - • +
MEF2C - + + + +
Fig. 4.2D COS7 cells were transfected with
deletion mutants of Cal4-NFATc3 fusions
with or without Flag-MEF2C. The data show
that the sensitivity of NFATc3 to MEF2C-
dependent activation depends on the C-TAD in
NFATc3. The data presented as fold activation
compared to Cal4-NFATc3 fusions in the
absence of MEF2C.
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Next, Flag- MEF2C, with either of the four distinct Cal4-NFAT fusions were
co-expressed in COS7 cells, followed by co-immunoprecipitation with a pan-
MEF2 antibody. Presence of the distinct Gal4-NFAT fusion proteins was scored by
Gal4 immunoreactivity. Among the interacting proteins detected were full length
NFATc3 (Figure 4.2E, lane 3) and the C-TAD of NFATc3 coupled to Gal4 (Figure
4.2E, lane 6). These data are in line with the transient transfection assays from
Figure 4.2D. Collectively, these findings indicate that specific interactions exist
between the MADS box of MEF2C with NFATc3, on the one hand, and the C-TAD of
NFATc3 with MEF2C, on the other (Figure 4.2C and 4.2F).
Fig 4.2EF Mapping of NFATc3 and
MEF2C interacting domains. (E) Protein
extracts from COS7 cells transfected
with empty vectors (Cal4), Gal4-NFATc3
deletion constructs and/or Flag-MEF2C
were immunoprecipitated using an
anti-MEF2 antibody, and subjected to
Western blotting using an anti-Cal4
antibody (top panel). The lower two
panels are loading controls for Cal4-
NFATc3 fusions or Flag-MEF2C. (F)
Schematic overview of the Cal4-NFATc3
deletion constructs and their ability to
bind MEF2C.
10% Input
\VB: ctFLAG
Jo —
IS —
Regulatory
Domain
I 314
Transactivation
Domain
732 1110 Interaction
With MEF2
Gal4-hNFATc3(FL> I Cal4 I
Cal4 hNFATc3(Al 314)
Gal4-hNFATc3(A314-732)
Gal4 hNFATc3(A732-l 110)
J-C
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Cardiac MEF2-NFAT complex formation and gene expression in vivo.
To assess the significance
of MEF2/NFAT/p300 complex
formation in terms of cardiac gene
expression, transcript levels of a
subset of genes were determined
by quantitative PCR in 1 month-
old wildtype and CnA transgenic
hearts.* Transgenic hearts
displayed a clear upregulation
of transcripts for (3-MyHC, the
/soform of t/?e regw/flrory
gtor c/7a/n-2 (MLC2A),
narr/urer/c factor (>4/Vf),
CTCF, and cx-s/ce/efa/ acr/n (aSkA)
(Figure 4.3A). Interestingly, the
expression levels of several other
genes, such as c-_/w«, desm/n, G/.L/T-
4 and MC7C, previously reported to
be MEF2-regulated," displayed no
discernable changes in expression
level between transgenic and
wildtype hearts. As the upregulated
genes roughly fell into two classes
(sarcomeric components; p-MyHC,
MLC2A, cxSKA; and signaling
molecules; ANF, CTCF) we
selected one gene with the highest
transcript upregulation from each
class (p-MyHC and CTCF) for further
analysis.
Fold change
C-jun
ANF
CTCF
Desmin
ct-MyHC
P-MyHC
Mlc2a
Mlc2v
a-SkA
Glut4
MCK
MCIP1EX4
L7
realtime PCR
-1.1
6.1
11
1.6
-1.3
187.7
59.4
-1.5
6.0
-3.1
-1.2
6.5
1
u
o
IN
X
MCIP1 ex4
L7
Fig. 4.3A Calcineurin activates MEF2-dependent
genes. Quantitive real time PCR indicate that
several MEF2 regulated genes are upregulated in
calcineurin transgenic hearts. These data were
verified for p-MyHC and CTCF by regular RT-PCR.
To define a regulatory mechanism involving NFAT and MEF2 in the
induction of p-MyHC and CTCF, large promoter regions for mouse, rat, and human
were analyzed and aligned for cross species-conservation. The promoter region
of the cardiac p-MyHC gene has been studied in various species, and a number
of potential regulatory elements within 300 bp of the transcriptional start site
have been identified. However, results from transgenic studies suggest that far-
upstream regulatory elements, including a consensus MEF2 site, reside in the 5'
flanking region of the p-MyHC gene." A fragment of p-MyHC gene between -2600
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bp and -2350 bp relative to the transcriptional start site in the murine sequence,
displayed a remarkable conservation with the corresponding rat and human
sequence and harbored multiple regulatory sequences, which have been shown
to be important for muscle-specific gene expression (Figure 4.3B). These include
three E-boxes (consensus CANNTC), one activator protein (AP)-2 site (data not
shown), one CArC motif, one CT/ACCC box and one A/T-rich MEF-2 binding site
(""TTATTTATAG), which is completely homologous with the consensus MEF2
binding sequence (C/T)TA(T/A)JA(G/A).
B (J-MyHC promoter
(-2715) ATTCTCT—TTCCACGCTCAGTTCTCll 11 AGTTCAAGACTGCAGACCCCCACCTCCCCC -M
(•4300) TTTCTCTC 11 I HCTGCTCAGCTCTll 111AGTTTAAOCCTOTCTACCCCC ACOTCACCC •«
(-2896) TTCCCCTCTCTCCATCCTOACATCGCITCTAATTCOCCCTOGTOTCTCCCTCCCTCAC-- -H
TAATTCCCAGCAGTAATTITAGCAAACTTTCCGCTGGTCT-CCACTOGCATGTTCACA'
TAATTCCCAOTAGTAATTTTAGCAAACTTTCCOCTGCTCT-CCACTOGTATOTTCTCA'
-AATTACTGGGAGTAATTITAGCAACTTTTCCTCTGAACTACCGCTGGCGTGTTCACAi
E-box Ebox
AAATG KTCCTATTTCGACCTCJ
AAATG iCCCCTGTTTTGGCTTGA
:ATTTG ITCAGTGTGGTGACAGAGCCCAGACAAAGCA
AAATG JCTCCTGGTTGGGCCTG1 ZATTTG LTCGGTGTGGTGACAGAGCCCAGACAAAGCA
:ACTTOITCAGGGTGGTGACAGAGTGCAGACAAAGCC
GGCACAATGCCTCGGGAG0GGAGGCTCGGGAGGCGGATCACCTTCCTTCTGT--CCAO
GACACAATGCCTGGGGAGGGGAGGCTAGGGAAGTGGATCACCTTCCTTCTATATCCAG'
GGCACAATGC—GGGOAGGGGAGGA-CGOGGGACAGATCACCTTCCTTTCAC-TTCAO
Fig 4.3B Aligment of the
mouse, rat and human
sequence of part of
the promoter region
for p-MyHC and CTCF,
indicating conserved
regions containing
muscle-specific
regulatory elements.
CarC MEF-2
CTTATTTGC rCGACCTCAGCGAAGCAGCCTCC CTTT
CTTATTTG< rCTACCTCAGCGAAGCAGCTTCCAGCCCAGTrcCTCTtrTATTTATAdCACT
CTTATTTGC rCTXCCTTGCCGAAGCGGCCCTCCTTCCAGCCTCTCl ITATTTATAC CATT
TOCTGCCCCTTTGTCTTGTCTC-TTGTCACTCTGTAGTGTGCTC--CACA-TCACCACCC
TGCTGTCCLI I 1OTCTTGTCTC-CTGTCACTCTGTAGTGTGTTC--CACAATCACCACCC
TTaTTTGCTCTCCTTTATCTTGCTATCACTTrGTAGCACACTCTGCACAATCCCCACCC
ACTCC TCACATGGGTTCGGGCCCC-CATTCTCTCCACTAGGAATGTCACGCACGCA (-2259)
ACTCC TCACATGGGTTCGGGCCCC-CATTCTCCCCACTAGGAATGTCACGCACGCA (-3834)
ACCCCAGCATGGTGCGGCCCCTGGCCCCTCACTCTCCCCACAAGGAATGT---GCATGT- (2439)
CTGF promoter
NFAT
(21 IS)
(-2264)
CAGATGAGCCTCACCCTT-CCCTTCCCTTCCCTTCCTCACTCATTCCACC
CAGATGAGGCTCACCCTAACCCATCCCTTCCCTTCCTCACCCATCCC
(-2103) TAGGTGAGACTCGCACTG-CACATCCCTACCCTTCCCCAGCCACCACICCTTTCCAA:CA -H
ACCTTTCTGA :CA HI
TTGCTGGTAGATATAATTGGGAGTTTAAGACTTGAAAGATTTCACTGTGOCTTCCCACIT
TTOCTGOTAGATATAATTGOGAGTTTAGGACTTGAAAGATTTCCCTGTGGCTTCCCACAT
TTAGAGGTAGATGTAATTGGGGGTTTAGGTCTrGAAAGGTTTCACTGTGGCTTCCCACAT
AGTTTGGACTTTAAAAAAAAAAATATCATCAAAGAAGACAGCAAAAGTGCAAGGCCAAGT
AGTTTGGACTTTAAAAAAAAAAA-ATCATC AAAGAGG AC AGC AAAAGC GTGAGGCC AAGT
Al 11 IGGAC1 1 11AAAA TCATCCACAAGGGAAGAAAAAGTTGAGGGCCAAGT
Ebox
:TTTAAATA<TOCCTATACTAC ICATC1 JGCrACTCACATAACTTGCCATGTTCTn 
TOCCTATAATAC kCATGl tGCTATTCACATAACTTCGAATOl IC 1 1 I :TITAAATAGfeAA
TGCCTTTAATAC HCATG1 3GCTATTAAGTTAACTTGGAATGTTCCTI ITTTAAATAG JAA
MEF-2
GTCTCGGGCCTCTTCTCTTTGAGGAA-TG<: rTCGAAACHACATTGAATAACAATGTCAGA
CTCTCAGACCTCTTCTCTTTGAGGAAATG1 rTCGAAAG IACATTGAATAACAATGTTGGA
CTCTTAGGCCTCTTC1 I 11 1GAGGAA-TGC nXKJAAAG >ACATTAAATAACAATGACGAA
AATCCTrCCAGCACIGCAGAGCCTttCTCACACTrCAAGCCACTCACACCTTTCGCTGTTG
AATCC TTC CTGCAC TC C AC AGAC TCCTC AC ACTTCC AGC C AC TCGC AC C GTTC ACTGTTG
AATTCTTCCTGAGCTrCAGAGCOCACCCCCACCCCT--TTGCTGGCCATTCACACTATTG
Ebox
ACATGTAACTGCACTGTACAGCATGTGGCTGOCTTAACAAGGTAATTCTGTqcAGATClAT (-1697)
ACATGTGACTGCACTCTACAGCCTGTGGCTGGCTTAACAAGGTAATTCTGTC CAGATC IT (1845)
ACATCCAACTACACTCTATAACATGTGGCTGCCTTAACGAOGTAATCGTGCJ CAGATC IT (1695)
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Also for the CTCF gene a highly conserved region was found between
-2075 bp and -1 71 5bp relative to the transcriptional start site of the mouse CTCF
gene, containing NFAT binding sites, E box consensus sites, and a MEF2 binding ,
site. The A/T-motif in the CTCF gene ('^TCTTTAAATAG) differs from the MEF2
A/T-rich binding site by two single nucleotide substitutions (underlined) although
the motif binds endogenous MEF2 (Figure 4.3B). ;• • .: •';? ?•
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Fig. 4.3C COS-7 cells
transiently transfected
with p-MyHC and CTCF
luciferase reporters proved
to be sensitive to combined
stimulation with MEF2C and
activated NFATc3.
To test whether MEF2/NFAT complex formation suffice to activate these
genes, we first tested reporter constructs containing the upstream regulatory
sequence of p-MyHC and CTCF driving luciferase. Only a modest increase in
reporter gene activation was observed in response to co-expression of NFATc3 and
ACnA (data not shown). As expected, the presence of MEF2C or MEF2A (data not
shown) induced transcriptional activation of both reporter constructs. However, a
synergistic activation pattern was observed when Flag-NFATc3 and ACnA was co-
transfected with MEF2 and this effect was even further enhanced in the presence
of the transcriptional cofactor p300 (Figure 4.3C).
To determine whether a MEF2/NFAT complex binds to the A/T-rich motifs
in the p-MyHC and CTCF regulatory sequences /n wVo, we performed ChIP
assays using anti-MEF2, anti-NFATc2, anti-NFATc3 and anti-acetylated histone
H3 antibodies. For these experiments, neonatal rat ventricular myocytes were
either infected with an adenovirus expressing ACnA (AdACnA) or not, and 24 hrs
later, soluble, fragmented chromatin was subjected to immunoprecipitation with
indicated antibodies. No antibody (Figure 4.3D, lane 9) or nonspecific rabbit IgC
(data not shown) were used as negative controls. Input chromatin served as a
positive control (Figure 4.3D, lane 10).
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As a positive control for the ability to detect NFAT bound to its regulatory
sequence /n wVo, when immunoprecipitated chromatin with antibodies against
NFATc2 or c3 was subjected to PCR with primers spanning multiple NFAT sites in
the intragenic (intron 3) region of DSCR1 (see table 4.1 for primer sequences), a
295-bp band was detected in the amplicons only after AdACnA stimulation (Figure
4.3D, lanes 5 and 6) and not in serum-free cultured cardiomyocytes (Figure 4.3D,
lanes 1, 2), nor in the antibody control (Figure 4.3D, lane 9), confirming that NFAT
sites were occupied by NFATc2/c3 /n wVo. Interestingly, NFAT occupation of the
regulatory sequence was accompanied by acetylation of the intragenic region,
suggesting that NFAT recruits p300 activity following calcineurin activation (Figure
4.3D, lanes 8).
When immunoprecipitated chromatin was subjected to PCR with primers
spanning the A/T-rich motifs in p-MyHC or CTCF, specific 273 bp and 1 51 bp-
bands were obtained after AdACnA stimulation with all antibodies, indicating that
a complex consisting of MEF2/NFAT and HAT activity (indicative of p300 presence)
occupied the MEF2 binding sites. Intriguingly, under serum free conditions, weak
MEF2 immunoreactivity was also detectable, which supports the notion that
MEF2 may be present in an actively repressed state in the absence of calcineurin
activity. Collectively, these data support the notion that a complex consisting of
MEF2, NFAT, and p300 accumulates on selected A/T-rich motifs in genes following
calcineurin activity in wVo.
6 x NFAT
MCIP1
P-MyHC
CTCF
ChIP a
MCIPlEx4
SF AdCnA
z z s s z z s s z - s
Fig 4.3D Chromatin
immunoprecipitation demonstrates
that activated NFATc2 and
NFATc3 associates with MEF2
in cardiomyocytes to form a
transcriptionally active complex
on A/T-rich motifs in the p-MyHC
and CTCF genes upon calcineurin
stimulation.
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Table 4.1 ChIP primers
Forward primer Reverse primer
MCIP1
p-MyHC
CTGF
5' gctgtttacagccacagaccttc 3'
5' tagtaattttagcaaactttcg 3'
5' ttgaaagatttcactgtggc 3'
5' gacagcaaattcctgagtca3'
5' tgtgaggagtgggtggtgattgt 3'
5' ctcaaagagaagaggtctga 3'
MEF2 is required for MEF2-NFAT cooperative cardiac gene activation.
To assess the requirement of MEF2 downstream of calcineurin-mediated
gene expression, we created a dominant negative MEF2 construct by placing the
first 11 7 amino acid residues from MEF2C with a terminal myc-epitope tag in a
vector under control of the CMV promoter. Additionally, we replaced the Arginine
residue at position 24 to Leucine (R24L), which creates a non-DNA binding mutant
form of MEF2 (Figure 4.4A)." The effectiveness of the dominant negative MEF2
construct, MEF2(R24L), was confirmed by co-transfecting MEF2C or MEF2A with
increasing amounts of the MEF2(R24L) construct using 3xMEF2-Luc reporter as a
readout, which dose-dependently abrogated MEF2-dependent transcription activity
(Figure 4.4A).
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Fig 4.4A Schematic
representation of the
dominant negative MEF2
construct (MEF2(R24L)).
COS7 cells were
transiently transfected
with a multimerized
MEF2 reporter in the
presence of either
expression plasmids
containing MEF2A or
MEF2C and increasing
amounts of MEF2(R24L).
Next, it was tested whether MEF2(R24L) was capable of inhibiting
the synergistic transcriptional activation of p-MyHC-Luc and CTCF-Luc. For
both cardiac gene promoter constructs, overexpression of MEF2(R24L) dose-
dependently decreased the activation induced by the presence of MEF2C or
MEF2A (data not shown), NFATc3, ACnA and p300. Likewise, co-transfection
of an expression vector for DSCR1, a protein inhibitor that antagonizes NFAT
signaling,^ also dose-dependently decreased reporter activity of either promoter
constructs, indicating that NFAT activation is required for calcineurin induced
activation of p-MyHC and CTCF (Figure 4.4B). Taken together, these findings
imply that both MEF2 and NFAT are required components in the transcriptional
activation of p-MyHC and CTCF following calcineurin stimulation.
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B
MyHC promoter
MEF2C/NFATc3/ACnA/p3OO
R24L
MCIP1
CTCF promoter
Fig. 4.4B MEF2(R24L) and MCIP1 dose-dependently inhibited transcriptional activation of
p-MyHC and CTCF promoter constructs.
MEF2 is required downstream of calcineurin-induced cardiomyoyte
hypertrophy
Apart from inducing a distinct gene expression profile in cardiac myocytes,
activation of calcineurin in myocytes is associated with hypertrophic remodeling.
To investigate the requirement of MEF2 in calcineurin-mediated cardiomyocyte
hypertrophy, we generated two replication-deficient adenoviral vectors expressing
either the dominant negative MEF2(R24L) construct and CFP under separate CMV
promoters (Figure 4.5A), or CFP alone. COS7 cells infected with AdMEF2(R24L)
at m.o.i. of 0.4, 0.8 or 1.0 demonstrated increasing immunoreactivity for Myc-
epitope tag (derived from the MEF2(R24L) construct) and CFP (Figure 4.5B, lane 1,
2, and 3 upper panel). Conversely, AdCFP infection, even at a higher m.o.i., only
resulted in strong CFP expression and no myc immuno reactivity (Figure 4.5B, lane
4). Taken together, these results demonstrate that AdMEF2(R24L) and AdCFP are
correctly expressed and should represent effective devices to inhibit MEF2 activity
in primary cardiomyocyte cultures.
B AdR24L AdCFP
MOI 0.4 0.8 1.2 3.0
Ik a myc
a CFP
Fig. 4.5AB (A) Schematic
representation of the
adenoviral vector expressing
MEF2(R24L). (B) Western
blot analysis with an anti-
Myc or anti-CFP antibody on
COS7 cell lysates infected
with either AdCFP, or
AdMEF2(R24L) to confirm
gene transfer.
page 120 | CHAPTER 4
To monitor the change in cell size or sarcomere organization, sarcomeric
actin was stained with Phalloidin (Figure 4.5C, panels a, c, e) and nuclei were
counterstained with DAPI. Cardiomyocytes were infected with the control
adenovirus AdGFP (Figure 4.5C, panels a-b), or infected with AdMEF2(R24L) (Figure
4.5C, panels c-d). After 24 h, the cells were either left untreated (Figure 4.5C,
panels a-c) or infected with AdACnA for 24 h (Figure 4.5C, panels b-d). The data
demonstrate that only AdMEF2(R24L) pre-infection abrogated cardiomyocyte
hypertrophy in response to AdACnA (Figure 4.5C, panels d). No discernable effects
on AdACnA-induced cellular enlargement were observed when cells were pre-
infected with AdCFP (Figure 4.5C, panels b).
SF AdCnA
AdCFP
AdR24L
Fig. 4.5C Representative images of immunostained cardiomyocytes infected with the
indicated adenoviruses. Phalloidin staining indicates less hypertrophy and sarcomere
organization in the presence of AdMEF2(R24L) following AdACnA infection. -Full colour
image page 180
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Quantitation of cardiomyocyte hypertrophy was performed by video
edge detection on large numbers of GFP-positive myocytes (Figure 4.5D). In
agreement with our previous findings, AdACnA resulted in a more than 2-fold
increase in cell surface area (3478±140 urn^ vs. 1 601 ±101 urn*, p<0.01 versus
AdCFP). AdMEF2(R24L) infection abrogated, but not completely inhibited, the
prohypertrophic effects of AdACnA (2272±76 urn', p<0.05 versus AdACnA, p<0.05
versus AdCFP). The data demonstrate that MEF2 is involved in some, but not
all, aspects of hypertrophic remodeling of cardiomyocytes following calcineurin
activation.
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Fig. 4.5D Quantitation
of cell surface areas
demonstrate that
inactivation of MEF2
signaling represses
cardiomyocyte
hypertrophy in response
to AdACnA. These data
represent the mean ±
SEM of three independent
experiments. * indicates
p < 0.05 vs serum free
conditions, t indicates p
< 0.05 vs SF with AdCnA
infection.
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DISCUSSION
MEF2 transcription factors play key roles as regulators of cardiac gene
expression." The data in this study provide evidence that, in cardiac myocytes,
NFAT proteins are actively recruited by MEF2 to target promoters in selected
genes. This observation is reminiscent of the cooperative interaction between
MEF2 proteins and myogenic basic-helix loop helix (bHLH) factors in skeletal
muscles," and MEF2 proteins with GATA factors in cardiac muscles," and suggest
that MEF2 factors interact with a variety of transcription factors to potentiate gene
expression. Given the co-expression of MEF2 and NFAT in smooth muscle, skeletal
muscle, neuronal and hematopoetic cells, the MEF2-dependent pathway described
in this work may provide a molecular paradigm for Ca^/calmodulin signaling in
many target cells.'*
In addition to the calcineurin-NFAT signaling pathway, calmodulin-
dependent kinases (CamK) have been reported to enhance MEF2 transcriptional
activity through relieving their repression by class II histone deactylases (HDACs)."
Whether this alternative modulation of MEF2 activity by CamK is complementary
to the mechanism described in this study remains to be elucidated. The
cooperative pathway between MEF2, NFAT and histone acetyltransferases
described here is, however, distinct from the molecular mode of action of CamK
to increase MEF2 transcriptional activity, suggesting that calcium signals can
activate MEF2 via two separate Ca^ * signaling paradigms; one utilizing CamK to
relieve the active repression of MEF2 by HDAC, and one employing calcineurin
to induce cytoplasmic-nuclear translocation of a transcriptional partner of
MEF2 to potentiate transcription of a subset of MEF2-dependent genes. In fact,
transgenic CamK activity in the heart is associated with a remarkably similar
pathophysiological outcome " as that resulting from transgenic calcineurin
activation,' suggesting that MEF2 functions as a unique integration target to
affect transcription in the heart. In this respect it is interesting to note that in
response to intracellular Ca** elevation, the activity of CamK proceeds calcineurin
activation." It is tempting to speculate that this early CamK activity may serve to
relieve the active HDAC repression of MEF2, sequentially followed by calcineurin-
induced nuclear translocation of NFAT, which allows (further) potentiation of MEF2
transcriptional activity. Whether such temporal aspects in Ca *^ signaling also exist
in the cardiac muscle cell should be explored in the future.
With respect to the nature of the target genes regulated by the MEF2/NFAT/
p300 complex in the heart, a relative large number of genes were fetal isoforms
of sarcomeric components, most notably p-MyHC, a-SKA and the MLC2a. Elevation
of transcripts for these genes are a general characteristic of cardiac hypertrophy
(hence their denotation as "hypertrophic markers"), and their upregulation is
generally observed at the expense of their adult corresponding isoforms (a-MyHC,
a-cardiac actin and MLC2v, respectively). Prior seminal work on the functional
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consequence of selective replacement experiments of the adult a-MyHC by the
fetal (VMyHC isoform indicated that this was associated with a dominant negative
effect on myofibrillar ATPase activity and reduced force generating capacity of
the sarcomere." Based upon our data, it is tempting to speculate that the MEF2/
NFAT interaction mediates remodeling of the sarcomere and profound functional
deterioration observed in calcineurin transgenic mice.
CTCF is a secreted protein implicated in multiple cellular events including
angiogenesis, skeletogenesis and wound healing." It is a member of the CCN
family of secreted proteins, named after CTGF, cysteine-rich 61 (CYR61), and
nephroblastoma overexpressed (NOV) proteins. CTCF is expressed in and
secreted from both cardiac myocytes and fibroblasts." Secreted CTGF signals
in part through the binding of BMP4/2 and TGF-pi in the extracellular space,
through its Chordin-like domain, leading to inhibition of BMP signaling, and
activation of TGF-pi. TGF-pi is a well-known inducer of extracellular matrix (ECM)
components such as collagen and fibronectin, also in the heart. The CTGF gene
may participate in this event, as its promoter contains a TGF-p response element'"
aside from a functional MEF2 site (this study). In support of this view, collagen
deposition and anchorage-independent growth induced by TGF-pi in fibroblasts
can be inhibited by adding neutralizing antibodies against CTGF," indicating a
synergistic relationship between CTGF and TGF-pi. Our results indicate that a
MEF2/NFAT complex controls CTGF expression downstream of calcineurin activity,
and suggest a potential crosstalk between calcineurin and TGF-pi governing
auto-paracrine signaling controlling fibroblast proliferation, ECM deposition
and excessive fibrosis, which are all characteristic for the calcineurin transgenic
cardiomyopathy.'
In conclusion, our data demonstrate the existence of a MEF2/NFAT
regulatory transcriptional pathway controlling genes such as CTGF and p-MyHC in
cardiac muscle cells. The documented function of the select target genes of this
transcriptional circuitry may open new avenues to explain parts of the maladaptive
characteristics associated with calcineurin activity in the heart.
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Chapter 5
An epigenetic pathway controlling cardiac
angiogenesis following cardiac injury
in a gender dependent manner
Eva van Rooij.Jens Fielitz, Roel van der Nagel, Victor Thijssen, Harry J. Crijns,
Rhonda Bassel-Duby, Eric N. Olson, and Leon J. De Windt
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SUMMARY JH
Upon an ischemic insult the heart undergoes a maladaptive remodeling
process involving dilation, hypertrophy of the non-infarcted area and collagen
deposition, which can eventually evolve into heart failure. Previously, we were
able to implicate the calcium/calmodulin-dependent phosphatase calcineurin as
a dominant player in the hypertrophic remodeling of the remote myocardium
following myocardial infarction (Ml). In addition, we recently discovered coordinate
transcriptional synergy between the main downstream target of calcineurin, NFAT,
and the myogenic transcription factor MEF2 to be present in cardiomyocytes. Since
MEF2 transcriptional activity is repressed by class II histone deacetylases (HDACs),
we speculated that HDAC ablation would render mice hypersensitive to Ml-induced
hypertrophic remodeling of the remote myocardium. Since HDAC9 is highly
expressed in the heart and very effective in suppressing hypertrophy in vitro,
we subjected these mice to Ml. Due to potential gender specific effects of HDAC
activity, we included a specific focus on the pathophysiological response of either
sex to Ml.
Our data indicate that HDAC9 ablation in the adult heart results in severely
increased mortality in males after Ml compared to wild type animals. Strikingly,
female HDAC9-null mice show an enhanced survival compared to wild type mice
accompanied by a better maintenance in function. Deleterious left ventricular
remodeling was largely absent in these animals due to the presence of a distinct
epicardial layer of surviving cells in the infarct area. Gene expression analysis
on the infarcted areas of female wild type and HDAC9-deficient mice revealed
an upregulation of angiogenetic factors, such as VECF and angiopoietin in the
HDAC9-null background. Histological examination clearly indicated a strong
angiogenic response, resulting in cardiomyocyte cell survival specifically in the
infarct zone in the HDAC9 knockout females. These data suggest an interaction
between HDAC9 and estrogen that induces neo-angiogenesis in response to
hypoxia. This enhanced angiogenic response protects these HDAC-null females
from maladaptive remodeling after Ml, which leads to sustained improvement in
cardiac function and survival.
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INTRODUCTION
Heart failure secondary to ischemic cardiomyopathy is the primary cause
of cardiovascular mortality, since it induces expansion and alterations in the
infarcted and non-infarcted regions of the heart that impinges upon cardiac
function. This remodeling process involves side-to-side slippage of myocytes
in the myocardium occurring in association with ventricular dilation and is
responsible for wall thinning. The resulting increase in internal load is thought
to promote further stress, dilation and hypertrophy of the non-infarcted area.'
Although neo-angiogenesis within the infarcted tissue is also an integral
component of the remodeling process, the newly developed microvascular
network is unable to support the greater demands of the hypertrophied
myocardium, causing progressive loss of viable tissue, infarct extension and
fibrous replacement.* To date, relatively little is still known about the molecular
pathways governing remodeling of the infarct area and remote myocardium in the
course of ischemic cardiomyopathy.
Previously, we were able to implicate the calcium/calmodulin-dependent
phosphatase calcineurin as a dominant player in the hypertrophic remodeling
of the remote myocardium following ML* Calcineurin functions through
dephosphorylation of its downstream transcription factor Nuclear Factor of
Activated T-cells (NFAT), enabling nuclear translocation and transcriptional
activation." There is evidence from other cell types that NFAT may directly interact
with the myogenic transcription factor Myocyte Enhancer Factor 2 (MEF2). MEF2
is a MADS (MCMI, agamous, deficiens, serum response factor) box transcription
factor that is expressed during the development of all three muscle lineages,
but is also activated during cardiac hypertrophy.^ Additionally, both NFAT
and MEF2 require interaction with the transcriptional coactivator p300 for their
full transcriptional activity, a coactivator that possesses intrinsic histone acetyl
transferase activity to promote a transcriptionally active chromatin configuration/'
Recently, we established a coordinate transcriptional synergy between MEF2 and
NFAT to be present in cardiomyocytes (van Rooij ef a/., submitted).
Histone acetyltransferases (HATs), like p300, catalyze the acetylation of core
histones of nucleosomes, resulting in chromatin relaxation and thereby allowing
access of the transcriptional machinery to specific regions of DNA. The activity of
HATs is antagonized by histone deacetylases (HDACs), which deacetylate histones
and transcription factors, resulting in chromatin condensation and transcriptional
repression.' In mammalian cells, HDACs comprise three distinct classes on the
basis of protein structure and homology to yeast HDACs. Class I (HDAC 1,2,3, 8,
and 11) and III HDACs (which form a structurally distinct class of NAD-dependent
enzymes) are ubiquitously expressed, whereas class II HDACs (HDACs 4, 5, 6, 7, 9,
and 10) are highly enriched in striated muscles and brain.'° Class II HDACs contain
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a unique amino-terminal extension that is responsive to cytoplasmic signals, ^
regulating its association with the myogenic family of MEF2 transcription factors."
'3 Because histone HATs and HDACs compete for the same binding site on MEF2,
class II HDACs may also indirectly inhibit binding of HATs to MEF2 and subsequent
histone acetylation and transcription.'''
To follow-up on the importance of transcriptional synergy between MEF2
and NFAT in cardiac remodeling, we subjected mutant mice lacking class II
HDAC9 to myocardial infarction (Ml). We focused on this isoform because MITR,
the primary product of the HDAC9 locus, was highly effective in suppressing
hypertrophy in vitro." Since HDAC9 knockout mice are sensitized to hypertrophic
stimuli and exhibit stress-dependent cardiomegaly, we speculated that these mice
would be hypersensitive to Ml-induced hypertrophic remodeling to the remote
myocardium. Since a previous report on class II HDAC mutant mice indicated a
possible gender difference,' and possible interactions between HDACs and the
estrogen receptor have been reported,'^™ we included a specific focus on the
pathophysiological response of either sex to Ml.
Here we show that ablation of HDAC9 in the adult heart, as expected, resulted in
severely increased mortality in male HDAC9 knockout animals compared to their
male wild type counterparts. Strikingly, however, female HDAC9 knockout mice
showed a significantly decreased mortality after Ml versus wild type mice coupled
to a better maintenance in function. This effect was attributable to a decrease in
deleterious left ventricular remodeling due to the presence of a distinct epicardial
layer of surviving cells in the infarct area of the HDAC9 knockout females.
Microarray comparison between female wild type and HDAC9-deficient infarcts
revealed an upregulation of an angiogenetic cluster of genes, such as VEGF and
angiopoietin in the HDAC9-null background, which was confirmed by quantitative
PCR analysis. Histological examination revealed new blood vessel formation in
the infarct zone in the HDAC9 knockout females, resulting in cardiomyocyte cell
survival. Since estrogen is known to positively influence endothelial cell growth
important in angiogenesis,*' these data support the existence of a gender-
dependent, epigenetic pathway involving HDAC, that regulates neo-angiogenesis
in response to hypoxia. This enhanced angiogenic response leads to sustained
improvement of cardiac function in female subjects, which predominates over
a MEF2-dependent pathway controlling hypertrophic remodeling in the remote
myocardium.
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EXPERIMENTAL PROCEDURES
Surgical procedures
All animal protocols were approved by the Institutional Animal Care and
Use Committee of the University of Texas Southwestern Medical Center. Five-
month old HDAC9 knockout (KO) mice and wild type (WT) mice of either sex were
anesthetized with 2.4% isoflurane and placed in a supine position on a heating pad
(37'C). Animals were intubated with a 19C stump needle and ventilated with room
air using a MiniVent mouse ventilator (Hugo Sachs Elektronik, Germany; stroke
volume 250 ul, respiratory rate 210 breaths per minute). Via left thoracotomy
between the fourth and fifth ribs, the left anterior coronary artery (LCA) was
visualized under a microscope and ligated using a 6-0 prolene suture. Regional
ischemia was confirmed by visual inspection under a dissecting microscope (Leica)
by discoloration of the occluded distal myocardium. Sham operated animals
underwent the same procedure without occlusion of the LCA. All surgeries and
subsequent analyses were performed in a blinded fashion for genotype.
Transthoracic echocardiography
Three days and 21 days following Ml two-dimensional echocardiography
was performed in conscious mice using the fully digital Vingmed System (CE
Vingmed Ultrasound, Horten, Norway) and a 11.5-MHz linear array transducer as
previously described." Briefly, cine loops and still images were digitally stored
for subsequent analysis using the EchoPac software (CE Vingmed Ultrasound).
Two-dimensional short-axis views of the LV at the level of the tip of the papillary
muscle were recorded with a typical frame rate of 263/s. Left ventricular (LV)
parameters and heart rates were obtained from M-mode interrogation in a short-
axis view. M-mode tracings were used to measure posterior wall thicknesses
at end-diastole and end-systole (PWthd, PWths, respectively), and LV internal
diameter (LVID)was measured as the largest anteroposterior diameter in either
diastole (LVIDd) or systole (LVIDs). The data were analyzed by a single observer
blinded to the murine genotype. LV fractional shortening (FS) was calculated
according to the following formula: FS (%) = [(LVIDd -LVIDs)/LVIDd] xlOO.
RNA extraction and RT-PCR analysis
Total RNA from the infarcted area was isolated using Trizol (Invitrogen). A
10 ug aliquot representative of three animals per sample group was then analyzed
on Affymetrix U74Av2 microarrays. A subset of differentially expressed RNAs was
further characterized by quantitative real time PCR. Briefly, 2 ug RNA from each
sample was used to generate cDNA using Super Script II reverse transcriptase
per manufacturer's specifications (Invitrogen Life Technologies Inc., Burlington,
Ontario, Canada). Real time PCR was cycled between 95 "C/30 s and 60 "C/30 for
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40 cycles, following an initial denaturation step at 95 "C for 3 min. Amplification
products were routinely checked using dissociation curve software (Biorad), and
transcript quantities were compared using the relative Ct method, where the
amount of target normalised to the amount of endogenous control (cyclophilin)
and relative to the control sample is given by 2 " ^ ^ ' . Real time PCR results were
verified by electrophoresis of the reverse transcribed material in 1.2% agarose gels
and visualized under UV illumination after ethidium bromide staining.
Histology and histochemistry
Three weeks after Ml heart tissue was incubated for 30 minutes in
Krebs buffer (11 8 mM NaCI, 4.7 mM KCL, 1.2 mM KH2PO4, 1.2 mM MgSO4,
25 mM NaHCO3, 11 mM glucose) to arrest the heart in diastole, fixed in 3.7%
paraformaldehyde, and embedded in paraffin. Sections were sampled from apex
to base at 1.0 mm intervals and stained with hematoxylin and eosin to visualize
infarcted area and stained with sirius red to visualize fibrosis.
Capillary-density analysis
Multiple paraffin sections were prepared from both sham and Ml operated
group of either sex of both WT and HDAC9 knockout mice (n = 3-6 in each
group). Endothelial cells were immunohistochemically stained to examine the
capillary density. All sections were pretreated with 1% hydrogen peroxide to
inhibit endogenous peroxidase activity and incubated for 45 minutes with 5%
BSA. Capillary endothelium was identified by staining sections with a rat anti-
rabbit Willebrand Factor (vWF) mAb that cross-reacts with mouse vWF (Abeam,
UK). Additionally, lectin histochemistry was performed as described previously""
with minor modifications. The sections were incubated with biotinylated
Cr;/jf/o«fl s/mp//c//o//fl lectin (Vector Laboratories, UK) for 2 hours at room
temperature. Subsequently all sections were stained for immunoperoxidase using
a commercially available kit (HRP DakoCytomation, Denmark). Final color products
were developed using a solution containing 3,3'diaminobenzidine (DAB) and the
sections were counterstained with eosin.
Statistical Analysis
The results are presented as means ± SEM. Statistical analyses were
performed by using INSTAT 3.0 software (CraphPad, San Diego) and ANOVA
followed by Tukey's post-test when appropriate. Statistical significance was
accepted at a P value < 0.05.
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RESULTS
HDAC9 ablation increases post-MI survival in female mice
Myocardial infarction elevates the workload on the heart and instigates
adverse cardiac remodeling, comprising dilation of the infarcted area, hypertrophy
of the remote myocardium and collagen deposition in the interstitium. Due to
the cooperative interaction between the cardiac transcription factors NFAT and
MEF2 in regulating hypertrophic gene expression profile, we speculated that mice
lacking the MEF2 repressor HDAC9 would rapidly develop an excessive cardiac
hypertrophic response in the remote myocardium after Ml. Since we previously
reported that Ml-induced hypertrophy of the remote myocardium is maladaptive,
we expected rapid deterioration of HDAC9 knockout mice after Ml compared to
their wild type counterparts.
When we monitored the survival rates up to three weeks after Ml, survival after
Ml was 63% for males and 64% for female mice in the wild type background.
Although, a dramatic decreased survival was evident in HDAC9 knockout males
compared to wild type mice (36%), female HDAC9-deficient mice displayed
remarkably improved postinfarction survival (85%) (Fig. 5.1).
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Fig. 5.1 HDAC9 knockout females show an enhanced survival after Ml. Post-MI mortality was
comparable between male and female WT mice. Although male HDAC9 knockout animals
suffered from an elevated mortality compared to wild type, contrarily the females showed a
highly increased survival after Ml.
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HDAC9 KO females maintain cardiac function after myocardial infarction
To further investigate the evident gender-dependent response after Ml in
the HDAC9 null background, we serially analyzed cardiac function and geometry
following infarct. At baseline, heart rate and fractional shortening in female
HDAC9 knockout mice was significantly lower as for female WT mice. The force-
frequency relationship, which indicates a positive correlation between heart rate
and contractile force, might partially explain the lower fractional shortening
for the HDAC9 knockout. Strikingly, while heart rate in WT female animals
significantly decreased after Ml, heart rate in HDAC9 knockout animals displayed
a progressive increase until, three weeks after Ml, it reached a level comparable to
WT heart rate (Table 5.1 and Fig. 5.2).
baseline 3 days after Ml 3 weeks after Ml
wild
type
HDAC9
KO
Fig. 5.2A Cardiac function after Ml better maintained in female HDAC9 knockout mice.
Representative M-mode images of sham or infarcted WT and HDAC9 kncokout females
3 days and 3 weeks after Ml. Data demonstrate comparable initial LV dilation in both
groups, with progressive dilation and loss of contractile behaviour in WT mice, which was
substantially attenuated in HDAC9 KO mice. (n=5-12 per group)
Three weeks after Ml wild type animals showed a severe dilation and
deterioration in function. Since the morphology of the HDAC9 knockout females
was better maintained after Ml, their hearts dilated significantly less, and
fractional shortening remained better. Three weeks after Ml the HDAC9 knockout
females even showed a significantly enhanced contractility compared to WT
females (Table 5.1 and Fig 5.2B). This increase might partially find it explanation
in the progressive increase in heart rate in female HDAC9 knockout mice after
Ml. Remarkably, three weeks after surgery we were also able to detect some
regeneration of contractile force of the infarcted wall, which also contributes to
the enhanced contractility (Fig. 5.2A).
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Fig. 5.2B Bargraph representation of HR, FS, and LVIDd. Although HDAC9 kneokout females
showed a depressed HR at baseline, after Ml it became elevated to a comparable level as
for WT mice. FS and LVIDd indicate that HDAC9 knockout females show a functional and
morphological deterioration after Ml (n = 5 in both sham groups; n = 8-12 in Ml groups). • P
<0.05 vs. sham operated group, # P < 0.05 vs. corresponding WT group.
Table 5.1 Echocardiographical characteristics in wild type ans HDAC9 KO
female mice after sham operation and after myocardial infarction.
n
HR
wild type
sham
5
630 i 26
3 days
post Ml
10
614 ±25
3 weeks
post Ml
8
592 ± 20
HDAC9 KO
sham
5
258± 12*
3 days
post Ml
12
453 ± 57
10 days
post Ml
12
549 ±41-
3 weeks
post Ml
10
594 ± 53-
PWthd. mm 0.81 ± 0.04 0.74 ± 0.04 0.95 ± 0.09
PWths. mm 1.31 ±0.05 1.30 ±0.04 1.45 ±0.05
0.83 ±0.07 0.86 ±0.04 0.90 ± 0.05 0.92 ± 0.03
1.30 ±0.07 1.32 ±0.06 1.44 ±0.07 1.47 ±0.06
LVIDd. mm 2.62 ± 0.07 3.07 ±0.12 4.02 ± 0.28-
LVIDs.mm 0.71 ± 0.04 2.14 ± 0.09- 3.08 ± 0.31-
*FS 73.3 ±1.5 33.0 ± 1 . 1 - 26.5 ± 2.3-
3 . 4 2 ± 0 . 0 7 3 .31 ± 0 . 0 8 3 . 5 4 ± 0 . 1 7 3 . 1 4 ± 0.1 7»
2 . 0 6 ± 0 . 0 4 ' 2 . 4 0 ± 0 . 0 8 2 . 4 6 ± 0 . 2 2 2 . 0 3 ± 0 . 3 0 '
3 9 . 6 ± 1 . 2 ' 2 7 . 4 ± 1 . 2 3 1 . 3 ± 4 . 2 4 6 . 8 ± 6 . 1 '
Data are expressed as means ± SEM. PWthd, posterior wall thickness in diastole; PWths, posterior wall thickness in systole;
LVIDd, left ventricular internal diameter in diastole; LVIDs, left ventricular internal diameter in diastole;
FS, left ventricular fractional shortening calculated as (LVIDdLVIDs)/LVIDd.
•P<0.05 vs. sham
'P<0.05 vs. corresponding wt group
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Attenuated post-infarction remodeling in HDAC9 KO females
Histological examination showed the
HDAC9 knockout females to be protected against
cardiac remodeling after Ml. H&E stained sections
indicated the infarct to span the entire free wall .
of the left ventricle for both WT and HDAC9
knockout mice.
RCA
LCA
Although occlusion of the LAD deprived the same circumferential left
ventricular area of oxygen in WT and knockout hearts, the HDAC9 knockout
female myocardium showed reduced dilation due to a non-transmural infarct.
These sections also clearly showed extensive hypertrophy of the remote
myocardium in the wild type animals in response to Ml, which was absent for the
HDAC9 knockout females (Fig. 5.3A).
wild type HDAC9 KO
Fig. 5.3A Reduced cardiac
remodeling in HDAC9 knockout
females after Ml. (A) Morphometric
analyses of H&E transversal
sections from apex to base
indicate no significant difference
in infarcted left ventricular
circumference between wild type
and HDAC9 knockout females, with
more dilation and an increased
hypertrophic response in the wild
type mice. - full colour image
page 181
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Geometric analysis confirmed these data: the ratio between the heart
weight or left ventricular weight and either the body weight or the tibia length
as a measure for hypertrophy, showed a severe hypertrophic response for the
WT females three weeks after Ml, while this response was lacking in the HDAC9
knockout female group. Hypertrophic remodeling in WT female mice was also
accompanied by signs of cardiac failure, as indicated by the increase in atrial
weights, lung weights and right ventricular weights (Table 5.2). In contrast, due
to the lack of maladaptive hypertrophy these features of cardiac failure were
absent in the female HDAC9 knockout mice. Due to the low survival rate in HDAC9
knockout animals this comparison could not be made between male wild type and
knockout animals.
Table 5.2 Echocardiographical characteristics in wild type ans HDAC9 KO
female mice after sham operation and after myocardial infarction.
n
BW operation, g
BW, g
HW, mg
LVW, mg
RVW, mg
Atria weight, mg
Lung weight, mg
Liver weight, mg
TL, mm
HW/BW, mg/g
HW/TL, mg/mm
LVW/BW, mg/g
LVW/TL. mg/mm
wild
sham
5
26.0 ± 0.9
26.3 ± 1.0
134.6±3
90.5 ± 2.6
24.S ± 0.9
12.0 1 0.6
173.8 ±9.3
1286 ±49
17.4 ±0.1
5.1 ±0.2
7.8 1 0.2
3.3 ±0.0
S.2 ± 0.2
type
3 weeks post Ml
9
26.2 ±0.7
24.0 ±0.6
196.1 ± 13-
111.5 ± 7.0-
35.0 ± 3.8
26.8 ± 6.7-
2S6.3 ± 36.5-
1161 ±41
17.5 ±0.1
8.1 ±0.4-
11.2 ±0.7-
4.7 ±0.2-
6.4 ± 0.4-
HDAC9KO
sham
5
25.1 ± 1.7
25.3 ± 1.7
141.8±6
88.0 ± 4.0
22.S ± 0.3
11.5 ±0.9
1S7.4± 8.9
1123 ± 54
16.9 ±0.3
5.6 ±0.2
8.4 ± 0.7
4.0 ±0.2
S.3 ± 0.2
3 weeks post Ml
1 1
25.5 ±0.9
24.4 ± 0.9
158.8 ± 8 '
99 ± 2.6
23.0 ± 0.8'
13.2 ± 1.0*
IS3± 16.0-
1034± 50
17.5 ±0.1
6.5 ±0.3 '
9.0 ± 0.4'
3.9 ±0.1*
5.6 ± 0 . 1 '
Data are expressed as means ± SEM. HW, heart weight; LVW, left ventricular weight; RVW, right ventricular weight;
TL, tibia length; BW, body weight.
•P<0.05 vs. sham
•P<0.05 vs. corresponding wt group
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Sections stained for sirius red indicated the presence of reactive fibrosis in
the noninfarcted regions of the left ventricle with more pronounced presence of
collagen deposition towards the infarct. However, WT mice showed a more severe
collagen deposit than the HDAC9 knockout females (Fig. 5.3B).
B sham sham Ml Ml
wild type HDAC9 KO wild type HDAC9 KO
•r-
• * .
Fig. 5.3B Sirius red staining indicates low levels of collagen deposition in the sham operated
mouse hearts from both phenotypes. Although massive accumulation of fibrillar collagen
(interstitial and perivascular fibrosis) is present after infarction in wild type mice, this
response is substantially attenuated in female HDAC9 knockout mice. Bar indicates 0.1 mm.
- full colour image page 181
These data indicate that HDAC9 ablation in female mice leads to a
significant reduction of the major structural alterations of the remote myocardium
in the postinfarcted heart, and results in a significant cardioprotective effect
against myocardial infarction.
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Increased expression of angiogenic factors in hypoxic cardiac region of
HDAC9 KO females
More detailed examination of the infarcted area in the HDAC9 knockout
females clearly indicated the presence of a distinct layer of surviving
cardiomyocytes at the epicardial surface of the infarcted region (Fig. 5.4). Due to
the presence of this additional layer of muscle cells the integrity of the infarcted
area was better maintained after Ml and prevented the heart to dilate in the same
extent as the WT mice. To explore this phenotype, we isolated total RNA from the
infarcted area and analyzed gene expression levels using an Affymetrix U74Av2
microarray. Based on the microarray data, expression levels of a subset of genes
was also examined by realtime PCR.
wild type
HDAC9
knockout
Fig. 5.4 Additional epicardial layer of surviving cells in infarcted area of female HDAC9
knockout mice. H&E stained sections show the presence of an additional layer of survival
cells at the epicardial surface of the infarcted area in the female HDAC9 knockout animals
compared to wild WT. Bar indicates 0.1 mm. - full colour image page 182
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The presence of estrogen in pre-menopausal women has been shown A
to have beneficial effects on the cardiovascular system. Although the exact
mechanism is still unknown, estrogens appear to facilitate angiogenesis and
collateral vessel formation.^' In addition, hypoxia also induces a well defined
angiogenic response directly after myocardial infarction."" Both hypoxia and
estrogens have been shown to stimulate the synthesis of the major angiogenic
factor called vascular endothelial growth factor (VEGF-A).^  "
Angiogenic profiling of the infarcted area indicated that several genes
known to be involved in angiogenesis were highly expressed in the infarcted
area of the HDAC9 knockout females (Table 5.3 and Fig. 5.5A). VEGF-A and its
receptors (VEGFR1 and VEGFR2) were found to be most highly upregulated (85, 67
and 101 fold vs. wild type females, respectively). This is in line with the fact that
VEGF-A induces overexpression of VEGFR1 and VEGFR2 to create a loop allowing
endothelial cells to become responsive and activated.™ Angiopoietins (Angl and
Ang 2) and the Tie2 receptor constitute an additional endothelial cell-specific
angiogenic system. It has been suggested that the Angl-Tie2 system regulates
the stability and maturation of vessel structures, and Ang2 functions as a natural
antagonist for Tie2.*' Previously Ang2, which was 10 fold upregulated in the
infarcted area of the HDAC9 knockout females, was shown to be upregulated by
hypoxia and angiogenic cytokines, including
Table 5.3 Primers angiogenic profiling
Forward target Reverse primer 5'-3' forward primer 5'-3'
Cyclophilin ACCTACACTTCAACCCGAATC
p-actin CCACCACCTCCAACCACCC
Ang iopo ie t in l GCAAGGCTGATAAGGTTATGA
Angiopoietin-2 TTCTTCTTTACGGATAGCAAC
Angiopoietin-3 GCAGTTGTTCCCTCTTCTCTT
VECF-A CTCCAGGGCTTCATCGTTA
VEGF-B TGCCCATGAGTTCCATGC
VEGFC TTTAAGGAAGCACTTCTGTGTGT
VEGF-D CGTGCTGAATGAGATCTCCC
VEGFR1 GCTGCTTGGACATCTCACTG
VEGF-R2 TTCCACATGCTGGGCAAGTC
VEGF-R3 TGCATGCTGGGTGGACTATCA
T1E-1 AATGGCAGACCAGGCAATC
T1E-2 GTTGACTCTAGCTCGGACTGT
bFGF CACATTTAGAAGCCAGTAATCT
ATTTCTTTTGACTTGCGCGC
GAAGCTGTGCTATGTTGCTCTA
AGCTACCAACAAACAACAGCA
AGCCACGGTCAACAACTGC
AACAGGGCCCTGGAGACC
CAGAAGGAGAGCAGAAGTCC
CCCAGTTTGATGGCCCCA
GTAAAAACAAACTTTTCCCTAATTC
GCAAGACGAGACTCCACTGC
TCAGCAGCTCAAGTGTCACC
ATGACATCTTGATTGTGGCAT
GCAGGAGGAGGAAGAGGAGC
CCCCACTGGTCTCCTTTAG
GAAGTCGACAGGCCATCCC
CCCGACGGCCGCGTGGAT
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Fig. 5.5A Hypoxia induces an enhanced angiogenic respons in the HDAC9 knockout females
after Ml. Quantitative PCR analysis of angiogenic factors indicate a severly increased
angiogenic response in the infarcted region of the HDAC9 knockout females versus the WT
female mice.
Interestly, the expression levels of the angiogenic factors tested, did not
show any significant differences in the sham operated animals between either
sex of wild type and HDAC9 knockout animals, nor did they differ between male
and female HDAC9 knockout mice (data not shown). Although it is known that
VECF and angiopoietins play complementary and coordinate roles during vascular
remodeling in normal tissue, our data indicate that these systems also interact
during hypoxia-induced angiogenesis in the heart of HDAC9 knockout female
mice.
Conclusively, gene expression profiling indicated upregulation of
angiogenic factors under hypoxic conditions in HDAC9 knockout females, and
implies an interaction between HDAC, estrogen signaling and hypoxia in the
induction of new vessel formation.
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Enhanced vessel formation in infarcted region HDAC9 KO females ob-^
To visualize the vasculature we stained transversal sections of the heart
for von Willebrand Factor and lectin. Von Willebrand factor (vWF) is a glycoprotein
produced uniquely by endothelial cells, and is routinely used to identify vessels
in tissue sections. Although we were unable to detect vWF in transversal sections
of sham operated mice, there were vWF positive vessels present in the infarcted
area of both WT and HDAC9 knockout females with a higher abundance in the
HDAC9 knockout females (Fig 5.5B). Although vWF is heterogeneously distributed
throughout the vasculature, previously it was reported that fibroblast growth
factor-2 and VECF synergistically up-regulate expression of vWF mRNA and protein
in cultured endothelial cells. The local upregulation of these angiogenic factors
in the infarcted area might explain the presence of the vWF positivity in a subset
of vessels exclusively in the infarcted region, especially for the HDAC9 knockout
females.
wild type HDAC9 knockout
sham
fer''f
/ • : . - ' •
infarcted • m ft ^ J > .'^
area • s ^ * ' '• ' "'
Fig 5.5B vWF stained images reveal only vWF positive vessels in the infarcted regions, with a
higher abundancy in the infarcted area of the female HDAC9 knockout mice. Bar indicates 0.1
mm. - full colour image page 182
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i Additionally, we used Gr/fifon/a S/mp//c7yo//fl lectin I (CS-I) as an endothelial
marker. There was a regular distribution of capillaries around cardiomyocytes
in both sham operated groups. Three weeks after Ml the border zone of the
infarcted region contained regions of low vascularity in the WT animals, which
was even more decreased in the infarct itself. However, both the border zone
and the infarcted region of the HDAC9 knockout females appeared to be highly
vascular, with enlarged, thin-walled vessels (Fig. 5.5C). This is in line with the
severe upregulation of VEGF-A in this area, since a characteristic feature of VEGF-A
mediated angiogenesis in a variety of models is the generation of dilated enlarged
vessels.'*" Although the sections need to be quantified extensively, these data
indicate a severely enhanced VEGF-A -induced angiogenic response in the infarcted
region of the HDAC9 knockout females, which is likely to be responsible for the
cardioprotective effect after myocardial infarction.
, . wild type HDAC9 knockout
sham
border zone -
infarct •? c
X
Infarcted
area
Fig. 5.5C Sections stained for lectin an equal distribution of capillaries surrounding
cardiomyocytes in the non-infarcted areas, while the ischemic region shows irregular
patterning of vasculature with additional and enlarged vessels in the border zone and the
infarcted region of the HDAC9 knockout females compared to the WT animals. Bar indicates
0.1 mm. - full colour image page 183
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DISCUSSION ' - " .fiSiH-5v^vw^;-i:,.
Heart failure secondary to ischemic cardiomyopathy is the primary cause of
cardiovascular mortality. When the myocardium is deprived of blood, a protective
response is triggered to improve myocardial perfusion by the formation of new -
capillaries (angiogenesis) and by the enlargement of pre-existing collateral vessels
(arteriogenesis). Although neo-angiogenesis within the infarcted tissue is also
an integral component of the remodeling process after myocardial ischemia, the
newly developed microvascular network is unable to support the greater demands
of the hypertrophied myocardium, resulting in progressive loss of viable tissue,
infarct extension and fibrous replacement.^
Animal studies evaluating gender difference collectively demonstrated that
estrogen exerts significant benefits on the cardiovascular system and showed that
estrogen replacement therapy in postmenopausal women reduces morbidity and
mortality associated with cardiovascular disease by ~50%. " • " The cardioprotective
effect of estrogen is partly due to its role in angiogenesis. Estrogens are known
to promote new vessel formation both in vitro and in vivo *°, and have been
postulated to be pro-angiogenic in ischemic tissues. Although the mechanisms
involved in the pro-angiogenic effects of estrogen are probably multifactorial,"•** it
includes upregulation of VECF-A, its receptors and additional angiogenic proteins,
which were all found to be highly upregulated in our study.
The biological actions of estrogens are mediated by the intracellular
estrogen receptor (ER) a and p that function as transcription factors in response
to ligand binding. Interestingly, current models of ER action suggest that it
modulates the rate of transcription initiation through interactions with the basal
transcription machinery and through the alterations in the state of chromatin
organization at the promoter of target genes via the recruitment of a variety of
cofactors. Coactivators, such as cAMP-response element binding protein (CREB)-
binding protein (CBP), p300 and p300/CBP-associated factor (pCAF) possess
intrinsic acetyltransferase (HAT) activity capable of modifying the chromatin
organization of the target genes."* In response to estrogen binding, there is a
cyclic recruitment of co-activators leading to hyperacetylation of target genes,
which decondenses nucleosomes and facilitates the binding of transcription
factors to the underlying DNA regulatory elements, leading to more efficacious
gene activation.""* This temporal presence of acetyltransferases is followed by a
transient wave of deacetylation, suggesting the presence of histone deacetylases
(HDAC) at the ER target promoters even under inducing conditions in the presence
of ligands. In the last few years several reports have indicated that coregulators
of ER, including repressor of estrogenreceptor activity (REA), ligand-dependent
corepressor (LcoR), metastatic-associated protein 1 (MTA1) and receptor
interacting protein (RIP)l 40, recruit HDAC to nuclear receptor target genes in the
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This interaction between the estrogen receptor and HDAC may provide
a plausible mechanism for the profoundangiogenic response observed in the
HDAC9 knockout female infarct under hypoxic conditions. Based on these data
it is tempting to speculate that ablation of HDAC9 removes the transcriptional
repressive effect on the estrogen receptor, thereby enhancing the estrogen-
induced upregulation of angiogenic genes. Since there were no significant
differences in angiogenic gene expression between WT and HDAC9 knockout
animals at baseline, nor between HDAC9 knockout male and female mice, the
angiogenic response is apparently triggered by the local ischemia, instead of
constituting a more generalized phenomenon in the HDAC9 knockout females.
It will be of great additional value to unravel which hypoxia related factors
are responsible for the cardioprotective phenotype of the HDAC9 knockout
females. Although to date several angiogenic molecules have been indentified
to be involved in hypoxia regulated angiogenesis, hypoxia-inducible factor 1
(HIF-la) might be a good candidate to interact in some way with the estrogen
receptor, since it is a transcriptional activator of VECF." VECF-A and its receptors
are critically involved in the regulation of pathological blood vessel growth in
the adult during various angiogenesis-dependent diseases associated with tissue
hypoxia, and were found to be highly upregulated in the infarcted tissue of the
HDAC9 knockout females. Since VECF synthesis is modulated not only by hypoxia,
but also by steroid hormones, our data reveal a novel complex interplay between
estrogen- and hypoxia-dependent pathways driving VECF expression.
Additionally, these results indicate a possible mechanism for stimulation
of collateral vessel formation in ischemic tissue by removal of the ER repressor
HDAC. Conclusive data on estrogens involvement on remodeling of the collateral
vasculature and thereby remodeling of the heart in response to an ischemic
event, will possibly result from further studies in the HDAC9 knockout mice on
the effects of gonadectomy and estrogen replacement previous to Ml. Eventually,
therapeutic stimulation of angiogenesis by the ovarian steroid hormone in
the absence of its transcriptional repressor HDAC, could be beneficial for the
treatment of ischemic heart disease.
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Cardiac hypertrophy:
the good, the bad and the ugly
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Cardiac hypertrophy; the good, the bad, and the ugly •n<r/*o
Cardiac hypertrophy is defined by an increase in heart size and/or
myofibrillar volume without a change in myocyte number in response to increased
workload, injury, or intrinsic defects in contractile performance. These changes
trigger a cardiac remodelling process in which the heart becomes abnormally
enlarged, which can eventually lead to heart failure and sudden death in humans.
Traditionally, it has been widely believed that hypertrophy occurs as an
adaptive response as a consequence of pressure overload or due to an increase in
demand during endurance exercise and pregnancy, and is termed "compensatory"
on the premise that it facilitates ejection performance by normalizing systolic wall
stress while maintaining a normal organization of cardiac structure. In the longer
term, beneficial, "compensated" hypertrophy may transition into maladaptive
"decompensated" hypertrophy and heart failure, a process during which the same
signaling routes are thought to be active.'
In the last few years, the general tendency to view hypertrophy as a
single entity with similar morphological and molecular manifestations, has shifted
towards the belief that the hypertrophic response of the myocyte is directed by
the extracellular signal that reaches the cell. Cardiac hypertrophy is initiated
by a wide array of endocrine, paracrine, and autocrine growth factors, which
all activate a different subset of intracellular signaling cascades. The cellular
response, which can either be genomic or non-genomic, is the combined resultant
of the activated signaling routes and directs the cell towards a predisposed fate.
Despite the complexity of this signaling network and the discrepancy between the
different types of hypertrophy, a rough distinction can be made between 'good'
physiological hypertrophy with normal organization of cardiac structure and
normal or enhanced cardiac function, and 'bad' pathological hypertrophy, which
is associated with an altered pattern of cardiac gene expression, fibrosis, cardiac
dysfunction, and increased morbidity and mortality.
Several research groups have applied transgenesis in an attempt to
elucidate the role of the distinct signaling cascades involved in different types of
hypertrophy. Elucidation of these distinct signaling cascades that play a role in
these two different forms of hypertrophy, might raise the prospect of modulating
pathological hypertrophic growth, while preserving the heart's ability to adapt to
an increase in physiological demands.
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Calcineurin's involvement in pathological hypertrophy
In 1998 Molkentin et al. first identified the calcium-dependent
phosphatase calcineurin as a key mediator of cardiac hypertrophy.* Cardiac
specific overexpression of an activated form of calcineurin revealed to be
sufficient to induce a robust hypertrophic response in transgenic mice and to
eventually result in a failing phenotype of the myocardium. Due to the apparent
pathological phenotype, calcineurin has gained a lot of interest. The studies
presented in the thesis have been dedicated to elucidate the precise mode of
action and physiological or pathological role of calcineurin in the hypertrophic
growth process of the heart.
Acute myocardial infarction induces left ventricular hypertrophy, and
eventually gives rise to congestive heart failure.' Although the role of calcineurin
in pressure overload hypertrophy has already been established,"* pharmacological
inhibition of calcineurin failed to clearly define its involvement in cardiac
remodeling after myocardial infarction.^ We were able to identify calcineurin
as a key player in the remodeling process of the remote myocardium following
myocardial infarction. Our data indicated that calcineurin-induced hypertrophic
remodeling leads to a predisposition to maladaptivity, characterized by fibrosis
and chamber dilation, fueling the transition to overt heart failure. The use of a
genetic mouse model with a mild myocyte-restricted overexpression of Modulatory
Calcineurin Interacting Protein 1 (MCIP1) to effectively block calcineurin activity
specifically in the heart," enabled us to indicate that inhibition of calcineurin
activity is able to largely prevent these characteristics (Chapter 2). These
findings not only indicate that calcineurin plays a significant role in hypertrophic
remodeling of the heart after Ml, but also show that inhibition of calcineurin and
subsequent hypertrophy may be of therapeutic benefit.
Since the MCIP1 transgene is under the transcriptional control of the
a-MyHC promoter, which is activated at birth,'" MCIP1 continuously inhibits
calcineurin activity. This directly prevents the myocardium from a hypertrophic
response after exposure to myocardial infarction, and favours the idea that cardiac
hypertrophy caused by activation of calcineurin is maladaptive in nature.
Wilkins et al. recently confirmed the existence of a divergence between
active signaling routes for different forms of cardiac hypertrophy by showing that
voluntary wheel running and swimming resulted in significant cardiac hypertrophy
without activation of calcineurin-NFAT signaling.® Although in most models of
pathological hypertrophy studied to date, inhibition of calcineurin-NFAT signaling
has yielded either a reduction in the hypertrophic response and/or a delay in the
progression from hypertrophy to heart failure, calcineurin proved to play no role
in regulating physiological or adaptive growth of the myocardium.
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The involvement of the calcineurin/NFAT signaling in maladaptive cardiac
hypertrophy intrigued us to more specifically unravel the calcineurin/NFAT
signaling route. In the initial description of calcineurin's involvement in cardiac
hypertrophy, calcineurin was shown to dephosphorylate the transcription factor
Nuclear Factor of Activated T-cells c4 (NFATc4) in cardiomyocytes, enabling it to
translocate to the nucleus and activate cardiac transcription.^ However, although
several lines of transgenic mice expressing activated mutants of NFATc4 in
a cardiac-selective manner showed NFATc4 to be sufficient to induce robust
hypertrophy, loss of NFATc4 did not compromise the ability of the myocardium
to undergo hypertrophic growth, which excluded the absolute requirement of
NFATc4 in the hypertrophic process. In contrast, NFATc3-null mice appeared to
be partially deficient in their ability to undergo cardiac hypertrophy in response
to calcineurin activation." Together these observations established NFATc3 to be
a critical downstream mediator of calcineurin-regulated hypertrophy in the heart
and validated the original hypothesis that the calcineurin-regulated hypertrophic
responses require NFAT effectors in vivo.
The high degree of homology for all calcineurin-sensitive NFAT isoforms
together with the observation the NFATc3-null mice were unable to completely
block calcineurin-induced hypertrophy" led us to hypothesize that this might be a
result of functional redundancy by other NFAT isoforms. Since only simultaneously
abrogation of all NFAT-dependent transcriptional activity renders cardiomyocytes
resistant to calcineurin- and agonist-induced hypertrophy (Chapter 3), partial
blockade of calcineurin activity in the NFAT-null mice might be due to functional
redundancy between NFAT isoforms.
Due to the ability of the NFAT isoforms to, at least in part, compensate
for each others function, in vivo confirmation of our findings would be possible by
generating transgenic mice overexpressing the dominant negative NFAT protein
in the heart. However, exhaustive attempts to generate dominant negative NFAT
transgenic mice using the a-MyHC promoter were unsuccessful due to embryonic
or early post-natal lethality, suggesting that NFAT factors are crucial during
developmental maturation of the myocardium. Inducible transgenic systems to
temporally regulate expression of the dominant negative NFAT construct should
be applied to bypass these developmental problems that arise from blocking all
cardiac NFAT isoforms at a neonatal stage. This temporal regulation will expand
our ability to dissect the effect of blocking transcriptional activity NFAT within the
hypertrophic, adult heart.
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Transcriptional synergy between MEF2 and NFAT
Despite the wealth of information linking calcineurin and the progression
of cardiac hypertrophy, to date little is known of the exact mechanism by which
calcineurin promotes growth of the cardiac myocyte through activating NFAT gene
targets. Although NFAT is a relatively weak transcriptional activator alone and only
a limited amount of genes involved in hypertrophy have been characterized to
harbor NFAT binding sequences in their regulatory promoter regions, the severity
of the cardiac phenotype in the calcineurin transgenic animals indicates the
relevance of this signaling route.
Assembly of synergistic transcription factors and coactivators on
promoters or enhancers results in a DNA-bound complex containing several
proteins, that overall is more efficient in inducing transcription than any of its
individual components alone. There is evidence from other cell types that NFAT
may directly interact with the myogenic transcription factor Myocyte Enhancer
Factor 2 (MEF2). MEF2 is a MADS box transcription factor that is expressed during
the development of all three muscle lineages, but is also activated during cardiac
hypertrophy.""' Additionally, both NFAT and MEF2 require interaction with the
transcriptional coactivator p300 for their full transcriptional activity, a protein that
is also known to possess intrinsic histone acetyl transferase activity to promote
a transcriptionally active chromatin configuration."" Due to the importance of
MEF2 in regulating the differentiation of myogenic lineages, we hypothesized that
if MEF2 would be downstream of calcineurin, it may, at least in part, explain the
dramatic remodeling effects of calcineurin in the heart.
Both //7 wfro and /n v/Vo we were able to demonstrate the existence of
a transcriptional regulatory complex in cardiomyocytes involving proteins of
the NFAT and MEF2 families in the presence of the transcriptional coactivator
p300, that integrate the Ca^-activated CnA/NFAT signaling pathway with the
myogenic transcriptional activity of MEF2. We demonstrated MEF2 to be a required
component for cardiomyocytes to undergo Ca^/CnA-induced hypertrophy,
as adenoviral overexpression of a dominant negative MEF2 abrogated the
characteristic hypertrophic remodeling in cultured cardiomyocytes (Chapter
4). These findings expand the significance of calcineurin signaling, since they
prove calcineurin to be able to induce expression of not only genes containing
NFAT binding sites, but also genes containing MEF2 binding sequences in their
promoter regions.
Interestingly, we only found a distinct subset of MEF2 sensitive genes to
be upregulated in calcineurin transgenic mice. This indicates that the synergistic
interaction between MEF2 and NFAT is not a general mechanism, but limited
to distinct genes. It will be very challenging to elucidate the mechanism for
the gene specificity of this synergy between MEF2 and NFAT. Currently, we are
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in the process of crossing inducible dominant negative MEF2 transgenic mice
with mice overexpressing a constitutively activated form of calcineurin. These
triple transgenic mice will indicate whether we can inhibit or even reverse the
calcineurin-induced pathological, hypertrophic phenotype of the heart. At the
same time, microarray analysis on cardiac tissue of these mice will provide us with
detailed insights into the MEF2 sensitive genes that are involved in hypertrophic
calcineurin signaling. • • • . . , . ; ; - , : • •
Transcriptional control of HDAC
Histone acetylation/deacetylation represents a central mechanism for the
control of gene expression. Histone acetyltransferases (HATs), like p300, catalyze
the acetylation of core histones of nucleosomes, resulting in chromatin relaxation
and transcriptional activation. The activity of HATs is antagonized by histone
deacetylases (HDACs), which deacetylate histones and transcription factors,
resulting in chromatin condensation and transcriptional repression.™ HDACs are
divided into three classes, of which class II HDACs (HDACs 4, 5, 6, 7, 9, and 10)
contain a unique amino-terminal extension that mediates association with MEF2
factors through which it respresses its transcriptional activity.*'"
Due to the coordinate interaction between NFAT, MEF2 and p300 and the
increase in calcineurin activity after Ml, we hypothesized that HDAC9 knockout
animals, which have been shown to be highly sensitive to hypertrophic stimuli and
spontaneously develop cardiac hypertrophy with advanced age," would be prone
to develop cardiac hypertrophy and failure after Ml due to calcineurin activation.
Since previously a gender difference was reported for mice overexpressing a
constitutively active class II HDAC," both sexes were included in this study.
Strikingly, although Ml resulted in severe deterioration in contractile
function and increased mortality for the male HDAC9 knockout animals compared
to wild type animals, female HDAC9 knockout animals showed less deleterious
remodeling, resulting in better maintained cardiac contractility and structure.
More detailed examination showed this effect to be attributable to an enhanced
angiogenic response in the infarct area of the HDAC9 knockout female mice,
rather than the result of sensitized MEF2 signaling (Chapter 5). A possible
explanation for this phenomenon might lay in the transcriptional repression the
estrogen receptor through HDAC." one might speculate that removal of HDAC9
might sensitize the estrogen receptor, thereby enhancing the angiogenic effects
estrogen signaling has been reported to provoke.
It will be very interesting to see whether ovariectomy in these female mice
will result in the apparent failing phenotype of the male HDAC9 knockout mice,
and whether estrogen replacement can rescues these ovarectamized females.
Additionally these results also indicate the necessity to specifically
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target the calcineurin/ NFAT pathway. Our speculation that HDAC ablation would
sensitize MEF2 signaling through the MEF2/NFAT interaction, thus enhance
calcineurin induced hypertrophic process after Ml, appeared premature. Although
the severe mortality for the male HDAC9 knockout mice might probably be
related to enhanced MEF2 signaling, the elevation in survival for the female
HDAC9 knockout mice indicates an interaction between HDAC and estrogens. This
indicates that the complexity and diversity of the signaling cascades involving
HDAC obviously interferes with the specifity of the outcomes, and a more defined
approach should be taken to give concluding results.
Experimental pitfalls and future therapeutic prospects
The data presented in this thesis suggest that calcineurin inhibition would
be desirable in treating certain forms of maladaptive hypertrophy. However, before
calcineurin can function as a clinical target there are several experimental and
therapeutic drawbacks we need to overcome.
An extensive amount of research has focused on elucidating the role
of calcineurin in pathologic hypertrophy, but, up to date, still no reliable,
standardized method has been developed to measure calcineurin activity in
vivo. Quantification of calcineurin phosphatase activity from tissue lysates using
biochemical assays is experimentally problematic, due to the dynamic, calcium/
calmodulin-dependent regulation of activity, and the sensitivity of calcineurin
to oxidation of the Fe-Zn active center." At the same time this assay does not
reflect the proportion of the enzymatic calcineurin pool that is actually in an active
state in vivo, but only indicates the amount of maximally activatable calcineurin
present in a specific tissue homogenate. Due to these flaws, we used several
other methods in parallel to monitor calcineurin activity, such as absolute protein
levels of the Ap subunit," the phosphorylation status of endogenous NFAT,"
the transcriptional activity of NFAT/ specifically the exon 4 splice isoform of
endogenous MCIP1 ,'* and biochemical phosphatase enzyme assays. Although all
these methods reflect calcineurin activity, optimization of a direct measurement of
calcineurin activity would be preferential.
Although there are a lot of benefits from using genetically modified
animal models to fully explore their phenotypes at the whole organ and whole
animal level, the extension of cardiovascular physiological methodologies to the
mouse is imperative.
Several animal studies have demonstrated that pharmacological or genetic
inhibition of calcineurin by overexpressing peptide inhibitors are beneficial
in preventing cardiac hypertrophy and failure (all reviewed in "•*"). The many
physiological roles of calcineurin signaling, such as in the immune response,
cause the existing calcineurin inhibitory drugs to have a relatively toxic profile.
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Therefore novel therapeutic agents would be needed to target calcineurin more S'-
specifically in the heart. Given the complexity and redundant nature of the
signaling network that drive cardiac pathogenesis, a potentially more efficacious
therapy would be to target downstream elements, like NFAT, in the pathological
calcineurin signaling cascades. However, even if it can be achieved to design
a drug that specifically target calcineurin's main downsteam effector NFAT,
there should be some caution in the application of this pharmacological tool.
Calcineurin inhibition may render the heart more susceptible to apoptotic cell
death,*' and although the exact cardioprotective mechanism of calcineurin against
myocyte apoptosis is unknown, it appears to require NFAT activation."
Conclusively, our findings as well as those from others, suggesting a
pivotal involvement of calcineurin in several forms of pathological hypertrophy in
cell culture, rodents and patients, suggest that calcineurin may be a valid target
for therapeutic intervention in patients. Recent advancements in understanding
calcineurin signaling, its interconnectivity with other hypertrophic signaling
pathways, as well as discoveries of effectors of calcineurin activity with cardiac
muscle specificity, should offer new entry points for more appropriate drug design
for the treatment of hypertrophic heart disease and heart failure.
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The heart consists of terminally differentiated cells, meaning that they
have lost their ability to divide. When the heart becomes exposed to growth
factors in response to increased workload, injury, or intrinsic defects in contractile
performance, the cardiac muscle cells therefore start to grow, which is called N
cardiomyocyte hypertrophy. In 1 998 Molkentin et al. first identified the calcium-
dependent phosphatase calcineurin as being a key mediator in this process of
cardiomyocyte hypertrophy.
As soon as the role of calcineurin in cardiomyocyte hypertrophy became
well established, pharmacological tools where applied to begin to determine
whether inhibition of calcineurin activity /n wVo might be an effective means
of preventing cardiac hypertrophy. In chapter 1 we review the use of the
pharmacological calcineurin inhibitors CsA and FK-506 to prevent hypertrophy in
response to a variety of pathological stimuli, and discuss the opportunities to use
genetically modified animals.
In chapter 2 we investigate calcineurin's involvement in left ventricular
hypertrophy as a consequence of acute myocardial infarction. We were able to
identify calcineurin as a key player in the maladaptive remodeling process of the
remote myocardium following myocardial infarction, characterized by fibrosis
and chamber dilation, resulting in overt heart failure. The use of a genetic mouse
model with a mild myocyte-restricted overexpression of Modulatory Calcineurin
Interacting Protein 1 (MCIP1) to effectively block calcineurin activity specifically
in the heart, enabled us to indicate that inhibition of calcineurin activity is able to
largely prevent these pathological characteristics.
Taken the apparent importance of calcineurin signaling in maladaptive
hypertrophy, in chapter 3 we attempted to further elucidate the downstream
substrate of calcineurin, the transcription factor nuclear factor of activated T-cells
(NFAT). Our data indicate both the presence and transcriptional activity of all four,
calcineurin-sensitive members of the NFAT family (NFATcl, c2, c3 and c4) in the
ventricular cardiomyocyte cell lineage. A dominant negative approach enabled us
to simultaneously abrogate NFAT-dependent transcriptional activity and rendered
cardiomyocytes resistant to calcineurin- and agonist-induced cardiomyocyte
hypertrophy, indicating the requirement of NFAT in cardiomyocyte hypertrophy.
Despite the wealth of information linking calcineurin and the progression
of cardiac hypertrophy, little is known of the exact mechanism by which
calcineurin promotes growth of the cardiac myocyte. In chapter 4 we were able
to both ;n wtra and ;n wVo indicate the existence of a transcriptional regulatory
complex in cardiomyocytes involving proteins of the NFAT and MEF2 families of
transcription factors. This interaction integrates the Ca**-activated CnA/NFAT
signaling pathway with the myogenic transcriptional activity of MEF2, that is
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required for cardiomyocytes to fully undergo Ca^/CnA-induced hypertrophy.
In chapter 5 we investigated cardiac remodeling after Ml in mice lacking the
histone deactylase, HDAC9. Since the transcriptional activity of MEF2 is repressed
by histone deacetylases, and due to the interaction between NFAT and MEF2, we
hypothesized that HDAC9-null animals would be hypersensitive to myocardial
infarction induced calcineurin activation and would therefore ultrarapid develop
cardiac hypertrophy and failure. However, although Ml resulted in an severe
deterioration in contractile function and increased mortality for the male HDAC9
knockout animals, surprisingly, compared to wild type animals, the female HDAC9
knockout animals showed less remodeling, which resulted in a better maintained
cardiac contractility and structure. More detailed examination showed this effect
to be attributable to an enhanced angiogenic respons in the infarcted area of the
HDAC9 knockout females.
In chapter 6 the major findings of this thesis and future directions
for research on calcineurin signaling are discussed. Our data emphasize the
significance of the calcineurin/NFAT pathway in cardiomyocyte hypertrophy,
reveal its maladaptive character and unravel the downstream effectors, and
might possibly attribute to future therapeutic drug design for the treatment of
hypertrophic heart disease.
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Het hart bestaat uit terminaal gedifferentieerde cellen, wat betekent dat
zij het vermogen om te delen zijn verloren. Zodra het hart, als gevolg van een
toename in werklast of intrinsieke defecten in contractiliteit, wordt blootgesteld
aan groeifactoren, beginnen de hartspiercellen te groeien, wat cardiomyocyt
hypertrofie wordt genoemd. In 1 998 ontdekte Molkentin era/, dat de calcium i.>
afhankelijke fosfatase calcineurine een belangrijke rol speelt in dit proces van
cardiomyocyt hypertrofie.
Zodra de rol van calcineurine in cardiomyocyt hypertrofie een
geaccepteerd gegeven werd, begon men farmacologische substraten te gebruiken
om te bepalen of inhibitie van calcineurine activiteit ;n v/Vo een effectieve manier
is om cardiale hypertrofie te voorkomen. In hoofdstuk 1 bediscussieren we het
gebruik van farmacologische inhibitie van calcineurine met behulp van CsA en FK-
506 om hypertrofie als gevolg van een verscheidenheid aan pathologische stimuli
te voorkomen en zetten we de mogelijkheden om genetisch gemodificeerde dieren
te gebruiken uiteen.
In hoofdstuk 2 onderzoeken we de betrokkenheid van calcineurine in
hypertrofie van het linker ventrikel als gevolg van een acuut myocard infarct.
Wij zijn in staat gebleken calcineurine aan te wijzen als een belangrijke factor in
het proces van maladaptieve remodellering van het niet-geinfarceerde deel van
het hart na een hartinfarct, wat wordt gekarakteriseerd door fibrose, dilatatie en
uiteindelijk hartfalen. Het gebruik van een genetisch gemodificeerde muis die
Modulatory Calcineurin Interacting Protein 1 (MCIP1) in hartspiercellen tot over
expressie brengt om calcineurine activiteit specifiek in deze cellen te blokkeren,
heeft ons in staat gesteld aan te tonen dat inhibitie van calcineurine activiteit deze
maladaptieve verschijnselen grotendeels voorkomt.
Doordat calcineurine klaarblijkelijk een belangrijke rol speelt in
pathologische hypertrofie, hebben we in hoofdstuk 3 getracht de onderliggende
effector van calcineurine, de transcriptie factor 'nuclear factor of activated T-
cells (NFAT)', verder uit te diepen. Onze data tonen aan dat alle vier calcineurine
gevoelige leden van de NFAT familie van transcriptiefactoren (NFATcl, c2, c3
en c4) aanwezig zijn in ventriculaire hartspiercellen en tevens transcriptioneel
actief zijn. Een dominant negatieve aanpak, waarmee we simultaan alle NFAT-
afhankelijke transcriptionele activiteit kunnen blokkeren, resulteerde in
cardiomyocyten die niet langer een hypertrofe respons vertoonden in reactie op
calcineurine of andere hypertrofe agonisten, wat aangeeft dat NFAT vereist is in
cardiomyocyt hypertrofie.
Ondanks de veelheid aan informatie over calcineurine en de ontwikkeling
van cardiale hypertrofie, is er nog maar weinig bekend over het mechanisme
waarmee calcineurine groei van hartspiercellen bewerkstelligt. In hoofdstuk 4
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tonen wij zowel /« w'tro als ;>? wVo het bestaan van een transcriptioneel regulerend
complex in hartspiercellen tussen NFAT eiwitten en MEF2 factoren aan. Deze
interactie integreert de Ca^-geactiveerde CnA/NFAT signaleringsroute en de
myogene transcriptionele activiteit van MEF2, welke in hartspiercellen vereist is om
een volledige Ca^/CnA geinduceerde hypertrofe respons te vertonen.
In hoofdstuk 5 hebben we de cardiale remodellering na een myocard
infarct onderzocht in muizen die de histon deacetylase 9 missen (HDAC9
knockout). Omdat de transcriptionele activiteit van MEF2 wordt onderdrukt
door histon deacetylases en door de interactie tussen NFAT en MEF2, was onze
hypothese dat deze HDAC9 knockout muizen hypersensitief zouden zijn voor
activatie van calcineurine als gevolg van het myocard infarct en daardoor extra
snel hypertrophy zouden ontwikkelen en in falen gaan. Hoewel het infarct in
de mannelijke HDAC9 knockout muizen resulteerde in een verslechtering van
cardiale contractiliteit en een verhoogde mortaliteit ten opzichte van wild type
muizen, vertoonden de vrouwelijke HDAC9 knockout muizen verrassend genoeg
een verminderde remodellering, wat resulteerde in behoud van contractiliteit en
structuur. Meer gedetailleerd onderzoek toonde aan dat dit effect toe te schrijven
is aan een verbeterde angiogene respons in het infarct gebied van de vrouwelijke
HDAC9 knockout muizen.
In hoofdstuk 6 bediscussieren we de belangrijkste bevindingen van dit
proefschrift en de toekomstige richting voor het calcineurine onderzoek. Onze
data benadrukken de significante bijdrage van de calcineurine/NFAT route in
hypertrofie van de hartspiercel, onthullen het maladaptieve karakter en ontrafelen
de onderliggende effectors en kunnen mogelijk een bijdrage leveren aan de
ontwikkeling van toekomstige therapeutische drugs voor de behandeling van
hypertrofe hartziekten.
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Figure 1.2. Genetic inhibition of calcineurin with calcineurin inhibitory protein (Cain)
abrogates the LV hypertrophy response. The left panel summarizes the in vitro results
obtained with adenoviral ACain gene transfer (AdACain) in cardiomyocytes. Phenylephrine
(PE) induces a massive increase in cardiomyocyte size in cultures infected with a control
adenovirus (Adpgal) compared to uninfected, non-stimulated cells (top left and middle left
panels). In contrast, blockade of calcineurin in the presence of ACain prevents PE-induced
hypertrophy (lower left panel). Cardiomyocytes were visualized by immunocytochemical
a-actinin detection, nuclei were visualized with bisbenzamide (white). Hematoxylin-Eosin
stained cross-sections demonstrate that similar effects were observed following ACain
overexpression in vivo. A 14-day pressure overload stimulus resulted in a visible increase in
heart weight in wildtype animals, as compared to sham-operated, wildtype mice (top right
and middle right panels). Mice overexpressing the non-competetive ACain protein in the
cardiomyocyte component are protected against this pressure-overload stimulus (lower right
panel).
sham Ml
wildtype
MCIP1
transgenic
Fig. 2.2C Laminin staining reveals a significant increase in cardiomyocyte size after Ml
compared to the sham operated animals, which is more pronounced in wildtype animals
compared to MCIP1 transgenic animals (n = 4 in both sham groups, n = 6 in both Ml groups).
Bar represents 0.1 mm.
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Fig. 2.4A MCIP1 transgenic animals are protected against Ml-induced structural remodeling.
Representative images of histological staining for the indicated groups. Upper panels are
H&E stained images, lower panels Sirius red stained images (Bar indicates 0.1 mm). H&E
stained images reveal remarkable myocyte hypertrophy, myofiber disarray and cellular
infiltrates (arrowheads) in a section from a representative postinfarcted wildtype mouse. In
contrast MCIP1 transgenic mice are largely protected against these structural alterations.
Sirius red staining indicates low levels of collagen deposition in the sham operated mouse
hearts from both phenotypes, a massive accumulation of fibrillar collagen (interstitial and
perivascular fibrosis) after infarction in wildtype mice, which is substantially attenuated in
MCIP1 transgenic mice.
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Fig. 3.2 Calcineurin-dependent nuclear translocation of NFATcl and c3 in cardiomyocytes.
Cultured cardiomyocytes were either left unstimulated (A, B), stimulated with AdCnA (C, D),
or endothelin-1 (Endo-1) (E, F) and immunostained for subcellular localization of NFATcl
(left Panel) or c3 (right Panel). Nuclei were stained with bisbenzemide (B, D, F, H). Under
serum free conditions, NFATcl and NFATc3 were localized cytoplasmatically (A). Following
stimulation with either AdCnA (C) or Endo-1 (E) both isoforms translocated to the nucleus.
Panels C and H represent negative controls by ommittance of the primary antibody.
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Fig. 3.6C Representative images of immunostained cardiomyocytes infected with the
indicated adenoviruses either or not in combination with the hypertrophic agonist CT-
1. Phalloidin/ANF double staining demonstrates less cellular enlargement, sarcomeric
organization and perinuclear ANF staining in the presence of AdNFATc4(PxlxlT) following
AdCnA infection or agonist stimulation.
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Fig. 4.5C Representative images of immunostained cardiomyocytes infected with the
indicated adenoviruses. Phalloidin staining indicates less hypertrophy and sarcomere
organization in the presence of AdMEF2(R24L) following AdACnA infection.
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Fig. 5.3A Reduced cardiac remodeling in HDAC9
knockout females after Ml. (A) Morphometric
analyses of H&E transversal sections from apex
to base indicate no significant difference in
infarcted left ventricular circumference between
wild type and HDAC9 knockout females, with
more dilation and an increased hypertrophic
response in the wild type mice.
sham
wild type
sham
HDAC9 KO
Ml
wild type
Ml
HDAC9 KO
Fig. 5.3B Sirius red staining indicates low levels of collagen deposition in the sham operated
mouse hearts from both phenotypes. Although massive accumulation of fibrillar collagen
(interstitial and perivascular fibrosis) is present after infarction in wild type mice, this
response is substantially attenuated in female HDAC9 knockout mice. Bar indicates 0.1 mm.
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Fig. 5.4 Additional epicardial layer of surviving cells in infarcted area of female HDAC9
knockout mice. H&E stained sections show the presence of an additional layer of survival
cells at the epicardial surface of the infarcted area in the female HDAC9 knockout animals
compared to wild WT. Bar indicates 0.1 mm.
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Fig 5.5B vWF stained images reveal only vWF positive vessels in the infarcted regions, with
a higher abundancy in the infarcted area of the female HDAC9 knockout mice. Bar indicates
0.1 mm.
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Fig. 5.5C Sections stained for lectin an equal distribution of capillaries surrounding
cardiomyocytes in the non-infarcted areas, while the ischemic region shows irregular
patterning of vasculature with additional and enlarged vessels in the border zone and the
infarcted region of the HDAC9 knockout females compared to the WT animals. Bar indicates
0.1 mm.
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